Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
IMIDAZOPYRAZINES AS LSD1 INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2016/007736
Kind Code:
A1
Abstract:
The present invention is directed to imidazo[1,2-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Inventors:
COURTER JOEL R (US)
LI JINGWEI (US)
WU LIANGXING (US)
HE CHUNHONG (US)
LU LIANG (US)
SUN YAPING (US)
WANG XIAOZHAO (US)
YAO WENQING (US)
ZHUO JINCONG (US)
ZHANG COLIN (US)
Application Number:
PCT/US2015/039734
Publication Date:
January 14, 2016
Filing Date:
July 09, 2015
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
INCYTE CORP (US)
COURTER JOEL R (US)
LI JINGWEI (US)
International Classes:
C07D487/04; A61K31/4985; A61P35/00
Domestic Patent References:
WO2010119264A12010-10-21
WO2004072081A12004-08-26
WO2002000196A22002-01-03
Foreign References:
Other References:
JASON G KETTLE ET AL: "Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT", vol. 55, no. 3, 1 March 2012 (2012-03-01), pages 1261 - 1273, XP002694269, ISSN: 0022-2623, Retrieved from the Internet [retrieved on 20120116], DOI: 10.1021/JM201394E
PORTELA, A; M. ESTELLER: "Epigenetic modifications and human disease", NAT BIOTECHNOL, vol. 28, no. 10, 2010, pages 1057 - 68
LUND, A.H.; M. VAN LOHUIZEN: "Epigenetics and cancer", GENES DEV, vol. 18, no. 19, 2004, pages 2315 - 35
DAWSON, M.A.; T. KOUZARIDES: "Cancer epigenetics: from mechanism to therapy", CELL, vol. 150, no. 1, 2012, pages 12 - 27
WALDMANN, T.; R. SCHNEIDER: "Targeting histone modifications—epigenetics in cancer", CURR OPIN CELL BIOL, vol. 25, no. 2, 2013, pages 184 - 9
SHEN, H.; P.W. LAIRD: "Interplay between the cancer genome and epigenome", CELL, vol. 153, no. 1, 2013, pages 38 - 55
SHI, Y. ET AL.: "Histone demethylation mediated by the nuclear amine oxidase homolog LSDl", CELL, vol. 119, no. 7, 2004, pages 941 - 53
FORNERIS, F. ET AL.: "Structural basis ofLSD I -C REST selectivity in histone H3 recognition", J BIOL CHEM, vol. 282, no. 28, 2007, pages 20070 - 4
ANAND, R.; R. MARMORSTEIN: "Structure and mechanism of lysine-specific demethylase enzymes", J BIOL CHEM, vol. 282, no. 49, 2007, pages 35425 - 9
STAVROPOULOS, P.; G. BLOBEL; A. HOELZ: "Crystal structure and mechanism of human lysine-specific demethylase-l", NAT STRUCT MOL BIOL, vol. 13, no. 7, 2006, pages 626 - 32
CHEN, Y. ET AL.: "Crystal structure of human histone lysine-specific demethylase 1 (LSD1)", PROC NATL ACAD SCI USA, vol. 103, no. 38, 2006, pages 13956 - 61
KARYTINOS, A. ET AL.: "A novel mammalian flavin-dependent histone demethylase", J BIOL CHEM, vol. 284, no. 26, 2009, pages 17775 - 82
KOOISTRA, S.M.; K. HELIN: "Molecular mechanisms and potential functions of histone demethylases", NAT REV MOL CELL BIOL, vol. 13, no. 5, 2012, pages 297 - 311
MOSAMMAPARAST, N.; Y. SHI: "Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases", ANNU REV BIOCHEM, vol. 79, 2010, pages 155 - 79
METZGER, E. ET AL.: "LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription", NATURE, vol. 437, no. 7057, 2005, pages 436 - 9
KAHL, P. ET AL.: "Androgen receptor coactivators lysine-specific histone demethylase I and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence", CANCER RES, vol. 66, no. 23, 2006, pages 11341 - 7
HUANG, J. ET AL.: "p53 is regulated by the lysine demethylase LSDl", NATURE, vol. 449, no. 7158, 2007, pages 105 - 8
KONTAKI, H.; I. TALIANIDIS: "Lysine methylation regulates E2Fl-induced cell death", MOL CELL, vol. 39, no. 1, 2010, pages 152 - 60
YANG, J. ET AL.: "Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes", PROC NATL ACAD SCI USA, vol. 107, no. 50, 2010, pages 21499 - 504
SAKANE, N. ET AL.: "Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1)", PLOS PATHOG, vol. 7, no. 8, 2011, pages E1002184
CHO, H.S. ET AL.: "Demethylation ofRB regulator MYPTI by histone demethylase LSD1 promotes cell cycle progression in cancer cells", CANCER RES, vol. 71, no. 3, 2011, pages 655 - 60
WANG, J. ET AL.: "The lysine demethylase LSD1 (KDMI) is requiredfor maintenance of global DNA methylation", NAT GENET, vol. 41, no. 1, 2009, pages 125 - 9
HAKIMI, M.A. ET AL.: "A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes", PROC NATL ACAD SCI USA, vol. 99, no. 11, 2002, pages 7420 - 5
LEE, M.G. ET AL.: "Functional interplay between histone demethylase and deacetylase enzymes", MOL CELL BIOL, vol. 26, no. 17, 2006, pages 6395 - 402
YOU, A. ET AL.: "CoREST is an integral component of the CoREST- human histone deacetylase complex", PROC NATL ACAD SCI USA, vol. 98, no. 4, 2001, pages 1454 - 8
SINGH, M.M. ET AL.: "Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors", NEURO ONCOL, vol. 13, no. 8, 2011, pages 894 - 903
HAN, H. ET AL.: "Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD] in cancer cells", PLOS ONE, vol. 8, no. 9, 2013, pages E75136
CHEN, Y. ET AL.: "Lysine-specific histone demethylase 1 (LSDl): A potential molecular targetfor tumor therapy", CRIT REV EUKARYOT GENE EXPR, vol. 22, no. 1, 2012, pages 53 - 9
SUN, G. ET AL.: "Histone demethylase LSD1 regulates neural stem cell proliferation", MOL CELL BIOL, vol. 30, no. 8, 2010, pages 1997 - 2005
ADAMO, A.; M.J. BARRERO; J.C. IZPISUA BELMONTE: "LSD1 and pluripotency: a new player in the network", CELL CYCLE, vol. 10, no. 19, 2011, pages 3215 - 6
ADAMO, A. ET AL.: "LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells", NAT CELL BIOL, vol. 13, no. 6, 2011, pages 652 - 9
CLEVERS, H.: "The cancer stem cell: premises, promises and challenges", NAT MED, vol. 17, no. 3, 2011, pages 313 - 9
BECK, B; C. BLANPAIN: "Unravelling cancer stem cell potential", NAT REV CANCER, vol. 13, no. 10, 2013, pages 727 - 38
ZHANG, X. ET AL.: "Pluripotent Stem Cell Protein Sox2 Confers Sensitivity to LSD1 Inhibition in Cancer Cells", CELL REP, vol. 5, no. 2, 2013, pages 445 - 57
WANG, J. ET AL.: "Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties", CANCER RES, vol. 71, no. 23, 2011, pages 7238 - 49
HARRIS, W.J. ET AL.: "The histone demethylase KDM1A sustains the oncogenic potential ofMLL-AF9 leukemia stem cells", CANCER CELL, vol. 21, no. 4, 2012, pages 473 - 87
SCHENK, T. ET AL.: "Inhibition of the LSD1 (KDMIA) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia", NAT MED, vol. 18, no. 4, 2012, pages 605 - 11
HAYAMI, S. ET AL.: "Overexpression of LSD 1 contributes to human carcinogenesis through chromatin regulation in various cancers", INT J CANCER, vol. 128, no. 3, 2011, pages 574 - 86
LV, T. ET AL.: "Over-expression of LSD 1 promotes proliferation, migration and invasion in non-small cell lung cancer", PLOS ONE, vol. 7, no. 4, 2012, pages E35065
SERCE, N. ET AL.: "Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast", BMC CLIN PATHOL, vol. 12, 2012, pages 13
LIM, S. ET AL.: "Lysine-specific demethylase 1 (LSDI) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology", CARCINOGENESIS, vol. 31, no. 3, 2010, pages 512 - 20
KONOVALOV, S.; I. GARCIA-BASSETS: "Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines", J OVARIAN RES, vol. 6, no. 1, 2013, pages 75
SAREDDY, G.R. ET AL.: "KDM1 is a novel therapeutic targetfor the treatment of gliomas", ONCOTARGET, vol. 4, no. 1, 2013, pages 18 - 28
DING, J. ET AL.: "LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer", BR J CANCER, vol. 109, no. 4, 2013, pages 994 - 1003
BENNANI-BAITI, I.M. ET AL.: "Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma", HUM PATHOL, vol. 43, no. 8, 2012, pages 1300 - 7
SCHULTE, J.H. ET AL.: "Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy", CANCER RES, vol. 69, no. 5, 2009, pages 2065 - 71
CREA, F. ET AL.: "The emerging role of histone lysine demethylases in prostate cancer", MOL CANCER, vol. 11, 2012, pages 52
SUIKKI, H.E. ET AL.: "Genetic alterations and changes in expression of histone demethylases in prostate cancer", PROSTATE, vol. 70, no. 8, 2010, pages 889 - 98
YU, Y. ET AL.: "High expression of lysine-specific demethylase 1 correlates with poor prognosis of patients with esophageal squamous cell carcinoma", BIOCHEM BIOPHYS RES COMMUN, vol. 437, no. 2, 2013, pages 192 - 8
KONG, L. ET AL.: "Immunohistochemical expression ofRBP2 and LSD1 in papillary thyroid carcinoma", ROM J MORPHOL EMBRYOL, vol. 54, no. 3, 2013, pages 499 - 503
LYNCH, J.T. ET AL.: "CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1", ANAL BIOCHEM, vol. 442, no. 1, 2013, pages 104 - 6
GREAVES, P.; J.G. GRIBBEN: "The role of B7 family molecules in hematologic malignancy", BLOOD, vol. 121, no. 5, 2013, pages 734 - 44
CHEN, L.; D.B. FLIES: "Molecular mechanisms ofT cell co-stimulation and co-inhibition", NAT REV IMMUNOL, vol. 13, no. 4, 2013, pages 227 - 42
LIANG, Y. ET AL.: "Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency", SCI TRANSL MED, vol. 5, no. 167, 2013, pages 167RA5
LIANG, Y. ET AL.: "Inhibition of the histone demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency", NAT MED, vol. 15, no. 11, 2009, pages 1312 - 7
SHI, L. ET AL.: "Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction", NAT MED, vol. 19, no. 3, 2013, pages 291 - 4
XU, J. ET AL.: "Corepressor-dependent silencing of fetal hemoglobin expression by BCLI ]A", PROC NATL ACAD SCI USA, vol. 110, no. 16, 2013, pages 6518 - 23
SANKARAN, V.G.; S.H. ORKIN: "The switch from fetal to adult hemoglobin", COLD SPRING HARB PERSPECT MED, vol. 3, no. 1, 2013, pages AO11643
BAUER, D.E.; S.C. KAMRAN; S.H. ORKIN: "Reawakening fetal hemoglobin: prospects for new therapies for the beta-globin disorders", BLOOD, vol. 120, no. 15, 2012, pages 2945 - 53
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
BERGE ET AL., J. PHARM. SCI., vol. 66, no. 1, 1977, pages 1 - 19
STAHL ET AL.: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY
P. G. M. WUTS; T. W. GREENE: "Protective Groups in Organic Synthesis", 2006, WILEY & SONS, INC.
KARL F. BLOM; BRIAN GLASS; RICHARD SPARKS; ANDREW P. COMBS: "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. COMBI. CHEM., vol. 6, no. 6, 2004, pages 874 - 883
K. BLOM: "Two-Pump At Column Dilution Configuration for Preparative LC-MS", J. COMBI. CHEM., vol. 4, 2002, pages 295
K. BLOM; R. SPARKS; J. DOUGHTY; G. EVERLOF; T. HAQUE; A. COMBS: "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. COMBI. CHEM., vol. 5, 2003, pages 670
K. BLOM; B. GLASS; R. SPARKS, A: "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", COMBS, J. COMBI. CHEM., vol. 6, 2004, pages 874 - 883
K. BLOM; B. GLASS; R. SPARKS; A. COMBS: "Preparative LCMS Purification: Improved Compound Specific Method Optimization", J. COMB. CHEM., vol. 6, 2004, pages 874 - 883
Attorney, Agent or Firm:
GODDARD, Christine, A. (P. O. Box 1022Minneapolis, Minnesota, US)
Download PDF:
Claims:
What is claimed is:

1. A compound of Formula I:

I

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is C6-io aryl or 5-10 membered heteroaryl comprising carbon and 1, 2, 3, or 4 heteroatoms selected from N, O, and S, wherein said C6-io aryl and 5-10 membered heteroaryl are each optionally substituted by 1, 2, 3, or 4 substituents independently selected from RA;

Ring B is C6-io aryl; 5-10 membered heteroaryl comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O, and S; C3-10 cycloalkyl; or 4-10 membered heterocycloalkyl comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O, and S; wherein said C6-io aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 substituents independently selected from RB;

R1 is halo, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Cy1, CN, ORal, SRal, C(0)Rbl, C(0)NRclRdl, C(0)ORal, OC(0)Rbl, OC(0)NRclRdl, NRclRdl, NRclC(0)Rbl,

NRclC(0)ORal, NRclC(0)NRclRdl, C(=NRel)Rbl, C(=NRel)NRclRdl, NRclC(=NRel)NRclRdl, NRclS(0)Rbl, NRclS(0)2Rbl, NRclS(0)2NRclRdl, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, or

S(0)2NRclRdl; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, halo, CN, OH, ORal, SRal, C(0)Rbl, C(0)NRclRdl, C(0)ORal, OC(0)Rbl, OC(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)ORal, NRclC(0)NRclRdl, C(=NRel)Rbl, C(=NRel)NRclRdl, NRclC(=NRel)NRclRdl, NRclS(0)Rbl, NRclS(0)2Rbl, NRclS(0)2NRclRdl, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, and

S(0)2NRclRdl;

R2 and R3 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Cy2, CN, ORa2, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, OC(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)ORa2, NRc2C(0)NRc2Rd2, C(=NRe2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy2, halo, CN, ORa2, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, OC(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)ORa2, NRc2C(0)NRc2Rd2, C(=NRe2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2,

S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2;

each RA is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, NO2, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, OC(0)Rb4, OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, C(=NRe4)Rb4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, NRc4S(0)Rb4, NRc4S(0)2Rb4, NRc4S(0)2NRc4Rd4, S(0)Rb4,

S(0)NRc4Rd4, S(0)2Rb4, and S(0)2NRc4Rd4, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, or 3, substituents independently selected from halo, Ci-e haloalkyl, CN, NO2, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, OC(0)Rb4, OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, C(=NRe4)Rb4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, NRc4S(0)Rb4, NRc4S(0)2Rb4, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2Rb4, and S(0)2NRc4Rd4;

each RB is independently selected from Cy3, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, CN, NO2, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5,

OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)ORa5, NRc5C(0)NRc5Rd5, C(=NRe5)Rb5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, NRc5S(0)Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, or 3 substituents independently selected from Cy3, halo, Ci-e haloalkyl, CN, NO2, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)ORa5, NRc5C(0)NRc5Rd5, C(=NRe5)Rb5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, NRc5S(0)Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, and S(0)2NRc5Rd5;

each Cy1, Cy2, Cy3, and Cy4 is independently selected from C6-io aryl, C3-10 cycloalkyl, 5- 10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from RCy;

each RCy is independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, and (4-7 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa6, SRa6, C(0)Rb6, C(0)NRc6Rd6, C(0)ORa6, OC(0)Rb6, OC(0)NRc6Rd6, C(=NRe6)NRc6Rd6,

NRc6C(=NRe6)NRc6Rd6, NRc6Rd6, NRc6C(0)Rb6, NRc6C(0)ORa6, NRc6C(0)NRc6Rd6,

NRc6S(0)Rb6, NRc6S(0)2Rb6, NRc6S(0)2NRc6Rd6, S(0)Rb6, S(0)NRc6Rd6, S(0)2Rb6, and

S(0)2NRc6Rd6, wherein said Ci-4 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, and (4-7 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted by 1, 2, or 3 substituents independently selected from Ci-6 alkyl, Ci-4 haloalkyl, Ci-e cyanoalkyl, halo, CN, NO2, ORa6, SRa6, C(0)Rb6, C(0)NRc6Rd6, C(0)ORa6, OC(0)Rb6, OC(0)NRc6Rd6, C(=NRe6)NRc6Rd6, NRc6C(=NRe6)NRc6Rd6, NRc6Rd6, NRc6C(0)Rb6, NRc6C(0)ORa6, NRc6C(0)NRc6Rd6, NRc6S(0)Rb6, NRc6S(0)2Rb6, NRc6S(0)2NRc6Rd6, S(0)Rb6, S(0)NRc6Rd6, S(0)2Rb6, and S(0)2NRc6Rd6;

each Ral is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Cy4; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy4, halo, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3,

NRc3C(0)NRc3Rd3, C(=NRe3)Rb3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3;

each Rbl, Rcl, and Rdl is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7; or any Rcl and Rdl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7,

NRc7C(0)ORa7, C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, C(=NRe7)NRc7Rd7,

NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

or any Rc2 and Rd2 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7,

C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7,

NRc7C(0)ORa7, C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, C(=NRe7)NRc7Rd7,

NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

each R33, Rb3, Rc3, and Rd3 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

or any Rc3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7,

C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7,

NRc7C(0)ORa7, C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, C(=NRe7)NRc7Rd7,

NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7; each R , R , R , and R is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci- 4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7,

OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7,

C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

or any Rc4 and Rd4 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-e alkyl, Ci-e haloalkyl, halo, CN, ORa7, SRa7, C(0)Rb7,

C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7,

NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

each Ra5, Rb5, Rc5, and Rd5 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

or any Rc5 and Rd5 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7,

NRc7C(0)ORa7, C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are each optionally substituted by 1 , 2, or 3 substituents independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, C(=NRe7)NRc7Rd7,

NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

each Ra6, Rb6, Rc6, and Rd6 is independently selected from H, Ci-e alkyl, Ci-4 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1 , 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci- 4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7,

OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

or any Rc6 and Rd6 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from Ci-e alkyl, Ci-e haloalkyl, halo, CN, ORa7, SRa7, C(0)Rb7,

C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7,

NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

each Ra7, Rb7, Rc7, and Rd7 is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein said C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl are each optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(Ci-4 alkyl)amino, C1-4 haloalkyl, and Ci-4 haloalkoxy; and

each Rel, Re2, Re3, Re4, Re5, Re6, and Re7 is independently selected from H, Ci-4 alkyl, and

CN.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

Ring A is phenyl optionally substituted by 1 , 2, or 3 substituents independently selected from RA; Ring B is phenyl or 5-6 membered heteroaryl comprising carbon and 1 or 2 heteroatoms selected from N; wherein said phenyl or 5-6 membered heteroaryl is optionally substituted by 1 , or 2 substituents independently selected from RB;

R1 is halo, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Cy1, CN, ORal, SRal, C(0)Rbl, C(0)NRclRdl, C(0)ORal, OC(0)Rbl, OC(0)NRclRdl, NRclRdl, NRclC(0)Rbl,

NRclC(0)ORal, NRclC(0)NRclRdl, NRclS(0)Rbl, NRclS(0)2Rbl, NRclS(0)2NRclRdl, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, or S(0)2NRclRdl; wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1 , 2, or 3 substituents independently selected from Cy1, halo, CN, OH, ORal, SRal, C(0)Rbl, C(0)NRclRdl, C(0)ORal, OC(0)Rbl, OC(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)ORal, NRclC(0)NRclRdl, NRclS(0)Rbl, NRclS(0)2Rbl,

NRclS(0)2NRclRdl, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, and S(0)2NRclRdl;

R2 is H, halo, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Cy2, CN, ORa2, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, OC(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2,

NRc2C(0)ORa2, NRc2C(0)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, or S(0)2NRc2Rd2; wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1 , 2, or 3 substituents independently selected from Cy2, halo, CN, ORa2, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, OC(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)ORa2, NRc2C(0)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2,

NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2;

R3 is H;

each RA is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4S(0)2Rb4, S(0)Rb4, S(0)NRc4Rd4, S(0)2Rb4, and S(0)2NRc4Rd4, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1 , 2, or 3, substituents independently selected from halo, Ci-e haloalkyl, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4S(0)2RM, S(0)Rb4, S(0)NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4;

each RB is independently selected from Cy3, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)ORa5, NRc5C(0)NRc5Rd5, NRc5S(0)Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1 , 2, or 3 substituents independently selected from Cy3, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5,

NRc5C(0)Rb5, NRc5C(0)ORa5, NRc5C(0)NRc5Rd5, NRc5S(0)Rb5, NRc5S(0)2Rb5,

NRc5S(0)2NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, and S(0)2NRc5Rd5;

each Cy1, Cy2, Cy3, and Cy4 is independently selected from C6-io aryl, C3-10 cycloalkyl, 5- 10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from RCy;

each RCy is selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, and (4-7 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa6, SRa6, C(0)Rb6, C(0)NRc6Rd6,

C(0)ORa6, OC(0)Rb6, OC(0)NRc6Rd6, NRc6Rd6, NRc6C(0)Rb6, NRc6C(0)ORa6,

NRc6C(0)NRc6Rd6, NRc6S(0)Rb6, NRc6S(0)2Rb6, NRc6S(0)2NRc6Rd6, S(0)Rb6, S(0)NRc6Rd6, S(0)2Rb6, and S(0)2NRc6Rd6, wherein said CM alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, and (4-7 membered

heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted by 1, 2, or 3 substituents

independently selected from Ci-6 alkyl, C 1-4 haloalkyl, Ci-6 cyanoalkyl, halo, CN, NO2, ORa6, SRa6, C(0)Rb6, C(0)NRc6Rd6, C(0)ORa6, OC(0)Rb6, OC(0)NRc6Rd6, NRc6Rd6, NRc6C(0)Rb6, NRc6C(0)ORa6, NRc6C(0)NRc6Rd6, NRc6S(0)Rb6, NRc6S(0)2Rb6, NRc6S(0)2NRc6Rd6, S(0)Rb6, S(0)NRc6Rd6, S(0)2Rb6, and S(0)2NRc6Rd6;

each Ral is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Cy4; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy4, halo, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3,

NRc3C(0)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3;

each Rbl, Rcl, and Rdl is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7,

NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

or any Rcl and Rdl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7,

NRc7C(0)ORa7, C(=NRe7)NRc7Rd7, NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, C(=NRe7)NRc7Rd7,

NRc7C(=NRe7)NRc7Rd7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7, NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7,

NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7; each R , R , R , and R is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(0)Rb7, C(0)NRc7Rd7, C(0)ORa7, OC(0)Rb7, OC(0)NRc7Rd7, NRc7Rd7, NRc7C(0)Rb7, NRc7C(0)NRc7Rd7, NRc7C(0)ORa7, S(0)Rb7, S(0)NRc7Rd7, S(0)2Rb7,

NRc7S(0)2Rb7, NRc7S(0)2NRc7Rd7, and S(0)2NRc7Rd7;

each Ra4, Rb4, Rc4, and Rd4 is independently selected from H and C1-3 alkyl;

each Ra5, Rb5, Rc5, and Rd5 is independently selected from H or C1-3 alkyl;

each Ra6, Rb6, Rc6, and Rd6 is independently selected from H or C1-3 alkyl; and

each Ra7, Rb7, Rc7, and Rd7 is independently selected from H or C1-3 alkyl.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

Ring A is phenyl optionally substituted by 1, 2, or 3 substituents independently selected from RA;

Ring B is phenyl, pyridyl, or pyrimidinyl, each optionally substituted by 1 or 2 substituents independently selected from RB;

R1 is halo, C1-3 alkyl, Cy1, ORal, SRal, C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, or

NRclC(0)NRclRdl; wherein said C1-3 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, halo, CN, OH, ORal, C(0)NRclRdl, NRclRdl, and

NRclC(0)Rbl;

R2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, Cy2, C(0)NRc2Rd2, NRc2Rd2, or NRc2C(0)Rb2; wherein said C1-3 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from Cy2, halo, CN, ORa2, C(0)NRc2Rd2, NRc2Rd2, and NRc2C(0)Rb2;

R3 is H;

each RA is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4S(0)2Rb4, S(0)RM, S(0)NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, or 3, substituents independently selected from halo, Ci-e haloalkyl, CN, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4S(0)2RM, S(0)Rb4, S(0)NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4;

each RB is independently selected from Cy3, halo, Ci-6 alkyl, Ci-6 haloalkyl, CN, ORa5, C(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)ORa5, NRc5C(0)NRc5Rd5, NRc5S(0)Rb5, NRc5S(0)2Rb5, and NRc5S(0)2NRc5Rd5, wherein said Ci-e alkyl is optionally substituted by 1, 2, or 3 substituents independently selected from Cy3, halo, Ci-e haloalkyl, CN, ORa5, C(0)NRc5Rd5, NRc5Rd5, and NRc5C(0)Rb5;

each Cy1, Cy2, Cy3, and Cy4 is independently selected from phenyl, cyclopropyl, azetidine, piperidine, pyrrolidine, diazapane, and diazaspirononane, each of which is optionally substituted with 1 or 2 substituents independently selected from RCy;

each RCy is independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, CN, ORa6, and NRc6Rd6;

each Ral is independently selected from C1-3 alkyl and Cy4; wherein said C1-3 alkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from Cy4, halo, CN, and ORa3, and NRc3Rd3;

each Rbl, Rcl, and Rdl is independently selected from H, C1-3 alkyl, C1-3 haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridine, pyrimidine, azetidine, piperidine, pyrrolidine, thiazolyl, phenyl-Ci-2 alkyl-, cyclopropyl-Ci-2 alkyl-, cyclobutyl-Ci-2 alkyl-, cyclopentyl-Ci-2 alkyl-, cyclohexyl-Ci-2 alkyl-, pyridine-Ci-2 alkyl-, pyrimidine-Ci-2 alkyl-, azetidine-Ci-2 alkyl-, piperidine-Ci-2 alkyl-, pyrrolidine-Ci-2 alkyl-, and thiazolyl-Ci-2 alkyl-, wherein said C1-3 alkyl, C1-3 haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridine, pyrimidine, azetidine, piperidine, pyrrolidine, thiazolyl, phenyl-Ci-2 alkyl-,

cyclopropyl-Ci-2 alkyl-, cyclobutyl-Ci-2 alkyl-, cyclopentyl-Ci-2 alkyl-, cyclohexyl-Ci-2 alkyl-, pyridine-Ci-2 alkyl-, pyrimidine-Ci-2 alkyl-, azetidine-Ci-2 alkyl-, piperidine-Ci-2 alkyl-, pyrrolidine-Ci-2 alkyl-, and thiazolyl-Ci-2 alkyl- are each optionally substituted with 1, 2, or 3 substituents independently selected from C1-3 alkyl, C1-3 haloalkyl, halo, CN, ORa7, and NRc7Rd7; or any Rcl and Rdl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with NRc7Rd7; each R , R , R , and R is independently selected from H, C1-3 alkyl, C1-3 haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopropyl-Ci-2 alkyl-, cyclobutyl-Ci-2 alkyl-, pyridine, pyrimidine, isoxazole, azetidine, piperidine, and pyrrolidine, wherein said C1-3 alkyl, C1-3 haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopropyl-Ci-2 alkyl-, cyclobutyl-Ci-2 alkyl-, pyridine, pyrimidine, isoxazole, azetidine, piperidine, and pyrrolidine are each optionally substituted with 1 or 2 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, ORa7, and NRc7Rd7;

each R33, Rb3, Rc3, and Rd3 is independently selected from H, C1-3 alkyl, C1-3 haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopropyl-Ci-2 alkyl-, cyclobutyl-Ci-2 alkyl-, pyridine, pyrimidine, isoxazole, azetidine, piperidine, and pyrrolidine, wherein said C1-3 alkyl, C1-3 haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopropyl-Ci-2 alkyl-, cyclobutyl-Ci-2 alkyl-, pyridine, pyrimidine, isoxazole, azetidine, piperidine, and pyrrolidine are each optionally substituted with 1 or 2 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, ORa7, and NRc7Rd7;

each Ra4, Rb4, Rc4, and Rd4 is independently selected from H and C1-3 alkyl;

each Ra5, Rb5, Rc5, and Rd5 is independently selected from H or C1-3 alkyl;

each Ra6, Rb6, Rc6, and Rd6 is independently selected from H or C1-3 alkyl; and each Ra7, Rb7, Rc7, and Rd7 is independently selected from H or C1-3 alkyl.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring A is phenyl optionally substituted by 1, 2, 3, or 4 substituents independently selected from RA.

5. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein Ring A is phenyl substituted by one RA

6. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein Ring A is phenyl substituted by CN.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring B is phenyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, or 5-6 membered heteroaryl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from RB.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring B is phenyl or 5-6 membered heteroaryl, each optionally substituted by 1 , 2, 3, or 4 substituents independently selected from RB.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring B is phenyl, pyridyl, 3-oxo-3,4-dihydro-2H-l ,4-benzoxazinyl, 2,3-dihydro-l ,4-benzodioxinyl, pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, 1 ,3-benzothiazolyl, 2-oxo-2,3-dihydro-l ,3- benzoxazolyl, indazolyl, 2-oxo-2,3-dihydro[l ,3]oxazolo[4,5-b]pyridinyl, 2,3-dihydro-lH- indenyl, 2-oxo-2,3-dihydro-lH-indolyl, quinoxalinyl, 2-oxo-l ,2,3,4-tetrahydroquinolinyl, benzimidazolyl, 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][l ,4]oxazinyl, 2-oxo-2,3-dihydro-lH- pyrrolo[2,3-b]pyridinyl, or pyrimidinyl, each optionally substituted by 1 , 2, 3, or 4 substituents independently selected from RB.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring B is phenyl, pyridyl, or pyrimidinyl, each optionally substituted by 1 , 2, 3, or 4 substituents independently selected from RB.

1 1. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein Ring B is phenyl, pyridyl, 3-oxo-3,4-dihydro-2H-l ,4-benzoxazinyl, 2,3-dihydro-l ,4- benzodioxinyl, pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, 1 ,3-benzothiazolyl, 2-oxo-2,3- dihydro-l ,3-benzoxazolyl, indazolyl, 2-oxo-2,3-dihydro[l ,3]oxazolo[4,5-b]pyridinyl, 2,3- dihydro-lH-indenyl, 2-oxo-2,3-dihydro-lH-indolyl, quinoxalinyl, 2-oxo-l , 2,3,4- tetrahydroquinolinyl, benzimidazolyl, 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][l ,4]oxazinyl, 2-oxo- 2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl, or pyrimidinyl, each optionally substituted by 1 , 2, 3, or 4 substituents independently selected from Cy3, halo, Ci-6 alkyl, Ci-6 haloalkyl, ORa5, CN, NRc5C(0)ORa5, and NRc5Rd5.

12. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein Ring B is phenyl, pyridyl, or pyrimidinyl, each optionally substituted by one substituent selected from Cy3, halo, Ci-e alkyl, Ci-e haloalkyl, ORa5, and NRc5Rd5.

13. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein Ring B is phenyl, pyridyl, 3-oxo-3,4-dihydro-2H-l ,4-benzoxazinyl, 2,3-dihydro-l ,4- benzodioxinyl, pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, 1 ,3-benzothiazolyl, 2-oxo-2,3- dihydro-l ,3-benzoxazolyl, indazolyl, 2-oxo-2,3-dihydro[l ,3]oxazolo[4,5-b]pyridinyl, 2,3- dihydro-lH-indenyl, 2-oxo-2,3-dihydro-lH-indolyl, quinoxalinyl, 2-oxo-l , 2,3,4- tetrahydroquinolinyl, benzimidazolyl, 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][l ,4]oxazinyl, 2-oxo- 2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl, or pyrimidinyl, each optionally substituted by 1 , 2, 3, or 4 substituents independently selected from chloro, methyl, trifluoromethyl, piperidinyl, methoxy, ethyl, 2-oxopyrrolidinyl, methyl(tetrahydrofuran-2-ylmethyl)amino, fluoro, 2-oxo-l ,3- oxazolidinyl, amino, cyano, hydroxymethyl, (4-(methylsulfonyl)piperazin-l-yl)methyl, hydroxyl, morpholin-4-ylmethyl, (CH30)(C=0)N(CH3), (CH30)(C=0)N(CH3)-methyl, 1- hydroxy ethyl, cyanomethyl, 3-methyl-2-oxoimidazolidinyl or dimethylamino.

14. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein Ring B is phenyl, pyridyl, or pyrimidinyl, each optionally substituted by chloro, methyl, trifluoromethyl, piperidinyl, methoxy, or dimethylamino.

15. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein Ring B is phenyl substituted by methyl.

16. The compound of any one of claims 1 and 4 to 15, or a pharmaceutically acceptable salt thereof, wherein R1 is Ci-e alkyl, Cy1, ORal, SRal, C(0)NRclRdl, NRclRdl, NRclC(0)Rbl, or NRclC(0)NRclRdl wherein said Ci-6 alkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from Cy1, halo, CN, OH, ORal, SRal, C(0)Rbl, C(0)NRclRdl, C(0)ORal, OC(0)Rbl, OC(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)ORal, NRclC(0)NRclRdl,

C(=NRel)Rbl, C(=NRel)NRclRdl, NRclC(=NRel)NRclRdl, NRclS(0)Rbl, NRclS(0)2Rbl,

NRclS(0)2NRclRdl, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, and S(0)2NRclRdl.

17. The compound of any one of claims 1 and 4 to 15, or a pharmaceutically acceptable salt thereof, wherein R1 is Ci-e alkyl, Cy1, ORAL, SRAL, C(0)NRCLRDL, NRCLRDL, NRclC(0)RBL, or NRclC(0)NRCLRDL, wherein said Ci-e alkyl is optionally substituted with Cy1, OH, or ORAL.

18. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R1 is ORAL.

19. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R1 is Ci-6 alkyl substituted with 1 or 2 substituents independently selected from Cy1 or ORAL .

20. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R1 is Cy1 optionally substituted with 1 or 2 substituents independently selected from CM alkyl or NRC6RD6.

21. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R1 is pyrrolidin-3-ylmethoxy, 2-pyrrolidin-3-ylethyl, [pyrrolidin-3- yloxy]methyl, [3 -(dimethylamino)pyrrolidin- 1 -yljmethyl, [3 -(dimethylamino)pyrrolidin- 1 - yl] ethyl, (l-methylpyrrolidin-3-yl)oxy, 3-(dimethylamino)propoxy, piperidin-3-ylmethoxy, [1 , methylpyrrolidin-3-yl]methoxy, [ 1 -methylpiperidin-3-yl]methoxy, [pyrrolidin-3-ylmethyl]thio, 4-(dimethylamino)piperidin- 1 -yl, 3-(dimethylamino)propyl](methyl)amino, [2-(l - methylpyrrolidin-2-yl)ethyl]amino, ( 1 -methylpiperidin-4-yl)amino, 4-methyl- 1 ,4-diazepan- 1 -yl, 2,7-diazaspiro[4.4]non-2-yl, 2,7-diazaspiro[3.5]non-7-yl, 3-(dimethylamino)-N- methylpyrrolidine, [2-(2-amino-l ,3-thiazol-4-yl)ethyl]amino, azetidin-3-ylmethylaminocarbonyl, 3 -(dimethylamino)piperidin- 1 -yl, [1 -(2-hydroxyethyl)piperidin-3 -yljmethoxy , [ 1 -(2- cyanoethyl)piperidin-3-yl]methoxy, [l-ethylpiperidin-3-yl]methoxy, or l-methylazetidin-3- ylaminocarbonyl.

22. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R1 is pyrrolidin-3-ylmethoxy, 2-pyrrolidin-3-ylethyl, [pyrrolidin-3- yloxy]methyl, [3 -(dimethylamino)pyrrolidin- 1 -yljmethyl, [3 -(dimethylamino)pyrrolidin- 1 - yl] ethyl, (l-methylpyrrolidin-3-yl)oxy, 3-(dimethylamino)propoxy, piperidin-3-ylmethoxy, [1, methylpyrrolidin-3-yl]methoxy, [ 1 -methylpiperidin-3-yl]methoxy, [pyrrolidin-3-ylmethyl]thio, 4-(dimethylamino)piperidin- 1 -yl, 3-(dimethylamino)propyl](methyl)amino, [2-(l - methylpyrrolidin-2-yl)ethyl]amino, ( 1 -methylpiperidin-4-yl)amino, 4-methyl- 1 ,4-diazepan- 1 -yl, 2,7-diazaspiro[4.4]non-2-yl, 2,7-diazaspiro[3.5]non-7-yl, 3-(dimethylamino)-N- methylpyrrolidine, [2-(2-amino-l ,3-thiazol-4-yl)ethyl]amino, azetidin-3-ylmethylaminocarbonyl, or 1 -methylazetidin-3-ylaminocarbonyl.

23. The compound of any one of claims 1 and 4 to 18, or a pharmaceutically acceptable salt thereof, wherein each Ral is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Cy4; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy4, halo, CN, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3, C(=NRe3)Rb3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3.

24. The compound of any one of claims 1 and 4 to 18, or a pharmaceutically acceptable salt thereof, wherein each Ral is Ci-6 alkyl optionally substituted with 1 or 2 substituents

independently selected from Cy4 and NRc3Rd3.

25. The compound of any one of claims 1 and 4 to 18, or a pharmaceutically acceptable salt thereof, wherein each Ral is C1-3 alkyl optionally substituted with pyrrolidinyl, piperidinyl, or dimethylamino, wherein said pyrrolidinyl and piperidinyl are each optionally substituted with 1, 2, or 3 substituents independently selected from methyl, ethyl, cyanoethyl, and hydroxyethyl.

26. The compound of any one of claims 1 and 4 to 25, or a pharmaceutically acceptable salt thereof, wherein R2 is H, Ci-e alkyl, Ci-e haloalkyl, Cy2, or C(0)NRc2Rd2, wherein said Ci-e alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from Cy2, halo, CN, ORa2, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, OC(0)NRc2Rd2, NRc2Rd2,

NRc2C(0)Rb2, NRc2C(0)ORa2, NRc2C(0)NRc2Rd2, C(=NRe2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2.

27. The compound of any one of claims 1 and 4 to 25, or a pharmaceutically acceptable salt thereof, wherein R2 is H, Ci-e alkyl, Ci-e haloalkyl, Cy2, or C(0)NRc2Rd2, wherein said Ci-e alkyl is optionally substituted with 1 or 2 substituents independently selected from Cy2, CN, ORa2, and

NRc2Rd2

28. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R2 is H, methyl, trifluoromethyl, 4-methylphenyl, cyanomethyl,

methylaminocarbonyl, dimethylammocarbonyl, cyclopropylammocarbonyl, l-methylazetidin-3- ylaminocarbonyl, hydroxymethyl, azetidin-l-ylmethyl, cyclopropylmethylammomethyl, (isoxazol-3-ylamino)methyl, dimethylaminomethyl, or dimethylaminoethyl.

29. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R2 is H.

30. The compound of any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, wherein R3 is H.

31. The compound of any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, wherein RA is CN.

32. The compound of any one of claims 1-31 , or a pharmaceutically acceptable salt thereof, wherein each RB is independently selected from Cy3, halo, Ci-6 alkyl, Ci-6 haloalkyl, CN, NRc5C(0)ORa5, NRc5Rd5 and ORa5.

33. The compound of any one of claims 1-31 , or a pharmaceutically acceptable salt thereof, wherein each RB is independently selected from Cy3, halo, Ci-6 alkyl, Ci-6 haloalkyl, and ORa5.

34. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein RB is Ci-6 alkyl.

35. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein RB is methyl, chloro, trifluoromethyl, piperidinyl, methoxy, ethyl, 2-oxopyrrolidinyl, methyl(tetrahydrofuran-2-ylmethyl)amino, fluoro, 2-oxo-l,3-oxazolidinyl, amino, cyano, hydroxymethyl, (4-(methylsulfonyl)piperazin-l-yl)methyl, hydroxyl, morpholin-4-ylmethyl, (CH30)(C=0)N(CH3), (CH30)(C=0)N(CH3)-methyl, 1-hydroxyethyl, cyanomethyl, 3-methyl-2- oxoimidazolidinyl or dimethylamino.

36. The compound of any one of claims 1 to 31, or a pharmaceutically acceptable salt thereof, wherein RB is methyl.

37. The compound of any one of claims 1, 2, and 4 to 36, or a pharmaceutically acceptable salt thereof, wherein each Cy1 is independently selected from 5-10 membered heteroaryl and 4- 10 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from RCy.

38. The compound of any one of claims 1, 2, and 4 to 36, or a pharmaceutically acceptable salt thereof, wherein each Cy1 is independently selected from 5-10 membered heteroaryl and 4- 10 membered heterocycloalkyl, each of which is optionally substituted with 1 or 2 substituents independently selected from C1-4 alkyl and NRc6Rd6.

39. The compound of any one of claims 1, 2, and 4 to 36, or a pharmaceutically acceptable salt thereof, wherein Cy1 is 4-10 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from RCy.

40. The compound of any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein Cy1 is azetidine, piperidine, pyrrolidine, diazapane, or diazaspirononane, each optionally substituted with 1 or 2 substituents independently selected from RCy. The compound of any one of claims 1, 7 to 29, and 31 to 40, having Formula II

II

or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, or 4.

42. The compound of any one of claims 1, 7 to 29, and 31 to 41, having Formula Ila:

Ila

or a pharmaceutically acceptable salt thereof.

43. The compound of claim 41 or 42, or a pharmaceutically acceptable salt thereof, wherein group:

is selected from any one of Formulae (B-l) to (B-15):

(B-10); (B-ll); (B-12);

(B-13); (B-14); (B-15); wherein any one of the groups of Formulae (B-l) to (B-15) is optionally substituted with 1, 2, 3, or 4 substituents independently selected from RB.

44. The compound of any on 40, having Formula III:

III

or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, or 4 and wherein m is 0, 1, 2, 3, or 4.

45. The compound of any one of claims 1-3, 16-29, and 32-40, having Formula IV:

IV

harmaceutically acceptable salt thereof, wherein m is 0, 1, 2, 3, or 4.

The compound of any d 37-40, having Formula V

v

or a pharmaceutically acceptable salt thereof.

The compound of any on 37-40, having Formula VI

VI

or a pharmaceutically acceptable salt thereof.

The compound of any one of claims 1-29, and 32 to 40, having Formula VII

VII

rmaceutically acceptable salt thereof.

The compound of claim 48, or a pharmaceutically acceptable salt thereof, wherein group

ed from any one of Formulae (B-la) to (B-15a): (B-4a); (B-5a); (B-6a); (B-7a); (B-8a); (B-9a); (B-10a); 11a); (B-12a); (B-13a); (B-14a); and (B-15a); wherein any one of the groups of Formulae (B-la) to (B-15a) is optionally substituted with 1, 2, 3, or 4 substituents independently selected from RB.

50. The compound of claim 1 selected from:

4- {5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[ 1 ,2-a]pyrazin-6- yl}benzonitrile;

4-[5-(4-methylphenyl)-8-(2-pyrrolidin-3-ylethyl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile; 4-(5-(4-methylphenyl)-8-{[(3R)-pyrrolidin-3-yloxy]methyl}imidazo[l,2-a]pyrazin-6- yl)benzonitrile;

4- [8- { [(3 S)-3 -(dimethylamino)pyrrolidin- 1 -yljmethyl} -5 -(4-methylphenyl)imidazo [1,2- a]pyrazin-6-yl]benzonitrile;

4- [8- { [(3 R)-3 -(dimethylamino)pyrrolidin- 1 -yljmethyl} -5 -(4-methylphenyl)imidazo [1,2- a]pyrazin-6-yl]benzonitrile;

4-[8-{2-[(3R)-3-(dimethylamino)pyrrolidin-l-yl]ethyl}-5-(4-methylphenyl)imidazo[l,2- a]pyrazin-6-yl]benzonitrile;

4-{5-(4-methylphenyl)-8-[(l-methylpyrrolidin-3-yl)oxy]imidazo[l,2-a]pyrazin-6- yl}benzonitrile;

4-[8-[3-(dimethylamino)propoxy]-5-(4-methylphenyl)imidazo[l,2-a]pyrazin-6- yljbenzonitrile;

4- {5-(4-methylphenyl)-8-[(3R)-piperidin-3-ylmethoxy]imidazo[ 1 ,2-a]pyrazin-6- yl}benzonitrile;

4-{5-(4-methylphenyl)-8-[(3S)-piperidin-3-ylmethoxy]imidazo[l,2-a]pyrazin-6- yl}benzonitrile;

4-(5-(4-methylphenyl)-8-{[(3R)-l-methylpyrrolidin-3-yl]methoxy}imidazo[l,2- a]pyrazin-6-yl)benzonitrile;

4-(5-(4-methylphenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methoxy}imidazo[l,2-a]pyrazin- 6-yl)benzonitrile;

4-(5 -(4-methylphenyl)-8- { [(3R)-pyrrolidin-3 -ylmethyljthio } imidazo [ 1 ,2-a]pyrazin-6- yl)benzonitrile;

4- [8- [4-(dimethylamino)piperidin- 1 -yl] -5 -(4-methylphenyl)imidazo [ 1 ,2-a]pyrazin-6- yljbenzonitrile;

4- [8- [ [3 -(dimethylamino)propyl](methyl)amino] -5 -(4-methylphenyl)imidazo [1,2- a]pyrazin-6-yl]benzonitrile;

4-(5-(4-methylphenyl)-8-{[2-(l-methylpyrrolidin-2-yl)ethyl]amino}imi

a]pyrazin-6-yl)benzonitrile;

4-{5-(4-methylphenyl)-8-[(l-methylpiperidin-4-yl)amino]imidazo[l,2-a]pyraz yl}benzonitrile;

4-[8-(4-methyl- 1 ,4-diazepan-l -yl)-5-(4-methylphenyl)imidazo[ 1 ,2-a]pyrazin-6- yljbenzonitrile;

4-[8-(2,7-diazaspiro[4.4]non-2-yl)-5-(4-methylphenyl)imidazo[l,2-a]pyrazin-6- yljbenzonitrile;

4-[8-(2,7-diazaspiro[3.5]non-7-yl)-5-(4-methylphenyl)imidazo[l,2-a]pyrazin-6- yljbenzonitrile;

(3R)-N-[6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo[l,2-a]pyrazin-8-yl]-3- (dimethylamino)-N-methylpyrrolidine- 1 -carboxamide;

(3S)-N-[6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo[l,2-a]pyrazin-8-yl]-3- (dimethylamino)-N-methylpyrrolidine- 1 -carboxamide;

4-[8- {[2-(2-amino- 1 ,3-thiazol-4-yl)ethyl]amino} -5-(4-methylphenyl)imidazo[ 1 ,2- a]pyrazin-6-yl]benzonitrile;

N-(azetidin-3-ylmethyl)-6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo[l,2-a]pyrazine- 8-carboxamide;

6-(4-cyanophenyl)-N-(l-methylazetidin-3-yl)-5-(4-methylphenyl)imidazo[l,2- a]pyrazine-8-carboxamide;

4-{(5-phenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[l,2-a]pyrazin-6-yl}benzonitrile;

4-{5-(4-chlorophenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[l,2-a]pyrazin-6- yl}benzonitrile;

4- {8-[(3R)-pyrrolidin-3-ylmethoxy]-5-[4-(trifluoromethyl)phenyl]imidazo[ 1 ,2-a]pyrazin- 6-yl}benzonitrile;

4- {5-(4-piperidin- 1 -ylphenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[ 1 ,2-a]pyrazin-6- yl}benzonitrile;

4-{5-(4-methoxyphenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[l,2-a]pyrazin-6- yl}benzonitrile;

4-{5-[2-(dimethylamino)pyrimidm^

a]pyrazin-6-yl}benzonitrile;

4-(5 - [6-(dimethylamino)pyridin-3 -yl] -8- { [(3R)- 1 -methylpyrrolidin-3 - yljmethoxy } imidazo [ 1 ,2-a]pyrazin-6-yl)benzonitrile;

4- {2-methyl-5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[ 1 ,2-a]pyrazin- 6-yl}benzonitrile;

4-[5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]-2-(trifluoromethyl)im

a]pyrazin-6-yl]benzonitrile;

4- {2,5-bis(4-methylphenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[ 1 ,2-a]pyrazin-6- yl}benzonitrile;

4- {2-(cyanomethyl)-5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[ 1 ,2- a]pyrazin-6-yl}benzonitrile;

6-(4-cyanophenyl)-N-methyl-5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3- ylmethoxy]imidazo-[ 1 ,2-a]pyrazine-2-carboxamide;

6-(4-cyanophenyl)-N,N-dimethyl-5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3- ylmethoxy]imidazo[ 1 ,2-a]pyrazine-2-carboxamide;

6-(4-cyanophenyl)-N-cyclopropyl-5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3- ylmethoxy]imidazo[ 1 ,2-a]pyrazine-2-carboxamide;

6-(4-cyanophenyl)-N-(l-methylazetidin-3-yl)-5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3- ylmethoxy]imidazo[ 1 ,2-a]pyrazine-2-carboxamide;

4- {2-(hydroxymethyl)-5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[ 1 ,2- a]pyrazin-6-yl}benzonitrile;

4-{2-[(dimethylamino)methyl]-5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3- ylmethoxy]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

4-{2-(azetidin-l-ylmethyl)-5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3- ylmethoxy]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile; 4-{2-{[(cyclopropylmethyl)amino]methyl}-5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3- ylmethoxy]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

4-{2-[(isoxazol-3-ylamino)methyl]-5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3- ylmethoxy]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

4-(2-[(dimethylamino)methyl]-5-(4-methylphenyl)-8-{[(3R)-l-methylpyrrolidin-3- yl]methoxy}imidazo[l ,2-a]pyrazin-6-yl)benzonitrile; and

4-{2-[2-(dimethylamino)ethyl]-5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3- ylmethoxy]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile,

or a pharmaceutically acceptable salt of any of the aforementioned.

51. The compound of claim 1 selected from:

4-{8-{[(3R)-l-methylpiperidin-3-yl]methoxy}-5-[6-(2-oxopyrrolidin-l-yl)pyridin-3- yl]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

4-(5-(4-methyl-3-oxo-3,4-dihydro-2H-l,4-benzoxazin-7-yl)-8-{[(3R)-l-methylpiperidin- 3-yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

4-(5-(2,3-dihydro- 1 ,4-benzodioxin-6-yl)-8- {[(3R)- 1 -methylpiperidin-3 - yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

4-(5-[6-(dimethylamino)pyridin-3-yl]-8-{[(3R)-l-methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

4-(8- {[(3R)- 1 -methylpiperidin-3 -yljmethoxy} -5- {6-[methyl(tetrahydrofuran-2- ylmethyl)amino]pyridin-3-yl}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

4- [8- { [(3 R)- 1 -methylpiperidin-3 -yljmethoxy} -5 -( 1 -methyl- 1 H-pyrrolo [2,3 -b]pyridin-5 - yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4-[8- {[(3 R)-l -methylpiperidin-3 -yl]methoxy} -5 -(1 -methyl- lH-pyrazolo[3,4-b]pyridin-5- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4-(5-(l,3-benzothiazol-5-yl)-8-{[(3R)-l-methylpiperidin-3-yl]methoxy}imidazo[l,2- a]pyrazin-6-yl)benzonitrile;

4- {8- { [(3 S)-3-(dimethylamino)pyrrolidin- 1 -yljmethyl} -5-[6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

4- {8-[4-(dimethylamino)piperidin- 1 -yl]-5-[6-(2-oxopyrrolidin- 1 -yl)pyridin-3- yl]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile; 4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(l -methyl- lH-pyrazolo[3,4-b]pyridin-5- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(3-methyl-2-oxo-2,3-dihydro-l,3-benzoxazol- 6-yl)imidazo[ 1 ,2-a]pyrazin-6-yl]benzonitrile;

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(4-methyl-3-oxo-3,4-dihydro-2H-l,4- benzoxazin-7-yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4- [8- {[(3R)- 1 -ethylpiperidin-3-yl]methoxy} -5-(l -methyl- 1 H-pyrrolo [2,3 -b]pyridin-5 - yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(5-fluoro-3-methyl-2-oxo-2,3-dihydro-l,3- benzoxazol-6-yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4-[8- {[(3R)- 1 -ethylpiperidin-3-yl]methoxy} -5-(3-methyl-2-oxo-2,3-dihydro- 1 ,3- benzoxazol-6-yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4-[8-{[(3R)-l-(2-cyanoethyl)piperidin-3-yl]methoxy}-5-(3-methyl-2-oxo-2,3-dihydro- 1 ,3-benzoxazol-6-yl)imidazo[l ,2-a]pyrazin-6-yl]benzonitrile;

4-[8-{[(3R)-l-(2-hydroxyethyl)piperidin-3-yl]methoxy}-5-(l-methyl-lH-indazol-5- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(3-methyl-2-oxo-2,3-dihydro[l,3]oxazolo[4,5- b]pyridin-6-yl)imidazo[ 1 ,2-a]pyrazin-6-yl]benzonitrile;

4- {8-[4-(dimethylamino)piperidin- 1 -yl]-5-[6-(2-oxo- 1 ,3-oxazolidin-3-yl)pyridin-3- yl]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

4- {5 -(3 -amino- 1 -methyl- 1 H-indazol-5 -yl)-8- [4-(dimethylamino)piperidin- 1 - yl]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

5- (6-(4-cyanophenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methoxy}imidazo[l,2-a]pyrazin- 5 -yl)-2-methylbenzonitrile;

4-(5-[3-(hydroxymethyl)-4-methylphenyl]-8-{[(3R)-l-methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

4-(5-(4-methyl-3-{[4-(methylsulfonyl)piperazin-l-yl]methyl}phenyl)-8-{[(3R)-l- methylpiperidin-3-yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

4-(5-[4-(hydroxymethyl)-3-methylphenyl]-8-{[(3R)-l-methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile; 4-(5-(3-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[(3R)-l-methylpiperidin-3- yljmethoxy } imidazo [ 1 ,2-a]pyrazin-6-yl)benzonitrile;

4-(5-[4-(hydroxymethyl)phenyl]-8- { [(3R)- 1 -methylpiperidin-3 -yljmethoxy} imidazo [ 1 ,2- a]pyrazin-6-yl)benzonitrile;

4-{8-{[(3R)-l-methylpiperidin-3-yl]methoxy}-5-[4-(morpholin-4- ylmethyl)phenyl] imidazo [ 1 ,2-a]pyrazin-6-yl}benzonitrile;

methyl [5-(6-(4-cyanophenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methoxy}imidazo[l,2- a]pyrazin-5-yl)-2-methylphenyl]methylcarbamate;

methyl [4-(6-(4-cyanophenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methoxy}imidazo[l,2- a]pyrazin-5-yl)phenyl]methylcarbamate;

4-(5-(2-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[(3R)-l-methylpiperidin-3- yljmethoxy} imidazo [l,2-a]pyrazin-6-yl)benzonitrile;

4-(5-(7-fluoro-3-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[(3R)-l-methylpiperidin-3- yljmethoxy} imidazo [l,2-a]pyrazin-6-yl)benzonitrile;

4-(5-(l-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[(3R)-l-methylpiperidin-3- yljmethoxy} imidazo [l,2-a]pyrazin-6-yl)benzonitrile;

4-(5-[3-fluoro-4-(hydroxymethyl)-5-methylphenyl]-8-{[(3R)-l-methylpiperidin-3- yljmethoxy} imidazo [l,2-a]pyrazin-6-yl)benzonitrile;

4-(5-[3-fluoro-4-(morpholin-4-ylmethyl)phenyl]-8-{[(3R)-l-methylpiperidin-3- yljmethoxy} imidazo [l,2-a]pyrazin-6-yl)benzonitrile;

4-(5 - [3 ,5 -difluoro-4-(hydroxymethyl)phenyl] -8- { [(3R)- 1 -methylpiperidin-3 - yljmethoxy} imidazo [l,2-a]pyrazin-6-yl)benzonitrile;

4-(5-(5-fluoro-6-methoxypyridin-3-yl)-8- {[(3R)- 1 -methylpiperidin-3 - yljmethoxy} imidazo [l,2-a]pyrazin-6-yl)benzonitrile;

methyl [4-(6-(4-cyanophenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methoxy}imidazo[l,2- a]pyrazin-5-yl)-2-fluorobenzyl]methylcarbamate;

4-(5 - [4-( 1 -hydroxy ethyl)-3 -methylphenyl] -8- { [(3R)- 1 -methylpiperidin-3 - yljmethoxy} imidazo [l,2-a]pyrazin-6-yl)benzonitrile;

4-(5 - [3 -( 1 -hydroxy ethyl)-4-methylphenyl] -8- { [(3R)- 1 -methylpiperidin-3 - yljmethoxy} imidazo [l,2-a]pyrazin-6-yl)benzonitrile; 4-(5-(7-fluoro- 1 -hydroxy-2,3-dihydro- lH-inden-5-yl)-8- {[(3R)- 1 -methylpiperidin-3 - yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

4-(5-[2-fluoro-4-(morpholin-4-ylmethyl)phenyl]-8-{[(3R)-l-methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

4-(5-[2-(hydroxymethyl)-4-methylphenyl]-8-{[(3R)-l-methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

4-(5 - [3 -(cyanomethyl)-4-methylphenyl] -8- { [(3R)- 1 -methylpiperidin-3 - yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

4- [8- [4-(dimethylamino)piperidin- 1 -yl] -5 -(5 ,6-dimethylpyridin-3 -yl)imidazo [ 1 ,2- a]pyrazin-6-yl]benzonitrile;

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(2-hydroxy-2,3-dihydro-lH-inden-5- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4-[8-[4-(dimethylamino)piperidin- 1 -yl]-5-(5-hydroxy-6-methylpyridin-3-yl)imidazo[ 1 ,2- a]pyrazin-6-yl]benzonitrile;

4- [8- [4-(dimethylamino)piperidin- 1 -yl] -5 -(3 -hydroxy-2,3 -dihydro- 1 H-inden-5 - yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4- {8-[4-(dimethylamino)piperidin- 1 -yl]-5-[3-(hydroxymethyl)-4- methylphenyl]imidazo[l,2-a]pyrazin-6-yl}benzonitrile;

4- {8-[4-(dimethylamino)piperidin- 1 -yl]-5-[3-fluoro-4-(hydroxymethyl)-5- methylphenyl]imidazo[l,2-a]pyrazin-6-yl}benzonitrile;

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(l-methyl-2-oxo-2,3-dihydro-lH-indol-5- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4- {8-[3-(dimethylamino)piperidin- 1 -yl]-5-[6-(2-oxopyrrolidin- 1 -yl)pyridin-3- yl]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

4-{8-[4-(dimethylamino)piperidin-l-yl]-5-[6-(3-methyl-2-oxoimidazolidin-l-yl)pyridin- 3-yl]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

4- {8-[4-(dimethylamino)piperidin- 1 -yl]-5-quinoxalin-6-ylimidazo[ 1 ,2-a]pyrazin-6- yl}benzonitrile;

4- [8- [4-(dimethylamino)piperidin- 1 -yl] -5 -( 1 -methyl-2-oxo- 1 ,2,3 ,4-tetrahydroquinolin-6- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile; 4- {8-[4-(dimethylamino)piperidin- 1 -yl]-5-[2-(hydroxymethyl)- 1 -methyl- lH-pyrrolo[2,3- b]pyridin-5-yl]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

4- {8-[(3S)-3-(dimethylamino)pyrrolidin- 1 -yl]-5-[6-(2-oxopyrrolidin- 1 -yl)pyridin-3- yl]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(3-ethyl-2-oxo-2,3-dihydro[l,3]oxazolo[4,5- b]pyridin-6-yl)imidazo[ 1 ,2-a]pyrazin-6-yl]benzonitrile;

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(l -methyl- lH-benzimidazol-5-yl)imidazo[l, 2- a] pyrazin-6-yl]benzonitrile;

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(4-methyl-3-oxo-3,4-dihydro-2H-pyrido[3,2- b] [ 1 ,4]oxazin-7-yl)imidazo [ 1 ,2-a]pyrazin-6-yl]benzonitrile;

4- [8- [4-(dimethylamino)piperidin- 1 -yl] -5 -( 1 -methyl-2-oxo- 1 ,2,3 ,4-tetrahydroquinolin-7- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4- {8-[4-(dimethylamino)piperidin- 1 -yl]-5-[6-(4-methyl-3-oxopiperazin- 1 -yl)pyridin-3- yl]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

4- {8-[4-(dimethylamino)piperidin- 1 -yl]-5-[3-(hydroxymethyl)- 1 -methyl- lH-indazol-5- yl]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile;

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(l-methyl-2-oxo-2,3-dihydro-lH-pyrrolo[2,3- b]pyridin-5-yl)imidazo[ 1 ,2-a]pyrazin-6-yl]benzonitrile;

4- [8- [4-(dimethylamino)piperidin- 1 -yl] -5 -( 1 -methyl- 1 H-pyrrolo [2,3 -b]pyridin-5 - yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4-(8- [4-(dimethylamino)piperidin- 1 -yl]-5 - {2- [( 1 R)- 1 -hydroxy ethyl]- 1 -methyl- 1 H- benzimidazol-5-yl}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

4-(8- [4-(dimethylamino)piperidin- 1 -yl]-5 - {2- [( 1 S)- 1 -hydroxy ethyl] - 1 -methyl- 1 H- benzimidazol-5-yl}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(l,2-dimethyl-lH-benzimidazol-5- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile;

4- [8- [4-(dimethylamino)piperidin- 1 -yl] -5 -(5 -methoxy-6-methylpyridin-3 -yl)imidazo [1,2- a]pyrazin-6-yl]benzonitrile;

5- (6-(4-cyanophenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methoxy}imidazo[l,2-a]pyrazin- 5-yl)-2-methylnicotinonitrile; 4- [8- [4-(dimethylamino)piperidin- 1 -yl] -5 -(5 -hydroxy-6-methoxypyridin-3 - yl)imidazo[ 1 ,2-a]pyrazin-6-yl]benzonitrile; and

4-(5 -(5 -hydroxy-6-methoxypyridin-3 -yl)-8- { [(3R)- 1 -methylpiperidin-3 - yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile;

or a pharmaceutically acceptable salt thereof.

52. A pharmaceutical composition comprising a compound of any one of claims 1 to 51, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

53. A method of inhibiting LSD1 comprising contacting a compound of any one of claims 1 to 50, or a pharmaceutically acceptable salt thereof, with said LSD1.

54. A method of treating a disease comprising administering to a patient a therapeutically effective amount of a compound of any one of claims 1 to 51 , or a pharmaceutically acceptable salt thereof, wherein said disease is cancer.

55. The method of claim 54 wherein said cancer is a hematological cancer.

56. The method of claim 54 wherein said hematological cancer is selected from acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma, Hodgkin lymphoma, primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET), myelodysplasia syndrome (MDS), or multiple myeloma.

57. The method of claim 54 wherein said cancer is a sarcoma, lung cancer, gastrointestinal cancer, genitourinary tract cancer, liver cancer, bone cancer, nervous system cancer, gynecological cancer, or skin cancer.

58. A method of treating a disease comprising administering to a patient a therapeutically effective amount of a compound of any one of claims 1 to 51 , or a pharmaceutically acceptable salt thereof, wherein said disease is a viral disease or a beta-globinopathy.

Description:
IMIDAZOPYRAZINES AS LSD1 INHIBITORS

FIELD OF THE INVENTION

The present invention is directed to imidazo[l,2-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer. BACKGROUND OF THE INVENTION

Epigenetic modifications can impact genetic variation but, when dysregulated, can also contribute to the development of various diseases (Portela, A. and M. Esteller, Epigenetic modifications and human disease. Nat Biotechnol, 2010. 28(10): p. 1057-68; Lund, A.H. and M. van Lohuizen, Epigenetics and cancer. Genes Dev, 2004. 18(19): p. 2315-35). Recently, in depth cancer genomics studies have discovered many epigenetic regulatory genes are often mutated or their own expression is abnormal in a variety of cancers (Dawson, M.A. and T.

Kouzarides, Cancer epigenetics: from mechanism to therapy. Cell, 2012. 150(1): p. 12-27;

Waldmann, T. and R. Schneider, Targeting histone modifications— epigenetics in cancer. Curr Opin Cell Biol, 2013. 25(2): p. 184-9; Shen, H. and P.W. Laird, Interplay between the cancer genome and epigenome. Cell, 2013. 153(1): p. 38-55). This implies epigenetic regulators function as cancer drivers or are permissive for tumorigenesis or disease progression. Therefore, deregulated epigenetic regulators are attractive therapeutic targets.

One particular enzyme which is associated with human diseases is lysine specific demethylase-1 (LSD1), the first discovered histone demethylase (Shi, Y., et al, Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell, 2004. 119(7): p. 941-53). It consists of three major domains: the N-terminal SWIRM which functions in nucleosome targeting, the tower domain which is involved in protein-protein interaction, such as transcriptional co-repressor, co-repressor of RE 1 -silencing transcription factor (CoREST), and lastly the C terminal catalytic domain whose sequence and structure share homology with the flavin adenine dinucleotide (FAD)-dependent monoamine oxidases (i.e., MAO-A and MAO-B) (Forneris, F., et al, Structural basis of LSD 1 -CoREST selectivity in histone H3 recognition. J Biol Chem, 2007. 282(28): p. 20070-4; Anand, R. and R. Marmorstein, Structure and mechanism oflysine-specific demethylase enzymes. J Biol Chem, 2007. 282(49): p. 35425-9; Stavropoulos, P., G. Blobel, and A. Hoelz, Crystal structure and mechanism of human lysine-specific demethylase- 1. Nat Struct Mol Biol, 2006. 13(7): p. 626-32; Chen, Y., et al, Crystal structure of human histone lysine-specific demethylase 1 (LSDl). Proc Natl Acad Sci U S A, 2006. 103(38): p. 13956-61). LSDl also shares a fair degree of homology with another lysine specific demethylase (LSD2) (Karytinos, A., et al., A novel mammalian flavin-dependent histone demethylase. J Biol Chem, 2009. 284(26): p. 17775-82). Although the biochemical mechanism of action is conserved in two isoforms, the substrate specificities are thought to be distinct with relatively small overlap. The enzymatic reactions of LSDl and LSD2 are dependent on the redox process of FAD and the requirement of a protonated nitrogen in the methylated lysine is thought to limit the activity of LSD 1/2 to mono- and di-methylated lysines at the position of 4 or 9 of histone 3 (H3K4 or H3K9). These mechanisms make LSD 1/2 distinct from other histone demethylase families (i.e. Jumonji domain containing family) that can demethylate mono-, di-, and tri-methylated lysines through alpha-ketoglutarate dependent reactions (Kooistra, S.M. and K. Helin, Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol, 2012. 13(5): p. 297-311; Mosammaparast, N. and Y. Shi, Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem, 2010. 79: p. 155-79).

Methylated histone marks on H3K4 and H3K9 are generally coupled with transcriptional activation and repression, respectively. As part of corepressor complexes (e.g., CoREST), LSDl has been reported to demethylate H3K4 and repress transcription, whereas LSDl, in nuclear hormone receptor complex (e.g., androgen receptor), may demethylate H3K9 to activate gene expression (Metzger, E., et al., LSDl demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature, 2005. 437(7057): p. 436-9; Kahl, P., et al., Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res, 2006. 66(23): p. 11341- 7). This suggests the substrate specificity of LSDl can be determined by associated factors, thereby regulating alternative gene expressions in a context dependent manner. In addition to histone proteins, LSDl may demethylate non-histone proteins. These include p53 (Huang, J., et dX., p53 is regulated by the lysine demethylase LSDl. Nature, 2007. 449(7158): p. 105-8.), E2F (Kontaki, H. and I. Talianidis, Lysine methylation regulates E2Fl-induced cell death. Mol Cell,

2010. 39(1): p. 152-60), STAT3 (Yang, J., et al., Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci U S A, 2010. 107(50): p. 21499-504), Tat (Sakane, N., et al., Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase I (LSD1/KDM1). PLoS Pathog,

2011. 7(8): p. el002184), and myosin phosphatase target subunit 1 (MYPT1) (Cho, H.S., et al, Demethylation ofRB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res, 2011. 71(3): p. 655-60). The lists of non-histone substrates are growing with technical advances in functional proteomics studies. These suggest additional oncogenic roles of LSD 1 beyond regulating chromatin remodeling. LSD1 also associates with other epigenetic regulators, such as DNA methyltransferase 1 (DNMTl) (Wang, J., et al., The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet, 2009. 41(1): p. 125-9) and histone deacetylases (HDACs) complexes (Hakimi, M.A., et al., A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc Natl Acad Sci U S A, 2002. 99(11): p. 7420-5; Lee, M.G., et al, Functional interplay between histone demethylase and deacetylase enzymes. Mol Cell Biol, 2006. 26(17): p. 6395-402; You, A., et al, CoREST is an integral component of the CoREST- human histone deacetylase complex. Proc Natl Acad Sci U S A, 2001. 98(4): p. 1454- 8). These associations augment the activities of DNMT or HDACs. LSD1 inhibitors may therefore potentiate the effects of HDAC or DNMT inhibitors. Indeed, preclinical studies have shown such potential already (Singh, M.M., et al, Inhibition of LSD I sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro Oncol, 2011. 13(8): p. 894-903; Han, H., et al, Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSDI in cancer cells. PLoS One, 2013. 8(9): p. e75136).

LSDI has been reported to contribute to a variety of biological processes, including cell proliferation, epithelial-mesenchymal transition (EMT), and stem cell biology (both embryonic stem cells and cancer stem cells) or self-renewal and cellular transformation of somatic cells (Chen, Y., et al., Lysine-specific histone demethylase I (LSDI): A potential molecular target for tumor therapy. Crit Rev Eukaryot Gene Expr, 2012. 22(1): p. 53-9; Sun, G., et al, Histone demethylase LSDI regulates neural stem cell proliferation. Mol Cell Biol, 2010. 30(8): p. 1997- 2005; Adamo, A., M.J. Barrero, and J.C. Izpisua Belmonte, LSDI and pluripotency: a new player in the network. Cell Cycle, 2011. 10(19): p. 3215-6; Adamo, A., et al, LSDl regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nat Cell Biol, 2011. 13(6): p. 652-9). In particular, cancer stem cells or cancer initiating cells have some pluripotent stem cell properties that contribute to the heterogeneity of cancer cells. This feature may render cancer cells more resistant to conventional therapies, such as chemotherapy or radiotherapy, and then develop recurrence after treatment (Clevers, H., The cancer stem cell: premises, promises and challenges. Nat Med, 2011. 17(3): p. 313-9; Beck, B. and C. Blanpain, Unravelling cancer stem cell potential. Nat Rev Cancer, 2013. 13(10): p. 727-38). LSDl was reported to maintain an undifferentiated tumor initiating or cancer stem cell phenotype in a spectrum of cancers (Zhang, X., et al., Pluripotent Stem Cell Protein Sox2 Confers Sensitivity to LSDl Inhibition in Cancer Cells. Cell Rep, 2013. 5(2): p. 445-57; Wang, J., et al, Novel histone demethylase LSDl inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res, 2011. 71(23): p. 7238-49). Acute myeloid leukemias (AMLs) are an example of neoplastic cells that retain some of their less differentiated stem cell like phenotype or leukemia stem cell (LSC) potential. Analysis of AML cells including gene expression arrays and chromatin immunoprecipitation with next generation sequencing (ChlP-Seq) revealed that LSDl may regulate a subset of genes involved in multiple oncogenic programs to maintain LSC (Harris, W.J., et al., The histone demethylase KDM1A sustains the oncogenic potential ofMLL- AF9 leukemia stem cells. Cancer Cell, 2012. 21(4): p. 473-87; Schenk, T., et al, Inhibition of the LSDl (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med, 2012. 18(4): p. 605-11). These findings suggest potential therapeutic benefit of LSDl inhibitors targeting cancers having stem cell properties, such as AMLs.

Overexpression of LSDl is frequently observed in many types of cancers, including bladder cancer, NSCLC, breast carcinomas, ovary cancer, glioma, colorectal cancer, sarcoma including chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma, neuroblastoma, prostate cancer, esophageal squamous cell carcinoma, and papillary thyroid carcinoma. Notably, studies found over-expression of LSDl was significantly associated with clinically aggressive cancers, for example, recurrent prostate cancer, NSCLC, glioma, breast, colon cancer, ovary cancer, esophageal squamous cell carcinoma, and neuroblastoma. In these studies, either knockdown of LSDl expression or treatment with small molecular inhibitors of LSD1 resulted in decreased cancer cell proliferation and/or induction of apoptosis. See, e.g., Hayami, S., et al, Over expression of LSD 1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer, 2011. 128(3): p. 574-86; Lv, T., et al., Over-expression of LSD 1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One, 2012. 7(4): p. e35065; Serce, N., et al, Elevated expression ofLSDl (Lysine- specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin Pathol, 2012. 12: p. 13; Lim, S., et al., Lysine-specific demethylase 1 (LSD I) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis, 2010. 31(3): p. 512-20; Konovalov, S. and I. Garcia-Bassets, Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines. J Ovarian Res, 2013. 6(1): p. 75; Sareddy, G.R., et al, KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget, 2013. 4(1): p. 18-28; Ding, J., et al., LSD 1 -mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. Br J Cancer, 2013. 109(4): p. 994-1003; Bennani-Baiti, I.M., et al, Lysine-specific demethylase 1

(LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in

chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol, 2012. 43(8): p. 1300-7; Schulte, J.H., et al., Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res, 2009. 69(5): p. 2065- 71; Crea, F., et al., The emerging role of histone lysine demethylases in prostate cancer. Mol Cancer, 2012. 11 : p. 52; Suikki, H.E., et al., Genetic alterations and changes in expression of histone demethylases in prostate cancer. Prostate, 2010. 70(8): p. 889-98; Yu, Y., et al., High expression of lysine-specific demethylase I correlates with poor prognosis of patients with esophageal squamous cell carcinoma. Biochem Biophys Res Comrnun, 2013. 437(2): p. 192-8; Kong, L., et al., Immunohistochemical expression ofRBP2 and LSD1 in papillary thyroid carcinoma. Rom J Morphol Embryol, 2013. 54(3): p. 499-503.

Recently, the induction of CD86 expression by inhibiting LSD1 activity was reported (Lynch, J.T., et al., CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1. Anal Biochem, 2013. 442(1): p. 104-6). CD86 expression is a marker of maturation of dendritic cells (DCs) which are involved in antitumor immune response. Notably, CD86 functions as a co-stimulatory factor to activate T cell proliferation (Greaves, P. and J.G. Gribben, The role of B7 family molecules in hematologic malignancy. Blood, 2013. 121(5): p. 734-44; Chen, L. and D.B. Flies, Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol, 2013. 13(4): p. 227- 42).

In addition to playing a role in cancer, LSD1 activity has also been associated with viral pathogenesis. Particularly, LSD1 activity appears to be linked with viral replications and expressions of viral genes. For example, LSD1 functions as a co-activator to induce gene expression from the viral immediate early genes of various type of herpes virus including herpes simplex virus (HSV), varicella zoster virus (VZV), and β-herpesvirus human cytomegalovirus (Liang, Y., et al., Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency. Sci Transl Med, 2013. 5(167): p. 167ra5; Liang, Y., et al., Inhibition of the histone demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency. Nat Med, 2009. 15(11): p. 1312-7). In this setting, a LSD1 inhibitor showed antiviral activity by blocking viral replication and altering virus associated gene expression.

Recent studies have also shown that the inhibition of LSD 1 by either genetic depletion or pharmacological intervention increased fetal globin gene expression in erythroid cells (Shi, L., et al., Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nat Med, 2013. 19(3): p. 291-4; Xu, J., et al., Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. Proc Natl Acad Sci U S A, 2013. 110(16): p. 6518-23). Inducing fetal globin gene would be potentially therapeutically beneficial for the disease of β-globinopathies, including β-thalassemia and sickle cell disease where the production of normal β-globin, a component of adult hemoglobin, is impaired (Sankaran, V.G. and S.H. Orkin, The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med, 2013. 3(1): p. aOl 1643; Bauer, D.E., S.C. Kamran, and S.H. Orkin, Reawakening fetal hemoglobin: prospects for new therapies for the beta-globin disorders. Blood, 2012. 120(15): p. 2945-53). Moreover, LSD1 inhibition may potentiate other clinically used therapies, such as hydroxyurea or azacitidine. These agents may act, at least in part, by increasing γ-globin gene expression through different mechanisms.

In summary, LSD1 contributes to tumor development by altering epigenetic marks on histones and non-histone proteins. Accumulating data have validated that either genetic depletion or pharmacological intervention of LSD 1 normalizes altered gene expressions, thereby inducing differentiation programs into mature cell types, decreasing cell proliferation, and promoting apoptosis in cancer cells. Therefore, LSDl inhibitors alone or in combination with established therapeutic drugs would be effective to treat the diseases associated with LSDl activity.

SUMMARY OF THE INVENTION

The present invention is directed to, inter alia, a compound of Formula I:

I

or a pharmaceutically acceptable salt thereof, wherein constituent variables are defined herein.

The present invention is further directed to a pharmaceutical composition comprising a compound of Formula I and at least one pharmaceutically acceptable carrier.

The present invention is further directed to a method of inhibiting LSDl comprising contacting the LSDl with a compound of Formula I.

The present invention is further directed to a method of treating an LSDl -mediated disease in a patient comprising administering to the patient a therapeutically effective amount of a compound of Formula I.

DETAILED DESCRIPTION

The present invention provides, inter alia, LSDl -inhibiting compounds such as a compound of Formula I:

I

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is C 6 -io aryl or 5-10 membered heteroaryl comprising (or having) carbon and 1, 2, 3, or 4 heteroatoms selected from N, O, and S, wherein said C 6 -io aryl and 5-10 membered heteroaryl are each optionally substituted by 1, 2, 3, or 4 substituents independently selected from R A ;

Ring B is C 6 -io aryl; 5-10 membered heteroaryl comprising (or having) carbon and 1, 2, 3 or 4 heteroatoms selected from N, O, and S; C3-10 cycloalkyl; or 4-10 membered heterocycloalkyl comprising (or having) carbon and 1, 2, 3 or 4 heteroatoms selected from N, O, and S; wherein said C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 substituents independently selected from R B ;

R 1 is halo, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Cy 1 , CN, OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)OR al , OC(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl ,

NR cl C(0)OR al , NR cl C(0)NR cl R dl , C(=NR el )R bl , C(=NR el )NR cl R dl , NR cl C(=NR el )NR cl R dl , NR cl S(0)R bl , NR cl S(0) 2 R bl , NR cl S(0) 2 NR cl R dl , S(0)R bl , S(0)NR cl R dl , S(0) 2 R bl , or

S(0) 2 NR cl R dl ; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy 1 , halo, CN, OH, OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)OR al , OC(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)OR al , NR cl C(0)NR cl R dl , C(=NR el )R bl , C(=NR el )NR cl R dl , NR cl C(=NR el )NR cl R dl , NR cl S(0)R bl , NR cl S(0) 2 R bl , NR cl S(0) 2 NR cl R dl , S(0)R bl , S(0)NR cl R dl , S(0) 2 R bl , and

S(0) 2 NR cl R dl ;

R 2 and R 3 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Cy 2 , CN, OR a2 , SR a2 , C(0)R b2 , C(0)NR c2 R d2 , C(0)OR a2 , OC(0)R b2 , OC(0)NR c2 R d2 , NR c2 R d2 , NR c2 C(0)R b2 , NR c2 C(0)OR a2 , NR c2 C(0)NR c2 R d2 , C(=NR e2 )R b2 , C(=NR e2 )NR c2 R d2 , NR c2 C(=NR e2 )NR c2 R d2 , NR c2 S(0)R b2 , NR c2 S(0) 2 R b2 , NR c2 S(0) 2 NR c2 R d2 , S(0)R b2 , S(0)NR c2 R d2 , S(0) 2 R b2 , and S(0) 2 NR c2 R d2 ; wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy 2 , halo, CN, OR a2 , SR a2 , C(0)R b2 , C(0)NR c2 R d2 , C(0)OR a2 , OC(0)R b2 , OC(0)NR c2 R d2 , NR c2 R d2 , NR c2 C(0)R b2 , NR c2 C(0)OR a2 , NR c2 C(0)NR c2 R d2 , C(=NR e2 )R b2 , C(=NR e2 )NR c2 R d2 , NR c2 C(=NR e2 )NR c2 R d2 , NR c2 S(0)R b2 , NR c2 S(0) 2 R b2 , NR c2 S(0) 2 NR c2 R d2 , S(0)R b2 ,

S(0)NR c2 R d2 , S(0) 2 R b2 , and S(0) 2 NR c2 R d2 ; each R A is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, NO2, OR a4 , SR a4 , C(0)R b4 , C(0)NR c4 R d4 , C(0)OR a4 , OC(0)R b4 , OC(0)NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R b4 , NR c4 C(0)OR a4 , NR c4 C(0)NR c4 R d4 , C(=NR e4 )R b4 , C(=NR e4 )NR c4 R d4 , NR c4 C(=NR e4 )NR c4 R d4 , NR c4 S(0)R b4 , NR c4 S(0) 2 R M , NR c4 S(0) 2 NR c4 R d4 , S(0)R b4 ,

S(0)NR c4 R d4 , S(0) 2 R M , and S(0) 2 NR c4 R d4 , wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1 , 2, or 3, substituents independently selected from halo, Ci-e haloalkyl, CN, NO2, OR a4 , SR a4 , C(0)R b4 , C(0)NR c4 R d4 , C(0)OR a4 , OC(0)R b4 , OC(0)NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R b4 , NR c4 C(0)OR a4 , NR c4 C(0)NR c4 R d4 , C(=NR e4 )R b4 , C(=NR e4 )NR c4 R d4 , NR c4 C(=NR e4 )NR c4 R d4 , NR c4 S(0)R b4 , NR c4 S(0) 2 R b4 , NR c4 S(0) 2 NR c4 R d4 , S(0)R b4 , S(0)NR c4 R d4 , S(0) 2 R M , and S(0) 2 NR c4 R d4 ;

each R B is independently selected from Cy 3 , halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, CN, NO2, OR a5 , SR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)OR a5 , OC(0)R b5 ,

OC(0)NR c5 R d5 , NR c5 R d5 , NR c5 C(0)R b5 , NR c5 C(0)OR a5 , NR c5 C(0)NR c5 R d5 , C(=NR e5 )R b5 , C(=NR e5 )NR c5 R d5 , NR c5 C(=NR e5 )NR c5 R d5 , NR c5 S(0)R b5 , NR c5 S(0) 2 R b5 , NR c5 S(0) 2 NR c5 R d5 , S(0)R b5 , S(0)NR c5 R d5 , S(0) 2 R b5 , and S(0) 2 NR c5 R d5 , wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1 , 2, or 3 substituents independently selected from Cy 3 , halo, Ci-e haloalkyl, CN, NO2, OR a5 , SR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)OR a5 , OC(0)R b5 , OC(0)NR c5 R d5 , NR c5 R d5 , NR c5 C(0)R b5 , NR c5 C(0)OR a5 , NR c5 C(0)NR c5 R d5 , C(=NR e5 )R b5 , C(=NR e5 )NR c5 R d5 , NR c5 C(=NR e5 )NR c5 R d5 , NR c5 S(0)R b5 , NR c5 S(0) 2 R b5 , NR c5 S(0) 2 NR c5 R d5 , S(0)R b5 , S(0)NR c5 R d5 , S(0) 2 R b5 , and S(0) 2 NR c5 R d5 ;

each Cy 1 , Cy 2 , Cy 3 , and Cy 4 is independently selected from C 6 -io aryl, C3-10 cycloalkyl, 5- 10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each of which is optionally substituted with 1 , 2, 3, or 4 substituents independently selected from R Cy ;

each R Cy is independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, and (4-7 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, OR a6 , SR a6 , C(0)R b6 , C(0)NR c6 R d6 , C(0)OR a6 , OC(0)R b6 , OC(0)NR c6 R d6 , C(=NR e6 )NR c6 R d6 ,

NR c6 C(=NR e6 )NR c6 R d6 , NR c6 R d6 , NR c6 C(0)R b6 , NR c6 C(0)OR a6 , NR c6 C(0)NR c6 R d6 ,

NR c6 S(0)R b6 , NR c6 S(0) 2 R b6 , NR c6 S(0) 2 NR c6 R d6 , S(0)R b6 , S(0)NR c6 R d6 , S(0) 2 R b6 , and

S(0)2NR c6 R d6 , wherein said Ci-4 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, and (4-7 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted by 1, 2, or 3 substituents independently selected from Ci-6 alkyl, Ci- 4 haloalkyl, Ci-e cyanoalkyl, halo, CN, NO2, OR a6 , SR a6 , C(0)R b6 , C(0)NR c6 R d6 , C(0)OR a6 , OC(0)R b6 , OC(0)NR c6 R d6 , C(=NR e6 )NR c6 R d6 , NR c6 C(=NR e6 )NR c6 R d6 , NR c6 R d6 , NR c6 C(0)R b6 , NR c6 C(0)OR a6 , NR c6 C(0)NR c6 R d6 , NR c6 S(0)R b6 , NR c6 S(0) 2 R b6 , NR c6 S(0) 2 NR c6 R d6 , S(0)R b6 , S(0)NR c6 R d6 , S(0) 2 R b6 , and S(0) 2 NR c6 R d6 ;

each R al is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Cy 4 ; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy 4 , halo, CN, OR a3 , SR a3 , C(0)R b3 , C(0)NR c3 R d3 , C(0)OR a3 , OC(0)R b3 , OC(0)NR c3 R d3 , NR c3 R d3 , NR c3 C(0)R b3 , NR c3 C(0)OR a3 ,

NR c3 C(0)NR c3 R d3 , C(=NR e3 )R b3 , C(=NR e3 )NR c3 R d3 , NR c3 C(=NR e3 )NR c3 R d3 , NR c3 S(0)R b3 , NR c3 S(0) 2 R b3 , NR c3 S(0) 2 NR c3 R d3 , S(0)R b3 , S(0)NR c3 R d3 , S(0) 2 R b3 , and S(0) 2 NR c3 R d3 ;

each R bl , R cl , and R dl is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ;

or any R cl and R dl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6 -io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 ,

NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 ,

NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 , wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C 6 -io aryl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 ,

NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ;

each R a2 , R b2 , R c2 , and R d2 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ;

or any R c2 and R d2 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 ,

C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 ,

NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 , wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 ,

NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ; each R , R , R , and R is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ;

or any R c3 and R d3 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 ,

C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 ,

NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 , wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 ,

NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ;

each R a4 , R b4 , R c4 , and R d4 is independently selected from H, Ci-e alkyl, Ci-4 haloalkyl,

C2-6 alkenyl, and C2-6 alkynyl, wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci- 4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 ,

OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 ,

C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ; or any R and R together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-e alkyl, Ci-e haloalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 ,

C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 ,

NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ;

each R a5 , R b5 , R c5 , and R d5 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ;

or any R c5 and R d5 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6 -io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 ,

NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 , wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C 6 -io aryl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 ,

NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ; each R a6 , R b6 , R c6 , and R d6 is independently selected from H, Ci-e alkyl, Ci-4 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1 , 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci- 4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 ,

OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 ,

C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ;

or any R c6 and R d6 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1 , 2, or 3 substituents independently selected from Ci-e alkyl, Ci-e haloalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 ,

C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 ,

NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ;

each R a7 , R b7 , R c7 , and R d7 is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein said C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl are each optionally substituted with 1 , 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(Ci-4 alkyl)amino, C1-4 haloalkyl, and Ci-4 haloalkoxy; and

each R el , R e2 , R e3 , R e4 , R e5 , R e6 , and R e7 is independently selected from H, Ci-4 alkyl, and CN.

In some embodiments:

Ring A is phenyl optionally substituted by 1 , 2, or 3 substituents independently selected from R A ;

Ring B is phenyl or 5-6 membered heteroaryl comprising (or having) carbon and 1 or 2 heteroatoms selected from N; wherein said phenyl or 5-6 membered heteroaryl is optionally substituted by 1 , or 2 substituents independently selected from R B ;

R 1 is halo, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Cy 1 , CN, OR al , SR al ,

C(0)R bl , C(0)NR cl R dl , C(0)OR al , OC(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl ,

NR cl C(0)OR al , NR cl C(0)NR cl R dl , NR cl S(0)R bl , NR cl S(0) 2 R bl , NR cl S(0) 2 NR cl R dl , S(0)R bl ,

S(0)NR cl R dl , S(0) 2 R bl , or S(0) 2 NR cl R dl ; wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy 1 , halo, CN, OH, OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)OR al , OC(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)OR al , NR cl C(0)NR cl R dl , NR cl S(0)R bl , NR cl S(0) 2 R bl ,

NR cl S(0) 2 NR cl R dl , S(0)R bl , S(0)NR cl R dl , S(0) 2 R bl , and S(0) 2 NR cl R dl ;

R 2 is H, halo, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, Cy 2 , CN, OR a2 , SR a2 ,

C(0)R b2 , C(0)NR c2 R d2 , C(0)OR a2 , OC(0)R b2 , OC(0)NR c2 R d2 , NR c2 R d2 , NR c2 C(0)R b2 ,

NR c2 C(0)OR a2 , NR c2 C(0)NR c2 R d2 , NR c2 S(0)R b2 , NR c2 S(0) 2 R b2 , NR c2 S(0) 2 NR c2 R d2 , S(0)R b2 , S(0)NR c2 R d2 , S(0) 2 R b2 , or S(0) 2 NR c2 R d2 ; wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy 2 , halo, CN, OR a2 , SR a2 , C(0)R b2 , C(0)NR c2 R d2 , C(0)OR a2 , OC(0)R b2 , OC(0)NR c2 R d2 , NR c2 R d2 , NR c2 C(0)R b2 , NR c2 C(0)OR a2 , NR c2 C(0)NR c2 R d2 , NR c2 S(0)R b2 , NR c2 S(0) 2 R b2 ,

NR c2 S(0) 2 NR c2 R d2 , S(0)R b2 , S(0)NR c2 R d2 , S(0) 2 R b2 , and S(0) 2 NR c2 R d2 ;

R 3 is H;

each R A is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, OR a4 , SR a4 , C(0)R b4 , C(0)NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R b4 , NR c4 S(0) 2 R b4 ,

S(0)R b4 , S(0)NR c4 R d4 , S(0) 2 R b4 , and S(0) 2 NR c4 R d4 , wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, or 3, substituents independently selected from halo, Ci-e haloalkyl, CN, OR a4 , SR a4 , C(0)R b4 , C(0)NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R b4 , NR c4 S(0) 2 R M , S(0)R b4 , S(0)NR c4 R d4 , S(0) 2 R M , and S(0) 2 NR c4 R d4 ;

each R B is independently selected from Cy 3 , halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,

Ci-e haloalkyl, CN, OR a5 , SR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)OR a5 , OC(0)R b5 , OC(0)NR c5 R d5 , NR c5 R d5 , NR c5 C(0)R b5 , NR c5 C(0)OR a5 , NR c5 C(0)NR c5 R d5 , NR c5 S(0)R b5 , NR c5 S(0) 2 R b5 , NR c5 S(0) 2 NR c5 R d5 , S(0)R b5 , S(0)NR c5 R d5 , S(0) 2 R b5 , and S(0) 2 NR c5 R d5 , wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, or 3 substituents independently selected from Cy 3 , halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, OR a5 , SR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)OR a5 , OC(0)R b5 , OC(0)NR c5 R d5 , NR c5 R d5 ,

NR c5 C(0)R b5 , NR c5 C(0)OR a5 , NR c5 C(0)NR c5 R d5 , NR c5 S(0)R b5 , NR c5 S(0) 2 R b5 ,

NR c5 S(0) 2 NR c5 R d5 , S(0)R b5 , S(0)NR c5 R d5 , S(0) 2 R b5 , and S(0) 2 NR c5 R d5 ;

each Cy 1 , Cy 2 , Cy 3 , and Cy 4 is independently selected from C 6 -io aryl, C3-10 cycloalkyl, 5- 10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R Cy ; each R Cy is selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, and (4-7 membered heterocycloalkyl)-Ci- 4 alkyl-, CN, NO2, OR a6 , SR a6 , C(0)R b6 , C(0)NR c6 R d6 ,

C(0)OR a6 , OC(0)R b6 , OC(0)NR c6 R d6 , NR c6 R d6 , NR c6 C(0)R b6 , NR c6 C(0)OR a6 ,

NR c6 C(0)NR c6 R d6 , NR c6 S(0)R b6 , NR c6 S(0) 2 R b6 , NR c6 S(0) 2 NR c6 R d6 , S(0)R b6 , S(0)NR c6 R d6 , S(0) 2 R b6 , and S(0) 2 NR c6 R d6 , wherein said CM alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, (5-6 membered heteroaryl)-Ci-4 alkyl-, and (4-7 membered

heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted by 1, 2, or 3 substituents

independently selected from Ci-6 alkyl, C 1-4 haloalkyl, Ci-6 cyanoalkyl, halo, CN, NO2, OR a6 , SR a6 , C(0)R b6 , C(0)NR c6 R d6 , C(0)OR a6 , OC(0)R b6 , OC(0)NR c6 R d6 , NR c6 R d6 , NR c6 C(0)R b6 , NR c6 C(0)OR a6 , NR c6 C(0)NR c6 R d6 , NR c6 S(0)R b6 , NR c6 S(0) 2 R b6 , NR c6 S(0) 2 NR c6 R d6 , S(0)R b6 , S(0)NR c6 R d6 , S(0) 2 R b6 , and S(0) 2 NR c6 R d6 ;

each R al is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Cy 4 ; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy 4 , halo, CN, OR a3 , SR a3 , C(0)R b3 , C(0)NR c3 R d3 , C(0)OR a3 , OC(0)R b3 , OC(0)NR c3 R d3 , NR c3 R d3 , NR c3 C(0)R b3 , NR c3 C(0)OR a3 ,

NR c3 C(0)NR c3 R d3 , NR c3 S(0)R b3 , NR c3 S(0) 2 R b3 , NR c3 S(0) 2 NR c3 R d3 , S(0)R b3 , S(0)NR c3 R d3 , S(0) 2 R b3 , and S(0) 2 NR c3 R d3 ;

each R bl , R cl , and R dl is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 ,

NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ; or any R cl and R dl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6 -io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 ,

NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 , NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 , wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C 6 -io aryl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , C(=NR e7 )NR c7 R d7 ,

NR c7 C(=NR e7 )NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 , NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ;

each R a2 , R b2 , R c2 , and R d2 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 ,

NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ;

each R 33 , R b3 , R c3 , and R d3 is independently selected from H, Ci-e alkyl, Ci-4 haloalkyl,

C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)- C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1 , 2, 3, 4, or 5 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, OR a7 , SR a7 , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 , OC(0)R b7 , OC(0)NR c7 R d7 , NR c7 R d7 , NR c7 C(0)R b7 , NR c7 C(0)NR c7 R d7 , NR c7 C(0)OR a7 , S(0)R b7 , S(0)NR c7 R d7 , S(0) 2 R b7 ,

NR c7 S(0) 2 R b7 , NR c7 S(0) 2 NR c7 R d7 , and S(0) 2 NR c7 R d7 ;

each R a4 , R b4 , R c4 , and R d4 is independently selected from H and C1-3 alkyl;

each R a5 , R b5 , R c5 , and R d5 is independently selected from H or C1-3 alkyl;

each R a6 , R b6 , R c6 , and R d6 is independently selected from H or C1-3 alkyl; and

each R a7 , R b7 , R c7 , and R d7 is independently selected from H or C1-3 alkyl. In some embodiments:

Ring A is phenyl optionally substituted by 1 , 2, or 3 substituents independently selected from R A ;

Ring B is phenyl, pyridyl, or pyrimidinyl, each optionally substituted by 1 or 2 substituents independently selected from R B ;

R 1 is halo, Ci-3 alkyl, Cy 1 , OR al , SR al , C(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , or

NR cl C(0)NR cl R dl ; wherein said C1-3 alkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from Cy 1 , halo, CN, OH, OR al , C(0)NR cl R dl , NR cl R dl , and

NR cl C(0)R bl ;

R 2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, Cy 2 , C(0)NR c2 R d2 , NR c2 R d2 , or NR c2 C(0)R b2 ; wherein said C1-3 alkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from Cy 2 , halo, CN, OR a2 , C(0)NR c2 R d2 , NR c2 R d2 , and NR c2 C(0)R b2 ;

R 3 is H;

each R A is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, OR a4 , SR a4 , C(0)R b4 , C(0)NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R b4 , NR c4 S(0) 2 R b4 , S(0)R b4 , S(0)NR c4 R d4 , S(0) 2 R b4 , and S(0) 2 NR c4 R d4 , wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1 , 2, or 3, substituents independently selected from halo, Ci-e haloalkyl, CN, OR a4 , SR a4 , C(0)R b4 , C(0)NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R b4 , NR c4 S(0) 2 R M , S(0)R b4 , S(0)NR c4 R d4 , S(0) 2 R M , and S(0) 2 NR c4 R d4 ;

each R B is independently selected from Cy 3 , halo, Ci-6 alkyl, Ci-6 haloalkyl, CN, OR a5 , C(0)NR c5 R d5 , NR c5 R d5 , NR c5 C(0)R b5 , NR c5 C(0)OR a5 , NR c5 C(0)NR c5 R d5 , NR c5 S(0)R b5 ,

NR c5 S(0) 2 R b5 , and NR c5 S(0) 2 NR c5 R d5 , wherein said Ci-e alkyl is optionally substituted by 1 , 2, or 3 substituents independently selected from Cy 3 , halo, Ci-e haloalkyl, CN, OR a5 , C(0)NR c5 R d5 , NR c5 R d5 , and NR c5 C(0)R b5 ;

each Cy 1 , Cy 2 , Cy 3 , and Cy 4 is independently selected from phenyl, cyclopropyl, azetidine, piperidine, pyrrolidine, diazapane, and diazaspirononane, each of which is optionally substituted with 1 or 2 substituents independently selected from R Cy ;

each R Cy is independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, CN, OR a6 , and NR c6 R d6 ;

each R al is independently selected from C1-3 alkyl and Cy 4 ; wherein said C1-3 alkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from Cy 4 , halo, CN, and OR a3 , and NR c3 R d3 ;

each R bl , R cl , and R dl is independently selected from H, C1-3 alkyl, C1-3 haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridine, pyrimidine, azetidine, piperidine, pyrrolidine, thiazolyl, phenyl-Ci-2 alkyl-, cyclopropyl-Ci-2 alkyl-, cyclobutyl-Ci-2 alkyl-, cyclopentyl-Ci-2 alkyl-, cyclohexyl-Ci-2 alkyl-, pyridine-Ci-2 alkyl-, pyrimidine-Ci-2 alkyl-, azetidine-Ci-2 alkyl-, piperidine-Ci-2 alkyl-, pyrrolidine-Ci-2 alkyl-, and thiazolyl-Ci-2 alkyl-, wherein said C1-3 alkyl, C1-3 haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridine, pyrimidine, azetidine, piperidine, pyrrolidine, thiazolyl, phenyl-Ci-2 alkyl-,

cyclopropyl-Ci-2 alkyl-, cyclobutyl-Ci-2 alkyl-, cyclopentyl-Ci-2 alkyl-, cyclohexyl-Ci-2 alkyl-, pyridine-Ci-2 alkyl-, pyrimidine-Ci-2 alkyl-, azetidine-Ci-2 alkyl-, piperidine-Ci-2 alkyl-, pyrrolidine-Ci-2 alkyl-, and thiazolyl-Ci-2 alkyl- are each optionally substituted with 1, 2, or 3 substituents independently selected from C1-3 alkyl, C1-3 haloalkyl, halo, CN, OR a7 , and NR c7 R d7 ; or any R cl and R dl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with NR c7 R d7 ;

each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C1-3 alkyl, C1-3 haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopropyl-Ci-2 alkyl-, cyclobutyl-Ci-2 alkyl-, pyridine, pyrimidine, isoxazole, azetidine, piperidine, and pyrrolidine, wherein said C1-3 alkyl, C1-3 haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopropyl-Ci-2 alkyl-, cyclobutyl-Ci-2 alkyl-, pyridine, pyrimidine, isoxazole, azetidine, piperidine, and pyrrolidine are each optionally substituted with 1 or 2 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, OR a7 , and NR c7 R d7 ; each R , R , R , and R is independently selected from H, C1-3 alkyl, C1-3 haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopropyl-Ci-2 alkyl-, cyclobutyl-Ci-2 alkyl-, pyridine, pyrimidine, isoxazole, azetidine, piperidine, and pyrrolidine, wherein said C1-3 alkyl, C1-3 haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopropyl-Ci-2 alkyl-, cyclobutyl-Ci-2 alkyl-, pyridine, pyrimidine, isoxazole, azetidine, piperidine, and pyrrolidine are each optionally substituted with 1 or 2 substituents independently selected from Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 cyanoalkyl, halo, CN, OR a7 , and NR c7 R d7 ;

each R a4 , R b4 , R c4 , and R d4 is independently selected from H and C1-3 alkyl;

each R a5 , R b5 , R c5 , and R d5 is independently selected from H or C1-3 alkyl;

each R a6 , R b6 , R c6 , and R d6 is independently selected from H or C1-3 alkyl; and each R a7 , R b7 , R c7 , and R d7 is independently selected from H or C1-3 alkyl.

In some embodiments, the compound is other than 5,6-diphenylimidazo[l,2-a]pyrazin-8- ol or a tautomer thereof.

In some embodiments, Ring A is phenyl optionally substituted by 1, 2, 3, or 4

substituents independently selected from R A .

In some embodiments, Ring A is phenyl substituted by one R A .

In some embodiments, Ring A is phenyl substituted by CN.

In some embodiments, Ring B is phenyl, C3-10 cycloalkyl, 4-10 membered

heterocycloalkyl, or 5-6 membered heteroaryl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from R B .

In some embodiments, Ring B is phenyl or 5-6 membered heteroaryl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from R B .

In some embodiments, Ring B is phenyl, pyridyl, 3-oxo-3,4-dihydro-2H-l,4- benzoxazinyl, 2,3-dihydro-l,4-benzodioxinyl, pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, 1,3-benzothiazolyl, 2-oxo-2,3-dihydro-l,3-benzoxazolyl, indazolyl, 2-oxo-2,3- dihydro[l,3]oxazolo[4,5-b]pyridinyl, 2,3-dihydro-lH-indenyl, 2-oxo-2,3-dihydro-lH-indolyl, quinoxalinyl, 2-oxo-l,2,3,4-tetrahydroquinolinyl, benzimidazolyl, 3-oxo-3,4-dihydro-2H- pyrido[3,2-b][l,4]oxazinyl, 2-oxo-2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl, or pyrimidinyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from R B . In some embodiments, Ring B is phenyl, pyridyl, or pyrimidinyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from R B .

In some embodiments, Ring B is phenyl, pyridyl, 3-oxo-3,4-dihydro-2H-l,4- benzoxazinyl, 2,3-dihydro-l,4-benzodioxinyl, pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, 1,3-benzothiazolyl, 2-oxo-2,3-dihydro-l,3-benzoxazolyl, indazolyl, 2-oxo-2,3- dihydro[l,3]oxazolo[4,5-b]pyridinyl, 2,3-dihydro-lH-indenyl, 2-oxo-2,3-dihydro-lH-indolyl, quinoxalinyl, 2-oxo-l,2,3,4-tetrahydroquinolinyl, benzimidazolyl, 3-oxo-3,4-dihydro-2H- pyrido[3,2-b][l,4]oxazinyl, 2-oxo-2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl, or pyrimidinyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from Cy 3 , halo, Ci-6 alkyl, Ci-e haloalkyl, OR a5 , CN, NR c5 C(0)OR a5 , and NR c5 R d5 .

In some embodiments, Ring B is phenyl, pyridyl, or pyrimidinyl, each optionally substituted by one substituent selected from Cy 3 , halo, Ci-6 alkyl, Ci-6 haloalkyl, OR a5 , and NR c5 R d5 .

In some embodiments, Ring B is phenyl, pyridyl, 3-oxo-3,4-dihydro-2H-l,4- benzoxazinyl, 2,3-dihydro-l,4-benzodioxinyl, pyrrolo[2,3-b]pyridinyl, pyrazolo[3,4-b]pyridinyl, 1,3-benzothiazolyl, 2-oxo-2,3-dihydro-l,3-benzoxazolyl, indazolyl, 2-oxo-2,3- dihydro[l,3]oxazolo[4,5-b]pyridinyl, 2,3-dihydro-lH-indenyl, 2-oxo-2,3-dihydro-lH-indolyl, quinoxalinyl, 2-oxo-l,2,3,4-tetrahydroquinolinyl, benzimidazolyl, 3-oxo-3,4-dihydro-2H- pyrido[3,2-b][l,4]oxazinyl, 2-oxo-2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl, or pyrimidinyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from chloro, methyl, trifluoromethyl, piperidinyl, methoxy, ethyl, 2-oxopyrrolidinyl, methyl(tetrahydrofuran-2- ylmethyl)amino, fluoro, 2-oxo-l,3-oxazolidinyl, amino, cyano, hydroxymethyl, (4- (methylsulfonyl)piperazin-l-yl)methyl, hydroxyl, morpholin-4-ylmethyl, (CH30)(C=0)N(CH3), (CH30)(C=0)N(CH3)-methyl, 1-hydroxyethyl, cyanomethyl, 3-methyl-2-oxoimidazolidinyl or dimethylamino.

In some embodiments, Ring B is phenyl, pyridyl, or pyrimidinyl, each optionally substituted by chloro, methyl, trifluoromethyl, piperidinyl, methoxy, or dimethylamino.

In some embodiments, Ring B is phenyl substituted by methyl.

In some embodiments, R 1 is Ci-e alkyl, Cy 1 , OR al , SR al , C(0)NR cl R dl , NR cl R dl ,

NR cl C(0)R bl , or NR cl C(0)NR cl R dl wherein said Ci-e alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from Cy 1 , halo, CN, OH, OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)OR al , OC(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl , NR cl C(0)OR al , NR cl C(0)NR cl R dl , C(=NR el )R bl , C(=NR el )NR cl R dl , NR cl C(=NR el )NR cl R dl , NR cl S(0)R bl , NR cl S(0) 2 R bl , NR cl S(0) 2 NR cl R dl , S(0)R bl , S(0)NR cl R dl , S(0) 2 R bl , and S(0) 2 NR cl R dl .

In some embodiments, R 1 is Ci-e alkyl, Cy 1 , OR al , SR al , C(0)NR cl R dl , NR cl R dl ,

NR cl C(0)R bl , or NR cl C(0)NR cl R dl , wherein said Ci-e alkyl is optionally substituted with Cy 1 , OH, or OR al .

In some embodiments, R 1 is OR al .

In some embodiments, R 1 is Ci-6 alkyl substituted with 1 or 2 substituents independently selected from Cy 1 or OR al .

In some embodiments, R 1 is Cy 1 optionally substituted with 1 or 2 substituents independently selected from C1-4 alkyl or NR c6 R d6 .

In some embodiments, R 1 is pyrrolidin-3-ylmethoxy, 2-pyrrolidin-3-ylethyl, [pyrrolidin- 3 -yloxy]methyl, [3 -(dimethylamino)pyrrolidin- 1 -yljmethyl, [3 -(dimethylamino)pyrrolidin- 1 - yl] ethyl, (l-methylpyrrolidin-3-yl)oxy, 3-(dimethylamino)propoxy, piperidin-3-ylmethoxy, [1, methylpyrrolidin-3-yl]methoxy, [ 1 -methylpiperidin-3-yl]methoxy, [pyrrolidin-3-ylmethyl]thio, 4-(dimethylamino)piperidin- 1 -yl, 3-(dimethylamino)propyl](methyl)amino, [2-(l - methylpyrrolidin-2-yl)ethyl]amino, ( 1 -methylpiperidin-4-yl)amino, 4-methyl- 1 ,4-diazepan- 1 -yl, 2,7-diazaspiro[4.4]non-2-yl, 2,7-diazaspiro[3.5]non-7-yl, 3-(dimethylamino)-N- methylpyrrolidine, [2-(2-amino-l ,3-thiazol-4-yl)ethyl]amino, azetidin-3-ylmethylaminocarbonyl, 3 -(dimethylamino)piperidin- 1 -yl, [1 -(2-hydroxyethyl)piperidin-3 -yljmethoxy , [ 1 -(2- cyanoethyl)piperidin-3-yl]methoxy, [l-ethylpiperidin-3-yl]methoxy, or l-methylazetidin-3- ylaminocarbonyl.

In some embodiments, R 1 is pyrrolidin-3-ylmethoxy, 2-pyrrolidin-3-ylethyl, [pyrrolidin- 3 -yloxy]methyl, [3 -(dimethylamino)pyrrolidin- 1 -yljmethyl, [3 -(dimethylamino)pyrrolidin- 1 - yl] ethyl, (l-methylpyrrolidin-3-yl)oxy, 3-(dimethylamino)propoxy, piperidin-3-ylmethoxy, [1, methylpyrrolidin-3-yl]methoxy, [ 1 -methylpiperidin-3-yl]methoxy, [pyrrolidin-3-ylmethyl]thio, 4-(dimethylamino)piperidin- 1 -yl, 3-(dimethylamino)propyl](methyl)amino, [2-(l - methylpyrrolidin-2-yl)ethyl]amino, ( 1 -methylpiperidin-4-yl)amino, 4-methyl- 1 ,4-diazepan- 1 -yl, 2,7-diazaspiro[4.4]non-2-yl, 2,7-diazaspiro[3.5]non-7-yl, 3-(dimethylamino)-N- methylpyrrolidine, [2-(2-amino-l ,3-thiazol-4-yl)ethyl]amino, azetidin-3-ylmethylaminocarbonyl, or 1 -methylazetidin-3-ylaminocarbonyl. In some embodiments, R al is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Cy 4 ; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1 , 2, or 3 substituents independently selected from Cy 4 , halo, CN, OR a3 , SR 33 , C(0)R b3 , C(0)NR c3 R d3 , C(0)OR a3 , OC(0)R b3 , OC(0)NR c3 R d3 , NR c3 R d3 , NR c3 C(0)R b3 , NR c3 C(0)OR a3 , NR c3 C(0)NR c3 R d3 , C(=NR e3 )R b3 , C(=NR e3 )NR c3 R d3 , NR c3 C(=NR e3 )NR c3 R d3 , NR c3 S(0)R b3 , NR c3 S(0) 2 R b3 , NR c3 S(0) 2 NR c3 R d3 , S(0)R b3 , S(0)NR c3 R d3 , S(0) 2 R b3 , and

S(0) 2 NR c3 R d3 .

In some embodiments, R al is Ci-6 alkyl optionally substituted with 1 or 2 substituents independently selected from Cy 4 and NR c3 R d3 .

In some embodiments, R al is C1-3 alkyl optionally substituted with pyrrolidinyl, piperidinyl, or dimethylamino, wherein said pyrrolidinyl and piperidinyl are each optionally substituted with 1 , 2, or 3 substituents independently selected from methyl, ethyl, cyanoethyl, and hydroxy ethyl.

In some embodiments, R 2 is H, Ci-6 alkyl, Ci-6 haloalkyl, Cy 2 , or C(0)NR c2 R d2 , wherein said Ci-6 alkyl is optionally substituted with 1 , 2, or 3 substituents independently selected from Cy 2 , halo, CN, OR a2 , SR a2 , C(0)R b2 , C(0)NR c2 R d2 , C(0)OR a2 , OC(0)R b2 , OC(0)NR c2 R d2 , NR c2 R d2 , NR c2 C(0)R b2 , NR c2 C(0)OR a2 , NR c2 C(0)NR c2 R d2 , C(=NR e2 )R b2 , C(=NR e2 )NR c2 R d2 , NR c2 C(=NR e2 )NR c2 R d2 , NR c2 S(0)R b2 , NR c2 S(0) 2 R b2 , NR c2 S(0) 2 NR c2 R d2 , S(0)R b2 ,

S(0)NR c2 R d2 , S(0) 2 R b2 , and S(0) 2 NR c2 R d2 .

In some embodiments, R 2 is H, Ci-e alkyl, Ci-e haloalkyl, Cy 2 , or C(0)NR c2 R d2 , wherein said Ci-6 alkyl is optionally substituted with 1 or 2 substituents independently selected from Cy 2 , CN, OR a2 , and NR c2 R d2 .

In some embodiments, R 2 is H, methyl, trifluoromethyl, 4-methylphenyl, cyanomethyl, methylaminocarbonyl, dimethylammocarbonyl, cyclopropylammocarbonyl, l-methylazetidin-3- ylaminocarbonyl, hydroxymethyl, azetidin-l-ylmethyl, cyclopropylmethylaminomethyl, (isoxazol-3-ylamino)methyl, dimethylaminomethyl, or dimethylaminoethyl.

In some embodiments, R 2 is H.

In some embodiments, R 3 is H.

In some embodiments, R A is CN.

In some embodiments, R B is independently selected from Cy 3 , halo, Ci-6 alkyl, Ci-6 haloalkyl, CN, NR c5 C(0)OR a5 , NR c5 R d5 and OR a5 . In some embodiments, R B is independently selected from Cy 3 , halo, Ci-6 alkyl, Ci-6 haloalkyl, and OR a5 .

In some embodiments, R B is Ci-6 alkyl.

In some embodiments, R B is methyl, chloro, trifluoromethyl, piperidinyl, methoxy, ethyl, 2-oxopyrrolidinyl, methyl(tetrahydrofuran-2-ylmethyl)amino, fluoro, 2-oxo-l,3-oxazolidinyl, amino, cyano, hydroxymethyl, (4-(methylsulfonyl)piperazin-l-yl)methyl, hydroxyl, morpholin- 4-ylmethyl, (CH 3 0)(C=0)N(CH 3 ), (CH 3 0)(C=0)N(CH 3 )-methyl, 1-hydroxyethyl, cyanomethyl,

3- methyl-2-oxoimidazolidinyl or dimethylamino.

In some embodiments, R B is methyl.

In some embodiments, Cy 1 is independently selected from 5-10 membered heteroaryl and

4- 10 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R Cy .

In some embodiments, Cy 1 is independently selected from 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, each of which is optionally substituted with 1 or 2 substituents independently selected from Ci-4 alkyl and NR c6 R d6 .

In some embodiments, Cy 1 is 4-10 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R Cy .

In some embodiments, Cy 1 is azetidine, piperidine, pyrrolidine, diazapane, or

diazaspirononane, each optionally substituted with 1 or 2 substituents independently selected from R Cy .

In some embodiments, the compounds of the invention have Formula II:

II

wherein n is 0, 1, 2, 3, or 4.

In some embodiments, the compounds of the invention have Formula Ila:

Ila.

In some embodiments, where the compound of the invention has Formula II or Ila, the roup:

wherein any one of the groups of Formulae (B-l) to (B-15) is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R B .

In some embodiments, the compounds of the invention have Formula III:

III

wherein n is 0, 1, 2, 3, or 4 and wherein m is 0, 1, 2, 3, or 4.

In some embodiments, the compounds of the invention have Formula IV:

IV

wherein m is 0, 1, 2, 3, or 4.

In some embodiments, the compounds of the invention have Formula V:

V.

In some embodiments, th e Formula VI:

VI.

In some embodiments, the compounds of the invention have Formula VII:

VII

In some embodiments, where the com ound of the invention has Formula VII, the group

> selected from any one of Formulae (B-la) to (B-15a):

10a); (B-lla); (B-12a);

wherein any one of the groups of Formulae (B-la) to (B-15a) is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R B .

In some embodiments, n is 0, 1, or 2.

In some embodiments, n is 1.

In some embodiments, m is 0, 1, or 2.

In some embodiments, m is 1.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination. As used herein, the phrase "optionally substituted" means unsubstituted or substituted. As used herein, the term "substituted" means that a hydrogen atom is removed and replaced by a monovalent substituent, or two hydrogen atoms are replaced with a divalent substituent like a terminal oxo group. It is to be understood that substitution at a given atom is limited by valency.

Throughout the definitions, the term "Ci-j" indicates a range which includes the endpoints, wherein i and j are integers and indicate the number of carbons. Examples include C1-4, Ci-6, and the like.

The term "z-membered" (where z is an integer) typically describes the number of ring- forming atoms in a moiety where the number of ring-forming atoms is z. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5- membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1 , 2, 3, 4- tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.

As used herein, the term "Ci-j alkyl," employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched, having i to j carbons. In some embodiments, the alkyl group contains from 1 to 6 carbon atoms or from 1 to 4 carbon atoms, or from 1 to 3 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, and t- butyl.

As used herein, the term "Ci-j alkoxy," employed alone or in combination with other terms, refers to a group of formula -O-alkyl, wherein the alkyl group has i to j carbons. Example alkoxy groups include methoxy, ethoxy, and propoxy (e.g., n-propoxy and isopropoxy). In some embodiments, the alkyl group has 1 to 3 carbon atoms.

As used herein, "Ci-j alkenyl," employed alone or in combination with other terms, refers to an unsaturated hydrocarbon group having one or more double carbon-carbon bonds and having i to j carbons. In some embodiments, the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like.

As used herein, "Ci-j alkynyl," employed alone or in combination with other terms, refers to an unsaturated hydrocarbon group having one or more triple carbon-carbon bonds and having i to j carbons. Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms.

As used herein, the term "Ci j alkylamino," employed alone or in combination with other terms, refers to a group of formula -NH(alkyl), wherein the alkyl group has i to j carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. In some embodiments, the alkylamino group is -NH(C 1-4 alkyl) such as, for example, methylamino, ethylamino, or propylamino.

As used herein, the term "di-Ci j-alkylamino," employed alone or in combination with other terms, refers to a group of formula -N(alkyl) 2 , wherein each of the two alkyl groups has, independently, i to j carbon atoms. In some embodiments, each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms. In some embodiments, the dialkylamino group is -N(C 1-4 alkyl) 2 such as, for example, dimethylamino or diethylamino.

As used herein, the term "Ci j alkylthio," employed alone or in combination with other terms, refers to a group of formula -S-alkyl, wherein the alkyl group has i to j carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. In some embodiments, the alkylthio group is C 1-4 alkylthio such as, for example, methylthio or ethylthio.

As used herein, the term "amino," employed alone or in combination with other terms, refers to a group of formula -NH 2 .

As used herein, the term "aryl," employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbon, such as, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, anthracenyl, phenanthrenyl, and the like. In some embodiments, aryl is C 6 -io aryl. In some embodiments, the aryl group is a naphthalene ring or phenyl ring. In some embodiments, the aryl group is phenyl.

As used herein, the term "aryl-Ci j alkyl," employed alone or in combination with other terms, refers to an alkyl group substituted by an aryl group. An example of a aryl-Ci j alkyl group is benzyl.

As used herein, the term "carbonyl", employed alone or in combination with other terms, refers to a -C(O)- group.

As used herein, the term "Ci j cycloalkyl," employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon moiety having i to j ring-forming carbon atoms, which may optionally contain one or more alkenylene groups as part of the ring structure. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclopentene, cyclohexane, and the like. One or more ring- forming carbon atoms of a cycloalkyl group can be oxidized to form carbonyl linkages. In some embodiments, cycloalkyl is C3-10 cycloalkyl, C3-7 cycloalkyl, or C5-6 cycloalkyl. Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, and the like. Further exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

As used herein, the term "Ci j cycloalkyl-G-j alkyl," employed alone or in combination with other terms, refers to an alkyl group substituted by a cycloalkyl group. An example of a G-j cycloalkyl-Ci-j alkyl group is cyclopropylmethyl.

As used herein, "Ci j haloalkoxy," employed alone or in combination with other terms, refers to a group of formula -O-haloalkyl having i to j carbon atoms. An example haloalkoxy group is OCF3. An additional example haloalkoxy group is OCHF2. In some embodiments, the haloalkoxy group is fluorinated only. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. In some embodiments, the haloalkoxy group is C1-4 haloalkoxy.

As used herein, the term "halo," employed alone or in combination with other terms, refers to a halogen atom selected from F, CI, I or Br. In some embodiments, "halo" refers to a halogen atom selected from F, CI, or Br. In some embodiments, the halo substituent is F.

As used herein, the term "Ci j haloalkyl," employed alone or in combination with other terms, refers to an alkyl group having from one halogen atom to 2s+l halogen atoms which may be the same or different, where "s" is the number of carbon atoms in the alkyl group, wherein the alkyl group has i to j carbon atoms. In some embodiments, the haloalkyl group is fluorinated only. In some embodiments, the haloalkyl group is fluoromethyl, difluoromethyl, or

trifluoromethyl. In some embodiments, the haloalkyl group is trifluoromethyl. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.

As used herein, the term "heteroaryl," employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic heterocylic moiety, having one or more heteroatom ring members selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl group has 1, 2, 3, or 4 heteroatom ring members. In some embodiments, the heteroaryl group has 1, 2, or 3 heteroatom ring members. In some embodiments, the heteroaryl group has 1 or 2 heteroatom ring members. In some embodiments, the heteroaryl group has 1 heteroatom ring member. In some embodiments, the heteroaryl group is 5- to 10-membered or 5- to 6-membered. In some embodiments, the heteroaryl group is 5-membered. In some embodiments, the heteroaryl group is 6-membered. When the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different. The nitrogen atoms in the ring(s) of the heteroaryl group can be oxidized to form N-oxides. Example heteroaryl groups include, but are not limited to, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, pyrazole, azolyl, oxazole, isoxazole, thiazole, isothiazole, imidazole, furan, thiophene, triazole, tetrazole, thiadiazole, quinoline, isoquinoline, indole, benzothiophene, benzofuran, benzisoxazole, imidazo[l, 2-b]thiazole, purine, triazine, and the like.

A 5-membered heteroaryl is a heteroaryl group having five ring-forming atoms wherein one or more of the ring-forming atoms are independently selected from N, O, and S. In some embodiments, the 5-membered heteroaryl group has 1, 2, 3, or 4 heteroatom ring members. In some embodiments, the 5-membered heteroaryl group has 1, 2, or 3 heteroatom ring members. In some embodiments, the 5-membered heteroaryl group has 1 or 2 heteroatom ring members. In some embodiments, the 5-membered heteroaryl group has 1 heteroatom ring member.

Example ring-forming members include CH, N, NH, O, and S. Example five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1, 2, 3-triazolyl, tetrazolyl, 1, 2, 3-thiadiazolyl, 1, 2, 3-oxadiazolyl, 1, 2, 4-triazolyl, 1, 2, 4-thiadiazolyl, 1, 2, 4-oxadiazolyl, 1, 3, 4-triazolyl, 1, 3, 4-thiadiazolyl, and 1, 3, 4- oxadiazolyl.

A 6-membered heteroaryl is a heteroaryl group having six ring-forming atoms wherein one or more of the ring-forming atoms is N. In some embodiments, the 6-membered heteroaryl group has 1, 2, or 3 heteroatom ring members. In some embodiments, the 6-membered heteroaryl group has 1 or 2 heteroatom ring members. In some embodiments, the 6-membered heteroaryl group has 1 heteroatom ring member. Example ring-forming members include CH and N. Example six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl, and pyridazinyl. As used herein, the term "heteroaryl-G-j alkyl," employed alone or in combination with other terms, refers to an alkyl group substituted by a heteroaryl group. An example of a heteroaryl-Ci-j alkyl group is pyridylmethyl.

As used herein, the term "heterocycloalkyl," employed alone or in combination with other terms, refers to non-aromatic heterocyclic ring system, which may optionally contain one or more unsaturations as part of the ring structure, and which has at least one heteroatom ring member independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heterocycloalkyl group has 1, 2, 3, or 4 heteroatom ring members. In some embodiments, the heterocycloalkyl group has 1, 2, or 3 heteroatom ring members. In some embodiments, the heterocycloalkyl group has 1 or 2 heteroatom ring members. In some embodiments, the heterocycloalkyl group has 1 heteroatom ring member. When the heterocycloalkyl group contains more than one heteroatom in the ring, the heteroatoms may be the same or different. Example ring-forming members include CH, CH 2 , C(O), N, NH, O, S, S(O), and S(0) 2 .

Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems, including spiro systems. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the non- aromatic ring, for example, 1, 2, 3, 4-tetrahydro-quinoline, dihydrobenzofuran and the like. The carbon atoms or heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, sulfmyl, or sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized. In some embodiments, the heterocycloalkyl is 5- to 10-membered, 4- to 10- membered, 4- to 7-membered, 5-membered, or 6-membered. Examples of heterocycloalkyl groups include 1, 2, 3, 4-tetrahydro-quinoline, dihydrobenzofuran, azetidine, azepane, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, and pyran. In further embodiments, the heterocycloalkyl group is azetidine, piperidine, pyrrolidine, diazapane, or diazaspirononane.

As used herein, the term "heterocycloalkyl-G-j alkyl," employed alone or in combination with other terms, refers to an alkyl group substituted by a heterocycloalkyl group. An example of a heterocycloalkyl-Ci j alkyl group is pyrrolidinylmethyl.

The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereoisomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.

When the compounds of the invention contain a chiral center, the compounds can be any of the possible stereoisomers. In compounds with a single chiral center, the stereochemistry of the chiral center can be (R) or (S). In compounds with two chiral centers, the stereochemistry of the chiral centers can each be independently (R) or (S) so the configuration of the chiral centers can be (R) and (R), (R) and (S); (S) and (R), or (S) and (S). In compounds with three chiral centers, the stereochemistry each of the three chiral centers can each be independently (R) or (S) so the configuration of the chiral centers can be (R), (R) and (R); (R), (R) and (S); (R), (S) and (R); (R), (S) and (S); (S), (R) and (R); (S), (R) and (S); (S), (S) and (R); or (S), (S) and (S).

Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt- forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as β-camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g., S and R forms, or diastereoisomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1, 2- diaminocyclohexane, and the like.

Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.

Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, amide - imidic acid pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1, 2, 4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.

Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers.

The term "compound" as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified.

All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., hydrates and solvates) or can be isolated.

In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By "substantially isolated" is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in a compound of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%>, at least about 80%>, at least about 90%>, at least about 95%, at least about 97%), or at least about 99% by weight of the compounds of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The expressions, "ambient temperature" and "room temperature," as used herein, are understood in the art, and refer generally to a temperature, e.g., a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 °C to about 30 °C.

The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g. , methanol, ethanol, iso-propanol, or butanol) or acetonitrile (MeCN) are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17 th Ed., (Mack Publishing Company, Easton, 1985), p. 1418, Berge et al., J. Pharm. Sci., 1977, 66(1), 1-19, and in Stahl et al., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (Wiley, 2002).

The following abbreviations may be used herein: AcOH (acetic acid); Ac 2 0 (acetic anhydride); aq. (aqueous); atm. (atmosphere(s)); Boc (t-butoxycarbonyl); BOP ((benzotriazol-1- yloxy)tris(dimethylamino)phosphonium hexafluorophosphate); br (broad); Cbz (carboxybenzyl); calc. (calculated); d (doublet); dd (doublet of doublets); DBU (l,8-diazabicyclo[5.4.0]undec-7- ene); DCM (dichloromethane); DIAD (N, N'-diisopropyl azidodicarboxylate); DIEA (N,N- diisopropylethylamine); DIPEA (N, N-diisopropylethylamine); DMF (N, N-dimethylformamide); Et (ethyl); EtOAc (ethyl acetate); g (gram(s)); h (hour(s)); HATU (N, N, N', N'-tetramethyl-0-(7- azabenzotriazol-l-yl)uronium hexafluorophosphate); HC1 (hydrochloric acid); HPLC (high performance liquid chromatography); Hz (hertz); IPA (isopropyl alcohol); J (coupling constant); LCMS (liquid chromatography - mass spectrometry); m (multiplet); M (molar); mCPBA (3- chloroperoxybenzoic acid); MS (Mass spectrometry); Me (methyl); MeCN (acetonitrile); MeOH (methanol); mg (milligram(s)); min. (minutes(s)); mL (milliliter(s)); mmol (millimole(s)); N (normal); nM (nanomolar); NMP (N-methylpyrrolidinone); NMR (nuclear magnetic resonance spectroscopy); OTf (trifluoromethanesulfonate); Ph (phenyl); pM (picomolar); RP-HPLC (reverse phase high performance liquid chromatography); s (singlet); t (triplet or tertiary); TBS (tert-butyldimethylsilyl); tert (tertiary); tt (triplet of triplets); TFA (trifluoroacetic acid); THF (tetrahydrofuran); μg (microgram(s)); μΙ_, (microliter(s)); μΜ (micromolar); wt % (weight percent).

Synthesis

Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.

The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the

intermediates, or products at the temperatures at which the reactions are carried out, e.g. , temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.

Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in P. G. M. Wuts and T. W. Greene, Protective Groups in Organic Synthesis, 4 th Ed., Wiley & Sons, Inc., New York (2006), which is incorporated herein by reference in its entirety. Protecting groups in the synthetic schemes are typically represented by "PG."

Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy {e.g., l H or 13 C), infrared spectroscopy, spectrophotometry {e.g., UV- visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin layer chromatography (TLC). Compounds can be purified by those skilled in the art by a variety of methods, including high performance liquid chromatography (HPLC) {"Preparative LC-MS Purification: Improved Compound Specific Method Optimization" Karl F. Blom, Brian Glass, Richard Sparks, Andrew P. Combs J. Combi. Chem. 2004, 6(6), 874-883, which is incorporated herein by reference in its entirety) and normal phase silica chromatography.

Compound of formula 11 can be prepared via the synthetic route outlined in Scheme 1. The commercially available starting material 1 can undergo Suzuki coupling with the boronic acid or ester of formula 2 (R is, e.g., H or Ci-6 alkyl) under standard Suzuki conditions (e.g., in the presence of a palladium catalyst and a base such as potassium carbonate) to afford compound 3.

The chloride in compound 3 can be coupled to compound of formula 4, in which M is a boronic acid, boronic ester or an appropriately substituted metal [e.g., M is B(OR) 2 , Sn(alkyl) 4 , or Zn-Hal], under standard Suzuki coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base) or standard Stille coupling conditions (e.g., in the presence of a palladium catalyst), or standard Negishi coupling conditions (e.g., in the presence of a palladium catalyst) to give the derivative of formula 5.

Alternatively, compound 4 can be a cyclic amine (where M is H and attached to a ring- forming nitrogen atom in Ring B) and the coupling of compound 4 to compound 3 can be achieved by direct SNAr displacement of the chlorine in compound 3 by the amine in compound 4 in the presence of a suitable base such diisopropylethylamme at elevated temperature. The coupling of arylchloride 3 with the cyclic amine 4 can also be performed under Buchwald amination conditions (e.g., in the presence of a palladium catalyst and a base such as sodium tert- butoxide).

Bromination of compound 5 can be performed under standard conditions [e.g., in the presence of N-bromosuccinimide (NBS)] to give compound 6. Installation of R 1 group can be achieved by SNAr displacement of the bromide in compound 6 with R^M (wherein R^M is an alcohol or an amine, e.g., M is H which is attached to an oxygen or nitrogen atom in R 1 ) in the presence of a suitable base such as sodium hydride, sodium hydroxide, potassium carbonate or diisopropylethylamme at elevated temperature. The coupling of compound 6 with R^M can also be performed under standard Suzuki conditions (when M is boronic acid or ester), or standard Stille coupling conditions [when M is Sn(alkyl) 4 ], or standard Negishi coupling conditions (when M is Zn-Hal) to give compound of formula 7.

Condensation of compound 7 with ketone derivatives of formula 8 (X is a leaving group such as CI or Br) at elevated temperature can generate the bicyclic compound of formula 9, which can be brominated with a suitable reagent such as NBS to give compound 10. Finally, installation of substituent R 3 can be achieved by coupling of bromide 10 with R 3 -M under standard cross coupling conditions, such as Suzuki coupling conditions (when M is boronic acid or ester), or Negishi coupling conditions (when M is Zn-Hal) or Stille coupling conditions [when M is Sn(alkyl) 4 ] to give compounds of formula 11.

Scheme 1

10 11

Methods of Use

Compounds of the invention are LSD1 inhibitors and, thus, are useful in treating diseases and disorders associated with activity of LSD 1. For the uses described herein, any of the compounds of the invention, including any of the embodiments thereof, may be used.

In some embodiments, the compounds of the invention are selective for LSD1 over LSD2, meaning that the compounds bind to or inhibit LSD1 with greater affinity or potency, compared to LSD2. In general, selectivity can be at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold or at least about 1000-fold.

As inhibitors of LSDl, the compounds of the invention are useful in treating LSD1- mediated diseases and disorders. The term "LSDl -mediated disease" or "LSDl -mediated disorder" refers to any disease or condition in which LSDl plays a role, or where the disease or condition is associated with expression or activity of LSDl . The compounds of the invention can therefore be used to treat or lessen the severity of diseases and conditions where LSDl is known to play a role.

Diseases and conditions treatable using the compounds of the invention include, generally cancers, inflammation, autoimmune diseases, viral induced pathogenesis, beta- globinopathies, and other diseases linked to LSDl activity.

Cancers treatable using compounds according to the present invention include, for example, hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, nervous system cancers, gynecological cancers, and skin cancers.

Example hematological cancers include, for example, lymphomas and leukemias such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma, myeloproliferative diseases (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET)), myelodysplasia syndrome (MDS), and multiple myeloma.

Example sarcomas include, for example, chondrosarcoma, Ewing's sarcoma,

osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, fibroma, lipoma, harmatoma, and teratoma.

Example lung cancers include, for example, non-small cell lung cancer (NSCLC), bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, and mesothelioma.

Example gastrointestinal cancers include, for example, cancers of the esophagus

(squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), and colorectal cancer.

Example genitourinary tract cancers include, for example, cancers of the kidney

(adenocarcinoma, Wilm's tumor [nephroblastoma]), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), and testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma).

Example liver cancers include, for example, hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.

Example bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors

Example nervous system cancers include, for example, cancers of the skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma,

meningiosarcoma, gliomatosis), brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma,

retinoblastoma, congenital tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), as well as neuroblastoma and Lhermitte-Duclos disease.

Example gynecological cancers include, for example, cancers of the uterus (endometrial carcinoma), cervix (cervical carcinoma, pre -tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma

(embryonal rhabdomyosarcoma), and fallopian tubes (carcinoma). Example skin cancers include, for example, melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids.

The compounds of the invention can further be used to treat cancer types where LSD1 may be overexpressed including, for example, breast, prostate, head and neck, laryngeal, oral, and thyroid cancers (e.g., papillary thyroid carcinoma).

The compounds of the invention can further be used to treat genetic disorders such as Cowden syndrome and Bannayan-Zonana syndrome.

The compounds of the invention can further be used to treat viral diseases such as herpes simplex virus (HSV), varicella zoster virus (VZV), human cytomegalovirus, hepatitis B virus (HBV), and adenovirus.

The compounds of the invention can further be used to treat beta-globinopathies including, for example, beta-thalassemia and sickle cell anemia.

As used herein, the term "contacting" refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, "contacting" a LSD1 protein with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having a LSD1 protein, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the LSD1 protein.

As used herein, the term "individual" or "patient, " used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.

As used herein, the phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician.

As used herein, the term "treating" or "treatment" refers to inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder {i.e.,, arresting further development of the pathology and/or symptomatology) or ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e.,, reversing the pathology and/or symptomatology) such as decreasing the severity of disease.

As used herein, the term "preventing" or "prevention" refers to preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.

Combination Therapies

The compounds of the invention can be used in combination treatments where the compound of the invention is administered in conjunction with other treatments such as the administration of one or more additional therapeutic agents. The additional therapeutic agents are typically those which are normally used to treat the particular condition to be treated. The additional therapeutic agents can include, e.g., chemotherapeutics, anti-inflammatory agents, steroids, immunosuppressants, as well as Bcr-Abl, Flt-3, RAF, FAK, JAK, PIM, PI3K inhibitors for treatment of LSD 1 -mediated diseases, disorders or conditions. The one or more additional pharmaceutical agents can be administered to a patient simultaneously or sequentially.

In some embodiments, the compounds of the invention can be used in combination with a therapeutic agent that targets an epigenetic regulator. Examples of epigenetic regulators include the histone lysine methyltransferases, histone arginine methyl transferases, histone demethylases, histone deacetylases, histone acetylases, and DNA methyltransferases. Histone deacetylase inhibitors include, e.g. , vorinostat.

For treating cancer and other proliferative diseases, the compounds of the invention can be used in combination with chemotherapeutic agents, agonists or antagonists of nuclear receptors, or other anti-pro liferative agents. The compounds of the invention can also be used in combination with medical therapy such as surgery or radiotherapy, e.g. , gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes. Examples of suitable chemotherapeutic agents include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, and zoledronate.

For treating cancer and other proliferative diseases, the compounds of the invention can be used in combination with ruxolitinib.

For treating autoimmune or inflammatory conditions, the compound of the invention can be administered in combination with a corticosteroid such as triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.

For treating autoimmune or inflammatory conditions, the compound of the invention can be administered in combination with an immune suppressant such as fluocinolone acetonide (Retisert®), rimexolone (AL-2178, Vexol, Alcon), or cyclosporine (Restasis®).

For treating autoimmune or inflammatory conditions, the compound of the invention can be administered in combination with one or more additional agents selected from Dehydrex™ (Holies Labs), Civamide (Opko), sodium hyaluronate (Vismed, Lantibio/TRB Chemedia), cyclosporine (ST-603, Sirion Therapeutics), ARG101(T) (testosterone, Argentis), AGR1012(P) (Argentis), ecabet sodium (Senju-Ista), gefarnate (Santen), 15-(s)-hydroxyeicosatetraenoic acid (15(S)-HETE), cevilemine, doxycycline (ALTY-0501, Alacrity), minocycline, iDestrin™ (NP50301, Nascent Pharmaceuticals), cyclosporine A (Nova22007, Novagali), oxytetracycline (Duramycin, MOLI1901, Lantibio), CF101 (2S, 3S, 4R, 5R)-3, 4-dihydroxy-5-[6-[(3- iodophenyl)methylamino]purin-9-yl]-N-methyl-oxolane-2-carbam yl, Can-Fite Biopharma), voclosporin (LX212 or LX214, Lux Biosciences), ARG103 (Agentis), RX- 10045 (synthetic resolvin analog, Resolvyx), DYN15 (Dyanmis Therapeutics), rivoglitazone (DE01 1 , Daiichi Sanko), TB4 (RegeneRx), OPH-01 (Ophtalmis Monaco), PCS 101 (Pericor Science), REV 1-31 (Evolutec), Lacritin (Senju), rebamipide (Otsuka-Novartis), OT-551 (Othera), PAI-2 (University of Pennsylvania and Temple University), pilocarpine, tacrolimus, pimecrolimus (AMS981 , Novartis), loteprednol etabonate, rituximab, diquafosol tetrasodium (INS365, Inspire), KLS- 061 1 (Kissei Pharmaceuticals), dehydroepiandrosterone, anakinra, efalizumab,

mycophenolate sodium, etanercept (Embrel®), hydroxychloroquine, NGX267 (TorreyPines Therapeutics), or thalidomide.

For treating beta-thalassemia or sickle cell disease, the compound of the invention can be administered in combination with one or more additional agents such as Hydrea® (hydroxyurea).

In some embodiments, the compound of the invention can be administered in

combination with one or more agents selected from an antibiotic, antiviral, antifungal, anesthetic, anti-inflammatory agents including steroidal and non-steroidal anti-inflammatories, and antiallergic agents. Examples of suitable medicaments include aminoglycosides such as amikacin, gentamycin, tobramycin, streptomycin, netilmycin, and kanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridine; sulfonamides; polymyxin; chloramphenicol; neomycin; paramomycin;

colistimethate; bacitracin; vancomycin; tetracyclines; rifampin and its derivatives ("rifampins"); cycloserine; beta-lactams; cephalosporins; amphotericins; fluconazole; flucytosine; natamycin; miconazole; ketoconazole; corticosteroids; diclofenac; flurbiprofen; ketorolac; suprofen;

cromolyn; lodoxamide; levocabastin; naphazoline; antazoline; pheniramine; or azalide antibiotic.

Other examples of agents, one or more of which a provided compound may also be combined with include: a treatment for Alzheimer's Disease such as donepezil and rivastigmine; a treatment for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinirole, pramipexole, bromocriptine, pergolide, trihexyphenidyl, and amantadine; an agent for treating multiple sclerosis (MS) such as beta interferon (e.g., Avonex® and Rebif®), glatiramer acetate, and mitoxantrone; a treatment for asthma such as albuterol and montelukast; an agent for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; an anti-inflammatory agent such as a corticosteroid, such as dexamethasone or prednisone, a TNF blocker, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; an immunomodulatory agent, including immunosuppressive agents, such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, an interferon, a corticosteroid, cyclophosphamide, azathioprine, and sulfasalazine; a neurotrophic factor such as an acetylcholinesterase inhibitor, an MAO inhibitor, an interferon, an anti- convulsant, an ion channel blocker, riluzole, or an anti-Parkinson's agent; an agent for treating cardiovascular disease such as a beta-blocker, an ACE inhibitor, a diuretic, a nitrate, a calcium channel blocker, or a statin; an agent for treating liver disease such as a corticosteroid, cholestyramine, an interferon, and an anti-viral agent; an agent for treating blood disorders such as a corticosteroid, an anti-leukemic agent, or a growth factor; or an agent for treating immunodeficiency disorders such as gamma globulin.

Formulation, Dosage Forms and Administration

When employed as pharmaceuticals, the compounds of the invention can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.

Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary {e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

This invention also includes pharmaceutical compositions which contain, as the active ingredient, the compound of the invention or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers (excipients). In some embodiments, the composition is suitable for topical administration. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is

substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.

The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art, e.g., see International App. No. WO 2002/000196.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. The active compound may be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, about 0.1 to about 1000 mg of the active ingredient of the present invention.

The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar

pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.

Topical formulations can contain one or more conventional carriers. In some

embodiments, ointments can contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white vaseline, and the like. Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g., glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, for example, glycerol, hydroxyethyl cellulose, and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2, or at least about 5 wt % of the compound of the invention. The topical formulations can be suitably packaged in tubes of, for example, 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition.

The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.

The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

The therapeutic dosage of a compound of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.

The compositions of the invention can further include one or more additional

pharmaceutical agents such as a chemotherapeutic, steroid, anti-inflammatory compound, or immunosuppressant, examples of which are listed hereinabove.

Labeled Compounds and Assay Methods

Another aspect of the present invention relates to labeled compounds of the invention

(radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quantitating LSDl in tissue samples, including human, and for identifying LSDl ligands by inhibition binding of a labeled compound.

Accordingly, the present invention includes LSDl assays that contain such labeled compounds.

The present invention further includes isotopically-labeled compounds of the invention.

An "isotopically" or "radio-labeled" compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 3 H (also written as T for tritium), n C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 18 F, 35 S, 36 C1, 82 Br, 75 Br, 76 Br, 77 Br, 123 I, 124 I, 125 I and 131 I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound.

It is to be understood that a "radio-labeled " or "labeled compound" is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of 3 H, 14 C, 125 1, 35 S and 82 Br. In some embodiments, the compound incorporates 1, 2, or 3 deuterium atoms.

The present invention can further include synthetic methods for incorporating radioisotopes into compounds of the invention. Synthetic methods for incorporating radio-isotopes into organic compounds are well known in the art, and an ordinary skill in the art will readily recognize the methods applicable for the compounds of invention.

A labeled compound of the invention can be used in a screening assay to

identify/evaluate compounds. For example, a newly synthesized or identified compound (i.e., test compound) which is labeled can be evaluated for its ability to bind LSD1 by monitoring its concentration variation when contacting with LSD1, through tracking of the labeling. For example, a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to LSD1 (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to LSD 1 directly correlates to its binding affinity. Conversely, in some other screening assays, the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.

The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples were found to be inhibitors of LSD 1 as described below. EXAMPLES

Experimental procedures for compounds of the invention are provided below.

Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass directed fractionation systems. The basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e.g. "Two- Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 4, 295 (2002); "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi.

Chem., 5, 670 (2003); and "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004). The compounds separated were typically subjected to analytical liquid chromatography mass spectrometry (LCMS) for purity check under the following conditions: Instrument; Agilent 1100 series, LC/MSD, Column: Waters Sunfire™ Cis 5μιη particle size, 2.1 x 5.0 mm, Buffers: mobile phase A: 0.025% TFA in water and mobile phase B: acetonitrile; gradient 2% to 80% of B in 3 minutes with flow rate 2.0 mL/minute.

Some of the compounds prepared were also separated on a preparative scale by reverse- phase high performance liquid chromatography (RP-HPLC) with MS detector or flash chromatography (silica gel) as indicated in the Examples. Typical preparative reverse-phase high performance liquid chromatography (RP-HPLC) column conditions are as follows:

pH = 2 purifications: Waters Sunfire™ Cis 5 μιη particle size, 19 x 100 mm column, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [see "Preparative LCMS Purification: Improved Compound Specific Method

Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with the 30 x 100 mm column was 60 mL/minute.

pH = 10 purifications: Waters XBridge Cis 5 μιη particle size, 19 x 100 mm column, eluting with mobile phase A: 0.15% NH4OH in water and mobile phase B: acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [See

"Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with 30 x 100 mm column was 60 mL/minute.

Example 1

4- {5-(4-methylphenyl)-8- [(3R)-pyrrolidin-3-ylmethoxy] imidazo [1 ,2-a] pyrazin-6- yl}benzonitrile

Step 1: 4-(5-amino-3-chloropyrazin-2- l)benzonitrile

A reaction vessel containing a mixture of 5-bromo-6-chloropyrazin-2-amine (1.04 g, 5.00 mmol), (4-cyanophenyl)boronic acid (0.882 g, 6.00 mmol), dichloro(bis{di-tert-butyl[4- (dimethylamino)phenyl]phosphoranyl})palladium (110 mg, 0.15 mmol), and sodium carbonate (1.06 g, 10.0 mmol) in 1,4-dioxane (12.0 mL) and water (2.0 mL) was evacuated then filled with nitrogen. The resulting mixture was stirred at 90 °C for 4 h then cooled to room temperature. The mixture was diluted with methylene chloride (15 mL) and water (5 mL). The precipitate was collected by filtration and washed with methyl t-butyl ether then dried to afford the desired product (1.05 g, 91 %). LC-MS calculated for CnH 8 ClN4 (M+H) + : m/z = 231.0; found 231.1.

Ste 2: 4-[ 5-amino-3-(4-methylphenyl)pyrazin-2-yl]benzonitrile

A reaction vessel containing a mixture of 4-(5-amino-3-chloropyrazin-2-yl)benzonitrile (1.15 g, 5.00 mmol), (4-methylphenyl)boronic acid (0.86 g, 6.4 mmol), sodium carbonate (1.06 g, 10.0 mmol) and [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1 : 1) (0.20 g, 0.25 mmol)in 1,4-dioxane (20.0 mL) and water (4.0 mL) was evacuated then refilled with nitrogen. The resulting mixture was stirred at 110 °C for 3 h then cooled to room temperature. The mixture was diluted with methylene chloride, washed with saturated NaHCC aqueous solution, water and brine. The organic layer was dried over Na 2 S0 4 , filtered and concentrated under reduced pressure. The residue was treated with DCM/diethyl- ether (1 : 1). The precipitate was collected by filtration to afford the desired product (0.61g). The filtrate was concentrated and the residue was purified by flash chromatography on a silica gel column eluting with 0 to 100 % EtOAc/DCM to afford another batch of the product (0.60 g). LC-MS calculated for C18H15N4 (M+H) + : m/z = 287.1; found 287.1.

Step 3: 4-f 5-amino-6-bromo-3-(4-methylphenyl)pyrazin-2-yl]benzonitrile

To a solution of 4-[5-amino-3-(4-methylphenyl)pyrazin-2-yl]benzonitrile (2.40 g, 8.38 mmol) in tetrahydrofuran (36 mL) at 0 °C was added N-bromosuccinimide (1.64 g, 9.22 mmol). The resulting mixture was stirred at 0 °C for 1 h then warmed to room temperature. The mixture was diluted with methylene chloride, washed with saturated NaHCCte aqueous solution, water, and brine. The organic layer was dried over Na 2 S0 4 , filtered and concentrated. The residue was purified on a silica gel column eluting with 0 to 60 % EtOAc/DCM to give the desired product (2.8 g, 92 %). LC-MS calculated for Ci8Hi 4 BrN 4 (M+H) + : m/z = 365.0; found 365.0.

Step 4: tert-butyl (3R)-3-({[3-amino-6-(4-cyanophenyl)-5-(4-methylphenyl)pyrazi n-2- ylj ' oxy}methyl)pyrrolidine-l -carboxylate

To a solution of tert-butyl (3R)-3-(hydroxymethyl)pyrrolidine-l-carboxylate (2.06 g, 10.2 mmol) in tetrahydrofuran (25 mL) at room temperature was added NaH (60 wt.% in mineral oil, 413 mg, 17.2 mmol). The resulting mixture was stirred at room temperature for 30 min then 4- [5-amino-6-bromo-3-(4-methylphenyl)pyrazin-2-yl]benzonitrile (1.50 g, 4.10 mmol) was added. The reaction mixture was stirred at 85 °C for 15 h then cooled to room temperature. The mixture was quenched with saturated NaHCCte aqueous solution and extracted with EtOAc. The combined organic layers were dried over Na 2 S0 4 , and concentrated. The residue was purified on a silica gel column eluting with 10 to 40 % EtOAc/DCM to give the product as a yellow solid. LC-MS calculated for C^H^NsOs (M-tBu+2H) + : m/z = 430.2; found 430.1.

Step 5: 4-{5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo [ l,2-a]pyrazin-6- yljbenzonitrile

A mixture of tert-butyl (3R)-3-({[3-amino-6-(4-cyanophenyl)

methylphenyl)pyrazin-2-yl]oxy}methyl)pyrrolidine-l-carbox ylate (87.5 mg, 0.180 mmol) and chloroacetaldehyde (50 wt. % in water, 1.0 mL, 7.5 mmol) in isopropyl alcohol (3.0 mL) was heated to 105 °C and stirred for 1.5 h. The reaction mixture was cooled to room temperature then purified by prep HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C 25 H 24 N 5 0 (M+H) + : m/z = 410.2; found 410.2. l H NMR (500 MHz, CDsOD) δ 7.76 (br, 1H), 7.62 - 7.54 (m, 5H), 7.37 (d, J= 8.0 Hz, 2H), 7.31 (d, J= 8.0 Hz, 2H), 4.76 - 4.68 (m, 2H), 3.64 - 3.52 (m, 2H), 3.46 - 3.33 (m, 2H), 3.12 - 3.02 (m, 1H), 2.44 (s, 3H), 2.41 - 2.33 (m, 1H), 2.16 - 2.06 (m, 1H).

Example 2

4- [5-(4-methylphenyl)-8-(2-pyrrolidin-3-ylethyl)imidazo [ 1 ,2-a] pyr azin-6-yl] benzonitrile

A mixture of 4-[5-amino-6-bromo-3-(4-methylphenyl)pyrazin-2-yl]benzonitri le {Example 1, step 3, 2.80 g, 7.67 mmol) and chloroacetaldehyde (50 wt. % in water, 12 mL, 90. mmol) in isopropyl alcohol (40 mL) was heated to 105 °C and stirred for 1.5 h. The reaction mixture was cooled to room temperature then concentrated. The residue was dissolved in ethyl acetate, washed with saturated NaHCCte aqueous solution, water and brine. The organic layer was dried over Na 2 S04, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 70 % EtOAc/Hexanes to afford the desired product (2.4 g, 91 %). LC-MS calculated for C20H14CIN4 (M+H) + : m/z = 345.1; found 345.0.

Step 2: tert-butyl 3-ethynylpyrrolidine-l-carboxylate

To a solution of tert-butyl 3-formylpyrrolidine-l-carboxylate (580 mg, 2.91

mmol) in methanol (15 mL) at room temperature was added potassium carbonate (1.00 g, 7.28 mmol) and dimethyl (l-diazo-2-oxopropyl)phosphonate (839 mg, 4.37 mmol). The resulting mixture was stirred at room temperature for 3 h then passed through a short pad of celite and concentrated. The residue was purified on a silica gel column eluting with 0 to 50 %

EtOAc/Hexanes to give the product as a colorless oil which solidified upon standing in fridge to give a white solid (374 mg, 66 %).

Step 3: tert-butyl 3-{ [6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo [ 1 ,2-a] pyrazin-8- yl]ethynyl}pyrrolidine-l-carboxylate

A reaction vessel containing a mixture of 4-[8-chloro-5-(4-methylphenyl)imidazo[l,2- a]pyrazin-6-yl]benzonitrile (30.0 mg, 0.0870 mmol), tert-butyl 3-ethynylpyrrolidine-l- carboxylate (34 mg, 0.17 mmol), copper(I) iodide (5 mg, 0.03 mmol) and

dichloro[bis(triphenylphosphoranyl)]palladium (3 mg, 0.004 mmol) in triethylamine (0.5 mL, 4 mmol) was evacuated then refilled with nitrogen. The resulting mixture was stirred at 95 °C overnight. The mixture was then cooled to room temperature, diluted with CH2CI2, filtered and concentrated. The residue was purified on a silica gel column eluting with 0 to 20 %

EtOAc/DCM to give the desired product (35 mg, 81 %). LC-MS calculated for C31H30N5O2 (M+H) + : m/z = 504.2; found 504.2.

Step 4: 4-[5-(4-methylphenyl)-8-(2^yrrolidin-3-ylethyl)imidazo[l,2-a ]pyrazin-6-yl]benzom

A mixture of tert-butyl 3-{[6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo[l,2-a]pyrazi n- 8-yl]ethynyl}pyrrolidine-l-carboxylate (29 mg, 0.057 mmol) and Pd (10 wt% on carbon, 20 mg) in methanol (2.0 mL) and ethyl acetate (2.0 mL) was stirred under a balloon of hydrogen for 6 h at room temperature. The reaction mixture was filtered and the filtrate was concentrated. The residue was dissolved in CH2CI2 (1 mL) and then TFA (0.5 mL) was added. The resulting mixture was stirred at room temperature for 30 min then concentrated. The residue was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC- MS calculated for C26H26N5 (M+H) + : m/z = 408.2; found 408.2.

Example 3

4-(5-(4-methylphenyl)-8- { [(3R)-pyr rolidin-3-yloxy] methyl} imidazo [ 1 ,2-a] pyr azin-6- yl)benzonitrile

Step 1: 4-[5-(4-methylphenyl)-8-vinylimidazo l,2-aJpyrazin-6-ylJbenzonitrile

A mixture of 4-[8-chloro-5-(4-methylphenyl)imidazo[l,2-a]pyrazin-6-yl]ben zonitrile (Example 2, Step 1, 120 mg, 0.35 mmol), 4,4,5, 5-tetramethyl-2-vinyl-l,3,2-dioxaborolane (86 mg, 0.56 mmol) , sodium carbonate (74 mg, 0.70 mmol) and [Ι,Γ- bis(diphenylphosphino)ferrocene]dichloro-palladium(II) complexed with dichloromethane (1 : 1) (28 mg, 0.035 mmol) in 1,4-dioxane (3 mL)/water (0.3 mL) was evacuated then refilled with nitrogen. The resulting mixture was heated to 110 °C and stirred for 3 h. The mixture was cooled to room temperature then diluted with methylene chloride, washed with saturated NaHCCte, water and brine. The organic layer was dried over Na 2 S0 4 , filtered and concentrated. The residue was purified on a silica gel column eluting with 0 to 40 % EtOAc/Hexanes to give the desired product. LC-MS calculated for C22H17N4 (M+H) + : m/z = 337.1; found 337.1. Step 2: 4-[8-formyl-5-(4-methylphen l)imidazo[l,2-a]pyrazin-6-yl]benzonitrile

To a mixture of 4-[5-(4-methylphenyl)-8-vinylimidazo[l,2-a]pyrazin-6-yl]benz onitrile (80.0 mg, 0.238 mmol) and sodium periodate (240 mg, 1.1 mmol) in tetrahydrofuran (3.0 mL) and water (0.3 mL) was added osmium tetraoxide (4 wt. % in water, 0.44 mL, 0.071 mmol). The resulting mixture was heated to 70 °C and stirred for 2 h. The mixture was cooled to room temperature then diluted with methylene chloride, washed with saturated NaHCCte aqueous solution, water and brine. The organic layer was dried over Na 2 S0 4 , filtered and concentrated. The residue was purified on a silica gel column eluting with 0 to 10 % EtOAc/DCM to give the desired product. LC-MS calculated for C21H15N4O (M+H) + : m/z = 339.1; found 339.1.

Step 3: 4-[8-(hydroxymethyl)-5-(4-methylphenyl)imidazo[ 1 ,2-a] pyrazin-6-yl] benzonitrile

To a solution of 4-[8-formyl-5-(4-methylphenyl)imidazo[l,2-a]pyrazin-6-yl]ben zonitrile (0.080 g, 0.24 mmol) in methanol (2 mL) at 0 °C was added sodium tetrahydroborate (18 mg, 0.47 mmol). The resulting mixture was warmed to room temperature and stirred for 30 min. The mixture was then diluted with methylene chloride, washed with saturated NaHCCte aqueous solution, water and brine. The organic layer dried over Na 2 S04, filtered and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C21H17N4O (M+H) + : m/z = 341.1 ; found 341.1.

Step 4: [6-( 4-cyanophenyl)-5- ( 4-methylphenyl)imidazo[ 1, 2 -a Jpyrazin-8-ylj 'methyl

methanesulfonate

To a solution of 4-[8-(hydroxymethyl)-5-(4-methylphenyl)imidazo[l,2-a]pyrazin -6- yljbenzonitrile (80.0 mg, 0.235 mmol) and N,N-diisopropylethylamine (0.091 g, 0.70 mmol) in methylene chloride (1.0 mL) at 0 °C was added methanesulfonyl chloride (0.040 g, 0.35 mmol). The resulting mixture was stirred at 0 °C for 1 h then diluted with methylene chloride, washed with saturated NaHCCte aqueous solution, water and brine. The organic layer was dried over Na 2 S04, filtered and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C22H19N4O3S (M+H) + : m/z = 419.1; found 419.0. Step 5: 4-(5-(4-methylphenyl)-8-{[(3R)^yrrolidin-3-yloxyJmethyl}imid azo[l,2-aJpyrazin-6- yl)benzonitrile

To a solution of tert-butyl (3R)-3-hydroxypyrrolidine-l-carboxylate (27 mg, 0.14 mmol) in tetrahydrofuran (0.5 mL) was added sodium hydride (3.4 mg, 0.14 mmol). The resulting mixture was stirred at room temperature for 1 h then a solution of [6-(4-cyanophenyl)-5-(4- methylphenyl)imidazo[l,2-a]pyrazin-8-yl]methyl methanesulfonate (10.0 mg, 0.0239 mmol) in tetrahydrofuran (0.5 mL) was added. The mixture was then stirred at 50 °C overnight. The mixture was cooled to room temperature, diluted with methylene chloride, washed with water and brine. The organic layer was dried over Na 2 S0 4 , filtered and concentrated. The residue was dissolved in CH2CI2 (0.5 mL) then HC1 (4N in 1,4-dioxane, 0.8 mL) was added. The mixture was stirred at room temperature for 30 min then concentrated. The residue was dissolved in MeOH and purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C25H24N5O (M+H) + : m/z = 410.2; found 410.2.

Example 4

4-[8-{[(3S)-3-(dimethylamino)pyrrolidin-l-yl]methyl}-5-(4 -methylphenyl)imidazo[l,2- a] pyrazin-6-yl] benzonitrile

To a solution of 4-[8-formyl-5-(4-methylphenyl)imidazo[l,2-a]pyrazin-6-yl]ben zonitrile {Example 3, Step 2: 10 mg, 0.03 mmol) and (3S)-N,N-dimethylpyrrolidin-3-amine (10 mg, 0.09 mmol) in methylene chloride (1 mL) was added acetic acid (10 μί). The resulting mixture was stirred at room temperature for 1 h then sodium triacetoxyborohydride (20 mg, 0.09 mmol) was added. The mixture was stirred at room temperature overnight then diluted with methylene chloride, washed with saturated NaHCCte solution, water and brine. The organic layer was dried over Na 2 S0 4 and concentrated. The residue was dissolved in acetonitrile then purified by prep- HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C27H29N6 (M+H) + : m/z = 437.2; found 437.3.

Example 5 4- [8- { [(3R)-3-(dimethylamino)pyrrolidin- 1-yl] methyl}-5-(4-methylphenyl)imidazo [ 1 ,2- a] pyrazin-6-yl] benzonitrile

This compound was prepared using procedures analogous to those for Example 4 with (3R)-N,N-dimethylpyrrolidin-3-amine replacing (3S)-N,N-dimethylpyrrolidin-3-amine. The product was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the compound as the TFA salt. LC-MS calculated for C27H29N6 (M+H) + : m/z = 437.2; found 437.2.

Example 6

4-[8-{2-[(3R)-3-(dimethylamino)pyrrolidin-l-yl]ethyl}-5-( 4-methylphenyl)imidazo[l,2- a] pyrazin-6-yl] benzonitrile

To a mixture of 4-[5-(4-methylphenyl)-8-vinylimidazo[l,2-a]pyrazin-6-yl]benz onitrile {Example 3, Step 1: 8.0 mg, 0.024 mmol) and (3R)-N,N-dimethylpyrrolidin-3-amine (4.1 mg, 0.036 mmol) in acetonitrile (0.5 mL) was added l,8-diazabicyclo[5.4.0]undec-7-ene (5.3 μί, 0.036 mmol). The resulting mixture was heated to 65 °C and stirred overnight. The mixture was then cooled to room temperature and purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H31N6 (M+H) + : m/z = 451.3; found 451.3.

Example 7

4-{5-(4-methylphenyl)-8-[(l-methylpyrrolidin-3-yl)oxy]imidaz o[l,2-a]pyrazin-6- yl}benzonitrile

To a solution of l-methyl-3-pyrrolidinol (12. mg, 0.12 mmol) in DMF (0.5 mL) was added sodium hydride (60 wt.% in mineral oil, 9.6 mg, 0.24 mmol). The mixture was stirred at room temperature for 20 min then a solution of 4-[8-chloro-5-(4-methylphenyl)imidazo[l,2- a]pyrazin-6-yl]benzonitrile {Example 2, Step 1 : 20.7 mg, 0.060 mmol) in DMF (0.5 mL) was added. The reaction mixture was heated to 80 °C and stirred for 1 h. The mixture was cooled to room temperature then diluted with methanol and purified by prep-HPLC (pH = 10,

acetonitrile/water+NH40H) to afford the desired product. LC-MS calculated for C25H24N5O (M+H) + : m/z = 410.2; found 410.2.

Example 8

4- [8- [3-(dimethylamino)propoxy] -5-(4-methylphenyl)imidazo [1 ,2-a] pyrazin-6- yl]benzonitrile

This compound was prepared using procedures analogous to those for Example 7 with 3- (dimethylamino)-l-propanol replacing l-methyl-3-pyrrolidinol. The product was purified by prep-HPLC (pH = 10, acetonitrile/water+NLUOH) to afford the desired compound. LC-MS calculated for C25H26N5O (M+H) + : m/z = 412.2; found 412.2.

Example 9

4- {5-(4-methylphenyl)-8- [(3R)-piperidin-3-ylmethoxy] imidazo [ 1 ,2-a] pyrazin-6- yl}benzonitrile

Step 1: tert-butyl (3R)-3-({ [6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo [ 1 ,2-a] pyrazin-8- ylj oxy}methyl)piperidine-l -carbox late

This compound was prepared using procedures analogous to those for Example 7 with tert-butyl (3R)-3-(hydroxymethyl)piperidine-l -carboxylate replacing l-methyl-3-pyrrolidinol. The product was purified by prep-HPLC (pH = 10, acetonitrile/water+NIHUOH) to afford the desired compound. LC-MS calculated for C31H34N5O3 (M+H) + : m/z = 524.3; found 524.2.

Step 2: 4-{5-(4-methylphenyl)-8- [(3R)-piperidin-3-ylmethoxy] imidazo [1 ,2-a] pyrazin-6- yljbenzonitrile

The product from Step I was dissolved in TFA/DCM (0.5 mL, 1 : 1) and stirred at room temperature for 1 h. The reaction mixture was concentrated and the residue was dissolved in methanol then purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to afford the desired product as the TFA salt. LC-MS calculated for C26H26N5O (M+H) + : m/z = 424.2; found 424.2.

Example 10

4- {5-(4-methylphenyl)-8- [(3 S)-piperidin-3-ylmethoxy ] imidazo [ 1 ,2-a] pyrazin-6- yl}benzonitrile

This compound was prepared using procedures analogous to those for Example 9 with tert-butyl (3 S)-3-(hydroxymethyl)piperidine-l -carboxylate replacing tert-butyl (3R)-3- (hydroxymethyl)piperidine-l-carboxylate in Step 1. The product was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to afford the desired product as the TFA salt. LC-MS calculated for C26H26N5O (M+H) + : m/z = 424.2; found 424.2. Example 11

4-(5-(4-methylphenyl)-8-{[(3R)-l-methylpyrrolidin-3-yl]metho xy}imidazo[l,2-a]pyrazin-6- yl)benzonitrile

To a solution of 4-{5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo [l,2- a]pyrazin-6-yl}benzonitrile {Example 1: 40.0 mg, 0.0977 mmol) in methylene chloride (3 mL) was added formaldehyde (37 wt. % in water, 73 μί, 0.98 mmol), followed by acetic acid (33 μί, 0.59 mmol). The resulting mixture was stirred at room temperature for 3 h then sodium triacetoxyborohydride (120 mg, 0.59 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then diluted with DCM and washed with saturated NaHCCte solution, water and brine. The organic layer was dried over Na 2 S04 and concentrated. The residue was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC- MS calculated for C26H26N5O (M+H) + : m/z = 424.2; found 424.2.

Example 12

4-(5-(4-methylphenyl)-8- { [(3R)- l-methylpiperidin-3-yl] methoxy}imidazo [ 1 ,2-a] pyrazin-6- yl)benzonitrile

This compound was prepared using procedures analogous to those for Example 11 with 4- {5-(4-methylphenyl)-8-[(3R)-piperidin-3-ylmethoxy]imidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile replacing 4- {5-(4-methylphenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[ 1 ,2-a]pyrazin-6- yl}benzonitrile. The product was purified by prep HPLC (pH = 2, acetonitrile/water+TFA) to give the compound as the TFA salt. LC-MS calculated for C27H28N5O (M+H) + : m/z = 438.2; found 438.2.

Example 13

4-(5-(4-methylphenyl)-8- { [(3R)-pyr rolidin-3-ylmethyl] thiojimidazo [ 1 ,2-a] py razin-6- yl)benzonitrile

This compound was prepared using procedures analogous to those for Example 9 with tert-butyl (3R)-3-(mercaptomethyl)pyrrolidine-l-carboxylate replacing tert-butyl (3R)-3-

(hydroxymethyl)piperidine-l-carboxylate in Step 1. The product was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to afford the desired product as the TFA salt. LC-MS calculated for C25H24N5S (M+H) + : m/z = 426.2; found 426.2. Example 14

4- [8- [4-(dimethylamino)piperidin-l-yl] -5-(4-methylphenyl)imidazo [ 1 ,2-a] pyrazin-6- yl]benzonitrile

A mixture of 4-[8-chloro-5-(4-methylphenyl)imidazo[l,2-a]pyrazin-6-yl]ben zonitrile {Example 2, Step 1: 20.7 mg, 0.060 mmol), N,N-dimethylpiperidin-4-amine (11.5 mg, 0.090 mmol), and N,N-diisopropylethylamine (20.9 μί, 0.12 mmol) in N-methyl-2-pyrrolidone (0.5 mL) was heated to 180 °C and stirred for 1 h. The mixture was then cooled to room temperature, diluted with methanol and purified by prep-HPLC (pH = 10, acetonitrile/water+NFUOH) to afford the desired product. LC-MS calculated for C27H29N6 (M+H) + : m/z = 437.2; found 437.2. Example 15

4- [8- [ [3-(dimethylamino)propyl] (methyl)amino] -5-(4-methylphenyl)imidazo [1 ,2-a] pyrazin- 6-yl]benzonitrile

This compound was prepared using procedures analogous to those for Example 14 with N,N,N'-trimethylpropane-l,3-diamine replacing N,N-dimethylpiperidin-4-amine. The product was purified by prep-HPLC (pH = 10, acetonitrile/water+NEUOH) to afford the desired compound. LC-MS calculated for C26H2 N6 (M+H) + : m/z = 425.2; found 425.2.

Example 16

4-(5-(4-methylphenyl)-8-{[2-(l-methylpyrrolidin-2-yl)ethyl]a mino}imidazo[l,2-a]pyrazin-6- yl)benzonitrile

This compound was prepared using procedures analogous to those for Example 14 with 2-(l-methylpyrrolidin-2-yl)ethanamine replacing N,N-dimethylpiperidin-4-amine. The product was purified by prep-HPLC (pH = 10, acetonitrile/water+NEUOH) to afford the desired compound. LC-MS calculated for C27H29N6 (M+H) + : m/z = 437.2; found 437.2.

Example 17

4- {5-(4-methylphenyl)-8- [(l-methylpiperidin-4-yl)amino] imidazo [1 ,2-a] pyrazin-6- yl}benzonitrile

This compound was prepared using procedures analogous to those for Example 14 with l-methylpiperidin-4-amine replacing N,N-dimethylpiperidin-4-amine. The product was purified by prep-HPLC (pH = 10, acetonitrile/water+NEUOH) to afford the desired compound. LC-MS calculated for C26H27N6 (M+H) + : m/z = 423.2; found 423.2.

Example 18

4- [8-(4-methyl-l ,4-diazepan- l-yl)-5-(4-methylphenyl)imidazo [ 1 ,2-a] pyrazin-6- yl]benzonitrile

This compound was prepared using procedures analogous to those for Example 14 with 1 -methyl- 1 ,4-diazepane replacing N,N-dimethylpiperidin-4-amine. The product was purified by prep-HPLC (pH = 10, acetonitrile/water+NEUOH) to afford the desired compound. LC-MS calculated for C26H27N6 (M+H) + : m/z = 423.2; found 423.2.

Example 19

4- [8-(2,7-diazaspiro [4.4] non-2-yl)-5-(4-methylphenyl)imidazo [ 1 ,2-a] pyr azin-6- yl]benzonitrile

This compound was prepared using procedures analogous to those for Example 14 with 2,7-diazaspiro[4.4]nonane replacing N,N-dimethylpiperidin-4-amine. The product was purified by prep-HPLC (pH = 10, acetonitrile/water+NEUOH) to afford the desired compound. LC-MS calculated for C27H27N6 (M+H) + : m/z = 435.2; found 435.2.

Example 20

4- [8-(2,7-diazaspiro [3.5] non-7-yl)-5-(4-methylphenyl)imidazo [ 1 ,2-a] pyr azin-6- yl]benzonitrile

This compound was prepared using procedures analogous to those for Example 14 with tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate replacing N,N-dimethylpiperidin-4-amine. The product was purified by prep-HPLC (pH = 10, acetonitrile/water+NEUOH) to afford the desired compound. LC-MS calculated for C27H27N6 (M+H) + : m/z = 435.2; found 435.2.

Example 21

(3R)-N- [6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo [ 1 ,2-a] pyr azin-8-yl] -3- (dimethylamino)-N-methylpyrrolidine-l-carboxamide

Step 1: 4-[8-(methylamino)-5-(4-methylphenyl)imidazo[ l,2-a]pyrazin-6-yl]benzonitrile

A mixture of 4-[8-chloro-5-(4-methylphenyl)imidazo[l,2-a]pyrazin-6-yl]ben zonitrile

{Example 2, Step 1, 40.0 mg, 0.116 mmol) and methylamine (8.0 M in methanol, 1.93 mL, 15.5 mmol) was stirred at 100 °C overnight. The mixture was then cooled to room temperature and concentrated. The residue was purified on a silica gel column eluting with 0 to 10 % MeOH/DCM to afford the desired product (30 mg, 76 %). LC-MS calculated for C21H18N5 (M+H) + : m/z = 340.2; found 340.1. Step 2: (3R)-N-[6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo[l,2-a]py razin-8-yl]-3- (dimethylamino)-N-methylpyrrolidine-l-carboxamide

To a solution of 4-[8-(methylamino)-5-(4-methylphenyl)imidazo[l,2-a]pyrazin-6 - yljbenzonitrile (15.0 mg, 0.0442 mmol) and N,N-diisopropylethylamine (30.0 0.172 mmol) in THF (1 mL) was added triphosgene (15.0 mg, 0.0505 mmol). The mixture was stirred at room temperature for 1 h then the volatiles were removed under vacuum. The residue was dissolved in acetonitrile (1 mL) then (3R)-N,N-dimethylpyrrolidin-3-amine (8.4 0.066 mmol) and N,N- diisopropylethylamine (30 μί) were added. The mixture was stirred at room temperature overnight then purified by prep-HPLC (pH = 10, acetonitrile/water+NlHUOH) to afford the desired product. LC-MS calculated for C28H30N7O (M+H) + : m/z = 480.3; found 480.2.

Example 22

(3 S)-N- [6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo [1 ,2-a] pyrazin-8-yl] -3- (dimethylamino)-N-methylpyrrolidine-l-carboxamide

This compound was prepared using procedures analogous to those for Example 21 with

(3S)-N,N-dimethylpyrrolidin-3-amine replacing (3R)-N,N-dimethylpyrrolidin-3-amine. The product was purified with prep-HPLC (pH = 10, acetonitrile/water+NIHUOH) to afford the desired product. LC-MS calculated for C28H30N7O (M+H) + : m/z = 480.3; found 480.2. Example 23

4- [8- { [2-(2-amino-l ,3-thiazol-4-yl)ethyl] amino}-5-(4-methylphenyl)imidazo [ 1 ,2-a] pyr azin- 6-yl]benzonitrile

This compound was prepared using procedures analogous to those for Example 14 with 4-(2-aminoethyl)-l,3-thiazol-2-amine replacing N,N-dimethylpiperidin-4-amine. The product was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to afford the desired compound as the TFA salt. LC-MS calculated for C25H22N7S (M+H) + : m/z = 452.2; found 452.2.

Example 24

N-(azetidin-3-ylmethyl)-6-(4-cyanophenyl)-5-(4-methylphenyl) imidazo [ 1 ,2-a] pyrazine-8- carboxamide

methyl 3-amino-6-(4-cyanophenyl)-5-(4-methylphenyl)pyrazine-2-carbo xylate

A mixture of methyl 3-amino-5,6-dichloropyrazine-2-carboxylate (1.00 g, 4.50 mmol), (4-methylphenyl)boronic acid (0.612 g, 4.50 mmol), sodium carbonate (0.955 g, 9.01 mmol) and [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1 : 1) (0.18 g, 0.22 mmol) in 1 ,4-dioxane (18 mL) and water (2 mL) was evacuated then refilled with nitrogen. The resulting mixture was stirred at 90 °C for 2 h. The mixture was cooled to room temperature then (4-cyanophenyl)boronic acid (0.66 g, 4.50 mmol) was added, followed by another portion of [l, -bis(diphenylphosphino)ferrocene]dichloro-palladium(II) complexed with dichloromethane (1 : 1) (0.2 g, 0.2 mmol). The vessel containing the mixture was evacuated then refilled with nitrogen and stirred at 90 °C for additional 2 h. The reaction mixture was cooled to room temperature and diluted with methylene chloride, washed with water and brine. The organic layer was dried over Na 2 S04, filtered and concentrated under reduced pressure. The residue was purified on a silica gel column eluting with 0 to 25 % EtOAc/DCM to give the desired product (1.2 g, 77 %). LC-MS calculated for C20H17N4O2 (M+H) + : m/z = 345.1; found 345.1.

Step 2: 6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo [ 1 ,2-a] pyrazine-8-carboxylic acid

To a mixture of methyl 3-amino-6-(4-cyanophenyl)-5-(4-methylphenyl)pyrazine-2- carboxylate (0.410 g, 1.19 mmol) in isopropyl alcohol (5 mL) was added chloroacetaldehyde (50 wt. % in water, 1.9 mL, 14 mmol). The mixture was stirred at 105 °C for 1.5 h then cooled to room temperature and concentrated. The residue was dissolved in ethyl acetate, washed with saturated NaHCC aqueous solution, water and brine. The organic layer was dried over Na 2 S04, filtered and concentrated under reduced pressure. The residue was purified by flash

chromatography on a silica gel column eluting with 0 to 70 % EtOAc/Hexane to afford the desired intermediate (0.35 g). To a solution of the above intermediate in tetrahydrofuran (3 mL)/water (3 mL) was added lithium hydroxide, monohydrate (0.25 g, 5.95 mmol). The resulting mixture was stirred at room temperature overnight then acidified with IN HCl and extracted with DCM/IPA (2:1). The combined extracts were dried over Na 2 S04, filtered and concentrated under reduced pressure to afford the desired product (0.336 g, 80 %), which was used in the next step without further purification. LC-MS calculated for C21H15N4O2 (M+H) + : m z = 355.1; found 355.1.

Step 3: tert-butyl 3- [({ [6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo [1 ,2-a] pyrazin-8- yl]carbonyl}amino)methyl]azetidine-l-carboxylate

To a solution of 6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo[l,2-a]pyrazine-8 - carboxylic acid (8.0 mg, 0.022 mmol) and tert-butyl 3-(aminomethyl)azetidine-l-carboxylate (8.41 mg, 0.0452 mmol) in N,N-dimethylformamide (0.5 mL) was added N,N- diisopropylethylamine (16 μΐ,, 0.094 mmol), followed by N,N,N',N'-tetramethyl-0-(7- azabenzotriazol-l-yl)uronium hexafluorophosphate (8.6 mg, 0.022 mmol). The resulting mixture was stirred at room temperature for 1 h then diluted with EtOAc and washed with water and brine. The organic layer was dried over Na 2 S04 and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C30H31N6O3 (M+H) + : m/z = 523.2; found 523.2. Step 4: N-(azetidin-3-ylmethyl)-6-(4-cyanophenyl)-5-(4-methylphenyl) imidazo[ l,2-a]pyrazine-8- carboxamide

The crude product from Step 3 was dissolve in DCM (1 mL) then TFA (0.5 mL) was added. The resulting mixture was stirred at room temperature for 1 h then concentrated. The residue was dissolved in acetonitrile then purified by prep HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C25H23N6O (M+H) + : m/z = 423.2; found 423.2.

Example 25

6-(4-cyanophenyl)-N-(l-methylazetidin-3-yl)-5-(4-methylpheny l)imidazo[l,2-a]pyrazine-8- carboxamide

To a solution of 6-(4-cyanophenyl)-5-(4-methylphenyl)imidazo[l,2-a]pyrazine-8 - carboxylic acid {Example 24, Step 2, 10.0 mg, 0.028 mmol) and l-methylazetidin-3 -amine (4.9 mg, 0.056 mmol) in N,N-dimethylformamide (0.5 mL) was added N,N-diisopropylethylamine (20 0.12 mmol), followed by N,N,N',N'-tetramethyl-0-(7-azabenzotriazol-l-yl)uronium hexafluorophosphate (11 mg, 0.028 mmol). The resulting mixture was stirred at room

temperature for 1 h then purified by prep HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C25H23N6O (M+H) + : m/z = 423.2; found 423.2.

Example 26

4- {(5-phenyl)-8- [(3R)-pyr rolidin-3- lmethoxy] imidazo [ 1 ,2-a] pyrazin-6-yl}benzonitrile

Step 1: tert-butyl (3R)-3-{[(3-amino-6-bromo-5-chloropyrazin-2-yl)oxy]methyl}py rrolidine-l- carboxylate

To a solution of 3,5-dibromo-6-chloropyrazin-2-amine (600.0 mg, 2.088 mmol) in 1,4- dioxane (5 mL) was added sodium hydroxide (110 mg, 2.7 mmol), followed by tert-butyl (3R)- 3-(hydroxymethyl)pyrrolidine-l-carboxylate (550 mg, 2.7 mmol). The resulting mixture was heated to 70 °C and stirred overnight. The reaction mixture was cooled to room temperature and concentrated. The residue was purified on a silica gel column eluting with 0 to 20 %

EtOAc/DCM to give the desired product (330 mg, 39 %). LC-MS calculated for

CioHi3BrClN 4 03 (M- t Bu+2H) + : m/z = 351.0; found 351.0. ¾ NMR (500 MHz, DMSO) δ 7.00 (br, 2H), 4.27 - 4.11 (m, 2H), 3.54 - 3.47 (m, 1H), 3.38 - 3.31 (m, 1H), 3.26 - 3.16 (m, 1H), 3.11 - 3.02 (m, 1H), 2.65 - 2.51 (m, 1H), 2.05 - 1.94 (m, 1H), 1.79 - 1.66 (m, 1H), 1.38 (s, 9H).

Step 2: tert-butyl (3R)-3-({[3-amino-5-chloro-6-(4-cyanophenyl)pyrazin-2- ylj ' oxy}methyl)pyrrolidine-l -carboxylate

A reaction vessel containing a mixture of tert-butyl (3R)-3-{[(3-amino-6-bromo-5- chloropyrazin-2-yl)oxy]methyl}pyrrolidine-l -carboxylate (660 mg, 1.6 mmol), (4- cyanophenyl)boronic acid (285 mg, 1.94 mmol), dichloro(bis{di-tert-butyl[4- (dimethylamino)phenyl]phosphoranyl})palladium (60 mg, 0.08 mmol) and sodium carbonate (340 mg, 3.2 mmol) in 1,4-dioxane (10 mL) and water (1 mL) was evacuated then refilled with nitrogen. The resulting mixture was heated to 90 °C and stirred overnight. The reaction mixture was cooled to room temperature then diluted with EtOAc and washed with water and brine. The organic layer was dried over Na 2 S0 4 and concentrated. The residue was purified on a silica gel column eluting with 0 to 30 % EtOAc/DCM to give the desired product (590 mg, 85 %). LC-MS calculated for CieHivClNsO (M-Boc+2H) + : m/z = 330.1; found 330.2.

Step 3: 4-{5-chloro-8- [(3R)-pyrrolidin-3- lmethoxy] imidazo [ 1 ,2-a] pyrazin-6-yl}benzonitrile

A mixture of tert-butyl (3R)-3-({[3-amino-5-chloro-6-(4-cyanophenyl)pyrazin-2- yl]oxy}methyl)pyrrolidine-l-carboxylate (456 mg, 1.06 mmol) and chloroacetaldehyde (50 wt. % in water, 1.2 mL, 9.0 mmol) in ethanol (7 mL) was heated to 95 °C and stirred overnight. The reaction mixture was then cooled to room temperature and concentrate. The residue was dissolved in DCM/IPA (2:1) then washed with saturated NaHCC aqueous solution, dried over Na 2 S0 4 and concentrated. The residue was triturated with hexanes then filtered and dried to give the desired product. LC-MS calculated for CisHivClNsO (M +H) + : m/z = 354.1; found 354.1.

Step 4: 4-{(5-phenyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[l,2-a]p

A mixture of 4-{5-chloro-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[l,2-a]pyr azin-6- yl}benzonitrile (20.0 mg, 0.0565 mmol), phenylboronic acid (14 mg, 0.11 mmol), [l,l'-bis(di- cyclohexylphosphino)ferrocene]-dichloropalladium(II) (2 mg, 0.003 mmol), sodium carbonate (12 mg, 0.11 mmol) in tert-butyl alcohol (1.0 mL)/water (0.5 mL) was evacuated then refilled with nitrogen. The resulting mixture was heated to 90 °C and stirred for 2 h. The mixture was cooled to room temperature then purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C24H22N5O (M +H) + : m/z = 396.2; found 396.1. Example 27

4- {5-(4-chlorophenyl)-8- [(3R)-pyr rolidin-3-ylmethoxy] imidazo [1 ,2-a] pyrazin-6- yl}benzonitrile

This compound was prepared using procedures analogous to those for Example 26, Step 4 with (4-chlorophenyl)boronic acid replacing phenylboronic acid. The product was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the compound as the TFA salt. LC-MS calculated for C24H21CIN5O (M +H) + : m/z = 430.1; found 430.1.

Example 28

4- {8- [(3R)-pyrrolidin-3-ylmethoxy] -5- [4-(trifluoromethyl)phenyl] imidazo [ 1 ,2-a] pyr azin-6- yl}benzonitrile

This compound was prepared using procedures analogous to those for Example 26, Step 4 with (4-trifluoromethylphenyl)boronic acid replacing phenylboronic acid. The product was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the compound as the TFA salt. LC-MS calculated for C25H21F3N5O (M +H) + : m/z = 464.2; found 464.1.

Example 29

4- {5-(4-piperidin-l-ylphenyl)-8- [(3R)-pyrrolidin-3-ylmethoxy] imidazo [ 1 ,2-a] pyr azin-6- yl}benzonitrile

This compound was prepared using procedures analogous to those for Example 26, Step 4 with l-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]pip eridine (Alfa Aesar, cat#H51922) replacing phenylboronic acid. The product was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the compound as the TFA salt. LC-MS calculated for

C29H31N6O (M +H) + : m/z = 479.3; found 479.2.

Example 30

4- {5-(4-methoxyphenyl)-8- [(3R)-pyrrolidin-3-ylmethoxy] imidazo [1 ,2-a] pyr azin-6- yl}benzonitrile

This compound was prepared using procedures analogous to those for Example 26, Step 4 with 4-methoxyphenylboronic acid replacing phenylboronic acid. The product was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the compound as the TFA salt. LC-MS calculated for C25H24N5O2 (M +H) + : m/z = 426.2; found 426.1.

Example 31

4- {5- [2-(dimethylamino)pyrimidin-5-yl] -8- [(3R)-pyr rolidin-3-ylmethoxy] imidazo [1 ,2- a]pyrazin-6-yl}benzonitrile

This compound was prepared using procedures analogous to those for Example 26, Step 4 with 2-dimethylamino-pyrimidine-5-boronic acid pinacol ester (Frontier, cat#D1773) replacing phenylboronic acid. The product was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the compound as the TFA salt. LC-MS calculated for C24H25N8O (M +H) + : m/z = 441.2; found 441.2.

Example 32

4-(5-[6-(dimethylamino)pyridin-3-yl]-8-{[(3R)-l-methylpyrrol idin-3- yl] methoxy}imidazo [ 1 ,2-a] pyr azin-6-yl)benzonitrile

Step 1: 4-(5-chloro-8-{[(3R)-l-methylpyrrolidin-3-yl]methoxy}imidazo [l,2-a]pyraz

yl)benzonitrile

To a solution of 4-{5-chloro-8-[(3R)-pyrrolidin-3-ylmethoxy]imidazo[l,2-a]pyr azin-6- yl}benzonitrile {Example 26, Step J, 215 mg, 0.608 mmol) in methylene chloride (10 mL) was added formaldehyde (37 wt. % in water, 452 iL, 6.08 mmol). The resulting mixture was stirred at room temperature for 30 min then sodium triacetoxyborohydride (390 mg, 1.8 mmol). The mixture was stirred at room temperature overnight then diluted with DCM and washed with saturated NaHCC aqueous solution, water and brine. The organic layer was dried over Na 2 S04 and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C19H19CIN5O (M +H) + : m/z = 368.1; found 368.1.

Step 2: 4-(5-[ 6-(dimethylamino)pyridin-3-yl]-8-{[(3R)-l-methylpyrrolidin-3 - yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile A mixture of 4-(5-chloro-8-{[(3R)-l-methylpyrrolidin-3-yl]methoxy}imidazo [l,2- a]pyrazin-6-yl)benzonitrile (20. mg, 0.054 mmol), 6-(dimethylamino)pyridine-3-boronic acid (Combi-Blocks, cat#FA-2296: 19 mg, 0.11 mmol), [l, -bis(di-cyclohexylphosphino)ferrocene]- dichloropalladium(II) (2 mg, 0.003 mmol), sodium carbonate (12 mg, 0.11 mmol) in tert-butyl alcohol (0.5 mL)/water (0.5 mL) was evacuated then filled with nitrogen. The resulting mixture was heated to 100 °C and stirred for 2 h. The mixture was cooled to room temperature then diluted with MeOH and purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C26H28N7O (M +H) + : m/z = 454.2; found 454.2.

Example 33

4- {2-methyl-5-(4-methylphenyl)-8- [(3R)-pyr rolidin-3-ylmethoxy] imidazo [ 1 ,2-a] pyrazin-6- yl}benzonitrile

A mixture of tert-butyl (3R)-3-({[3-amino-6-(4-cyanophenyl)-5-(4- methylphenyl)pyrazin-2-yl]oxy}methyl)pyrrolidine-l-carboxyla te {Example 1, Step 4: 20 mg, 0.04 mmol) and chloroacetone (82.0 μί, 1.03 mmol) in isopropyl alcohol (1.0 mL) was stirred at 105 °C overnight at which time LC-MS indicated the reaction was not complete. The reaction mixture was then heated to 130 °C and stirred for 1 h. The mixture was cooled to room temperature then purified by prep-HPLC (pH = 10, acetonitrile/water+NH40H) to give the desired product. LC-MS calculated for C26H26N5O (M +H) + : m/z = 424.2; found 424.2.

Example 34

4- [5-(4-methylphenyl)-8- [(3R)-pyrrolidin-3-ylmethoxy] -2-(trifluor omethyl)imidazo [1 ,2- a]pyrazin-6-yl]benzonitrile

A mixture of tert-butyl (3R)-3-({[3-amino-6-(4-cyanophenyl)-5-(4- methylphenyl)pyrazin-2-yl]oxy}methyl)pyrrolidine-l-carboxyla te {Example 1, Step 4: 35.0 mg, 0.0721 mmol), sodium carbonate (38.2 mg, 0.360 mmol) and 3-bromo-l,l,l-trifluoroacetone (74.84 μΐ ^ , 0.7208 mmol) in isopropyl alcohol (1.5 mL) was stirred at 155 °C for 15 min. The reaction mixture was then cooled to room temperature, filtered and concentrated. The residue was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C26H23F3N5O (M +H) + : m/z = 478.2; found 478.1. Example 35

4- {2,5-bis(4-methylphenyl)-8- [(3R)-pyrrolidin-3-ylmethoxy] imidazo [ 1 ,2-a] pyrazin-6- yl}benzonitrile

A mixture of tert-butyl (3R)-3-({[3-amino-6-(4-cyanophenyl)

methylphenyl)pyrazin-2-yl]oxy}methyl)pyrrolidine-l-carbox ylate (Example 1, Step 4: 30.0 mg, 0.0618 mmol), sodium carbonate (65.48 mg, 0.6178 mmol) and 2-bromo-l-(4-methylphenyl)- ethanone (65.8 mg, 0.309 mmol) in isopropyl alcohol (1.5 mL) was stirred at 155 °C for 3 h. The reaction mixture was then cooled to room temperature, filtered and concentrated. The residue was dissolved in methylene chloride (1.5 mL) then trifluoroacetic acid (0.5 mL) was added. The reaction mixture was stirred at room temperature for 1 h and concentrated. The crude material was then purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C32H30N5O (M +H) + : m/z = 500.2; found 500.3. Example 36

4- {2-(cyanomethyl)-5-(4-methylphenyl)-8- [(3R)-pyr rolidin-3-ylmethoxy] imidazo [1 ,2- a]pyrazin-6-yl}benzonitrile

A mixture of tert-butyl (3R)-3-({[3-amino-6-(4-cyanophenyl)-5-(4- methylphenyl)pyrazin-2-yl]oxy}methyl)pyrrolidine-l-carboxyla te (50.0 mg, 0.103 mmol), disodium hydrogen phosphate (146 mg, 1.03 mmol) and l,3-dichloro-2-propanone (130.7 mg, 1.030 mmol) in isopropyl alcohol (1.5 mL) was stirred at 110 °C for 4.5 h then cooled to room temperature, filtered and concentrated. The residue was dissolved in N,N-dimethylformamide (1.5 mL) then sodium cyanide (50.4 mg, 1.03 mmol) was added. The resulting mixture mixture was stirred at 65 °C for 30 min then cooled to room temperature and diluted with EtOAc, washed with saturated NaHCCte aqueous solution, water and brine. The organic layer was dried over Na 2 SC"4 and concentrated. The residue was dissolved in methylene chloride (1.5 mL) then trifluoroacetic acid (1.0 mL) was added. The reaction mixture was stirred at room temperature for 1 h then concentrated. The crude material was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C 2 7H 25 N 6 0 (M +H) + : m/z = 449.2; found 449.3. Example 37

6-(4-cyanophenyl)-N-methyl-5-(4-methylphenyl)-8-[(3R)-pyrrol idin-3-ylmethoxy]imidazo- [ 1 ,2-a] pyr azine-2-carboxamide

Step 1: 8-{[(3R)-l-(tert-butoxycarbonyl)pyrrolidin-3-yl]methoxy}-6-( 4-cyanophenyl)-5-(4- methylphenyl)imidazof 1 ,2-a] pyrazine-2-carbox lic acid

A mixture of tert-butyl (3R)-3-({[3-amino-6-(4-cyanophenyl)-5-(4- methylphenyl)pyrazin-2-yl]oxy}methyl)pyrrolidine-l-carboxyla te (150.0 mg, 0.3089 mmol), disodium hydrogen phosphate (439 mg, 3.09 mmol) and ethyl bromopyruvate (387.6 μί, 3.089 mmol) in isopropyl alcohol (3.0 mL) was stirred at 95 °C for 2 h then cooled to room

temperature, filtered and concentrated. The residue was purified on a silica gel column to give the desired intermediate. To a solution of the above intermediate in methanol (2.5 mL) and water (1.5 mL) was added sodium hydroxide (62 mg, 1.5 mmol). The resulting mixture mixture was stirred at 55 °C for 2 h then cooled to room temperature and acidified to pH 1~3 with 1 M HCl. The mixture was extracted with EtOAc. The organic layer was dried over Na 2 S04, and concentrated to give the desired product, which was used in the next step without further purification. LC-MS calculated for CsiffeNsOs (M +H) + : m/z = 554.2; found 554.1.

Step 2: 6-(4-cyanophenyl)-N-methyl-5-(4-methylphenyl)-8-[ (3R)-pyrrolidin-3- ylmethoxyjimidazof 1, 2-a] pyrazine-2-carboxamide

To a mixture of 8-{[(3R)-l-(tert-butoxycarbonyl)pyrrolidin-3-yl]methoxy}-6-( 4- cyanophenyl)-5-(4-methylphenyl)imidazo[l ,2-a]pyrazine-2-carboxylic acid (35.0 mg, 0.0632 mmol), benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorophosphate (55.9 mg, 0.126 mmol), and triethylamine (44.0 0.316 mmol) in methylene chloride (1.5 mL) was added methylamine (2M in THF, 158 0.316 mmol). The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in methylene chloride (1.5 mL) then trifluoroacetic acid (1.0 mL) was added. The mixture was stirred at room temperature for 1 h then concentrated. The residue was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C 2 7H 27 N 6 0 2 (M +H) + : m/z = 467.2; found 467.1. Example 38

6-(4-cyanophenyl)-N,N-dimethyl-5-(4-methylphenyl)-8-[(3R)-py rrolidin-3- ylmethoxy] imidazo [ 1 ,2-a] pyr azine-2-carboxamide

This compound was prepared using procedures analogous to those for Example 37 with dimethylamine (2M in THF) replacing methylamine in Step 2. The product was purified by prep- HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H29N6O2 (M +H) + : m/z = 481.2; found 481.2.

Example 39

6-(4-cyanophenyl)-N-cyclopropyl-5-(4-methylphenyl)-8-[(3R)-p yrrolidin-3- ylmethoxy] imidazo [ 1 ,2-a] pyr azine-2-carboxamide

This compound was prepared using procedures analogous to those for Example 37 with cyclopropylamine replacing methylamine in Step 2. The product was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H29N6O2 (M +H) + : m/z = 493.2; found 493.1.

Example 40

6-(4-cyanophenyl)-N-(l-methylazetidin-3-yl)-5-(4-methylpheny l)-8-[(3R)-pyrrolidin-3- ylmethoxy] imidazo [ 1 ,2-a] pyr azine-2-carboxamide

This compound was prepared using procedures analogous to those for Example 37 with l-methylazetidin-3 -amine replacing methylamine in Step 2. The product was purified by prep- HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C30H32N7O2 (M +H) + : m/z = 522.3; found 522.2.

Example 41

4- {2-(hydr oxymethyl)-5-(4-methylphenyl)-8- [(3R)-pyrrolidin-3-ylmethoxy] imidazo [1 ,2- a] pyr azin-6-yl}benzonitrile

Step 1: tert-butyl (3R)-3-({[6-(4-cyanophenyl)-2-(hydroxymethyl)-5-(4- methylphenyl)imidazofl,2-aJp razin-8-ylJoxy}methyl)pyrrolidine-l-carboxylate

To a solution of 8-{[(3R)-l-(tert-butoxycarbonyl)pyrrolidin-3-yl]methoxy}-6-( 4- cyanophenyl)-5-(4-methylphenyl)imidazo[l,2-a]pyrazine-2-carb oxylic acid (Example 37, Step 1 190 mg, 0.34 mmol) in tetrahydrofuran (3.0 mL) at 0 °C was added 4-methylmorpholine (56 μί, 0.51 mmol) and isobutyl chloroformate (66 μί, 0.51 mmol). The reaction mixture was stirred at 0 °C for 30 min and then the resulting solid was filtered off and washed with 1.5 mL of THF. To the filtrate at 0 °C was added a solution of sodium tetrahydroborate (26 mg, 0.68 mmol) in water (0.5 mL). The reaction mixture was warmed to room temperature and stirred for 15 min. The mixture was then quenched with saturated NaHCCte aqueous solution and extracted with EtOAc. The combined organic layers were dried over Na 2 S04 and concentrated. The residue was purified on a silica gel column to give the desired product. LC-MS calculated for C31H34N5O4 (M +H) + : m/z = 540.3; found 540.2.

Step 2: 4-{2-(hydroxymethyl)-5-(4-methylphenyl)-8-[ (3R)-pyrrolidin-3-ylmethoxy]imidazo[ 1,2- a] pyrazin-6-yl}benzonitrile

To a solution of tert-butyl (3R)-3-({[6-(4-cyanophenyl)-2-(hydroxymethyl)-5-(4- methylphenyl)imidazo[l,2-a]pyrazin-8-yl]oxy}methyl)pyrrolidi ne-l-carboxylate (30 mg) in DCM (1 mL) was added TFA (0.5 mL). The resulting mixture was stirred at room temperature for 1 h then concentrated. The residue was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C26H26N5O2 (M +H) + : m/z = 440.2; found 440.1.

Example 42

4- {2- [(dimethylamino)methyl] -5-(4-methylphenyl)-8- [(3R)-pyrrolidin-3- ylmethoxy] imidazo [ 1 ,2-a] pyrazin-6-yl}benzonitrile

Step 1: tert-butyl (3R)-3-({ [6-(4-cyanophenyl)-2-formyl-5-(4-methylphenyl)imidazo [ 1 ,2- aJpyrazin-8-ylJ oxy}methyl)pyrrolidine-l -carboxylate

To a solution of tert-butyl (3R)-3-({[6-(4-cyanophenyl)-2-(hydroxymethyl)-5-(4- methylphenyl)imidazo[l,2-a]pyrazin-8-yl]oxy}methyl)pyrrolidi ne-l-carboxylate {Example 41, Step 1: 122 mg, 0.226 mmol) in methylene chloride (3.0 mL) was added sodium bicarbonate (57 mg, 0.68 mmol) and Dess-Martin periodinane (140 mg, 0.34 mmol). The resulting mixture was then stirred at room temperature overnight. The mixture was loaded directly into a silica gel column eluting with 0 to 50 % EtOAc/DCM to give the desired product. LC-MS calculated for C3iH3 2 N 5 04(M +H) + : m/z = 538.2; found 538.1.

Step 2: 4-{2-[ (dimethylamino)methyl]-5-(4-methylphenyl)-8-[(3R)-pyrrolidin -3- ylmethoxyj 'imidazo [1 ,2-a] pyrazin-6-yl}benzonitrile

To a solution of tert-butyl (3R)-3-({[6-(4-cyanophenyl)-2-formyl-5-(4- methylphenyl)imidazo[l,2-a]pyrazin-8-yl]oxy}methyl)pyrrolidi ne-l-carboxylate (30.0 mg, 0.0558 mmol) and dimethylamine (2M in THF, 140 0.28 mmol) in methylene chloride (1.5 mL) was added acetic acid (16 0.28 mmol). The resulting mixture was stirred at room temperature for 3 h then sodium triacetoxyborohydride (59 mg, 0.28 mmol) was added. The reaction mixture was stirred at room temperature overnight then diluted with DCM and washed with saturated NaHCCte aqueous solution, water and brine. The organic layer was dried over Na 2 S04 and concentrated. The residue was dissolved in DCM (1 mL) then trifluoroacetic acid (0.5 mL) was added. The resulting mixture was stirred at room temperature for 1 h and concentrated. The crude material was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H3iNeO(M +H) + : m/z =

467.3; found 467.2. ¾ NMR (500 MHz, DMSO) δ 10.12 (br, 1H), 9.01 (br, 2H), 7.76 - 7.72 (m, 2H), 7.69 (s, 1H), 7.54 - 7.50 (m, 2H), 7.38 - 7.32 (m, 4H), 4.65 - 4.53 (m, 2H), 4.39 (s, 2H), 3.48 - 3.38 (m, 1H), 3.36 - 3.28 (m, 1H), 3.27 - 3.17 (m, 1H), 3.14 - 3.05 (m, 1H), 2.96 - 2.85 (m, 1H), 2.75 (s, 6H), 2.38 (s, 3H), 2.21 - 2.11 (m, 1H), 1.90 - 1.76 (m, 1H).

Example 43

4- {2-(azetidin- l-ylmethyl)-5-(4-methylphenyl)-8- [(3R)-pyr rolidin-3-ylmethoxy] imidazo [ 1 ,2- a]pyrazin-6-yl}benzonitrile

This compound was prepared using procedures analogous to those for Example 42 with azetidine hydrochloride replacing dimethylamine in Step 2. The product was purified by prep- HPLC (pH = 2, acetonitrile/water+TFA) to give the compound as the TFA salt. LC-MS calculated for C 2 9H3iN 6 0(M +H) + : m/z = 479.3; found 479.2.

Example 44

4-{2-{[(cyclopropylmethyl)amino]methyl}-5-(4-methylphenyl)-8 -[(3R)-pyrrolidin-3- ylmethoxy] imidazo [ 1 ,2-a] pyrazin-6-yl}benzonitrile

This compound was prepared using procedures analogous to those for Example 42 with cyclopropylmethylamine replacing dimethylamine in Step 2. The product was purified by prep- HPLC (pH = 2, acetonitrile/water+TFA) to give the compound as the TFA salt. LC-MS calculated for CsoftssNeOCM +H) + : m/z = 493.3; found 493.2.

Example 45

4- {2- [(isoxazol-3-ylamino)methyl] -5-(4-methylphenyl)-8- [(3R)-pyrrolidin-3- ylmethoxy] imidazo [ 1 ,2-a] pyrazin-6-yl}benzonitrile

This compound was prepared using procedures analogous to those for Example 42 with isoxazol-3 -amine replacing dimethylamine in Step 2. The product was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the compound as the TFA salt. LC-MS calculated for C29H28N7O2 (M +H) + : m/z = 506.2; found 506.2.

Example 46

4-(2-[(dimethylamino)methyl]-5-(4-methylphenyl)-8-{[(3R)-l-m ethylpyrrolidin-3- yl] methoxy}imidazo [ 1 ,2-a] pyr azin-6-yl)benzonitrile

To a solution of 4-{2-[(dimethylamino)methyl]-5-(4-methylphenyl)-8-[(3R)-pyrr olidin-3- ylmethoxy]imidazo[l,2-a]pyrazin-6-yl}benzonitrile {Example 42: 10 mg, 0.02 mmol) in 1,2- dichloroethane (1.5 mL) was added formaldehyde (37 wt. % in water, 21 μΕ, 0.29 mmol), followed by acetic acid (10 0.2 mmol). The resulting mixture was stirred at room

temperature for 3 h, followed by the addition of sodium triacetoxyborohydride (40 mg, 0.2 mmol). The mixture was stirred at room temperature for another 2 h and concentrated. The resulting residue was then purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the compound as the TFA salt. LC-MS calculated for C29H33N6O (M +H) + : m/z = 481.3; found 481.2.

Example 47

4- {2- [2-(dimethylamino)ethyl] -5-(4-methylphenyl)-8- [(3R)-pyrr olidin-3- ylmethoxy] imidazo [ 1 ,2-a] pyrazin-6-yl}benzonitrile

Step 1: tert-butyl (3R)-3-({[6-(4-cyanophenyl)-5-(4-methylphenyl)-2-(2-oxoethyl )imidazo[l,2- aJpyrazin-8-ylJ oxy}methyl)pyrrolidine-l -carboxylate

To a solution of chloro(methoxymethyl)triphenylphosphorane (255 mg, 0.744 mmol) in tetrahydrofuran (3.5 mL) at -78 °C was added 0.5 M potassium bis(trimethylsilyl)amide in toluene (1.30 mL, 0.65 mmol). The resulting mixture was stirred at 0 °C for 30 min, and then a solution of tert-butyl (3R)-3-({[6-(4-cyanophenyl)-2-formyl-5-(4-methylphenyl)imida zo[l,2- a]pyrazin-8-yl]oxy}methyl)pyrrolidine-l -carboxylate (Example 42, Step i: 100 mg, 0.2 mmol) in tetrahydrofuran (1.5 mL) was added. The reaction mixture was warmed to room temperature and stirred overnight then quenched with saturated NaHCCte aqueous solution, and extracted with EtOAc. The combined extracts were dried over Na 2 S0 4 and concentrated. The crude material was purified on a silica gel column to give the desired intermediate. To a solution of the above intermediate in tetrahydrofuran (3.0 mL) and water (0.3 mL) at 0 °C was added mercury(II) acetate (178 mg, 0.558 mmol). The reaction mixture was warmed to room temperature and stirred for 3 h then quenched by saturated solution of KI. The resulting mixture was stirred at room temperature for 1 h then extracted with EtOAc. The combined extracts were dried over Na 2 S0 4 and concentrated. The crude material was purified on a silica gel column to give the desired product. LC-MS calculated for C32H34N5O4 (M +H) + : m/z = 552.3; found 552.2.

Step 2: 4-{2-[2-(dimethylamino)ethyl]-5-(4-methylphenyl)-8-[(3R)-pyr rolidin-3- ylmethoxy]imidazo[l,2-a]pyrazin-6-yl}benzonitrile

To a solution of tert-butyl (3R)-3-({[6-(4-cyanophenyl)-5-(4-methylphenyl)-2-(2- oxoethyl)imidazo[l,2-a]pyrazin-8-yl]oxy}methyl)pyrrolidine-l -carboxylate (20 mg, 0.04 mmol) and dimethylamine (2M in THF, 90 μί, 0. 18 mmol) in methylene chloride (1.5 mL) was added acetic acid (10. 0.18 mmol). The resulting mixture was stirred at room temperature for 1 h then sodium triacetoxyborohydride (23 mg, 0.11 mmol) was added. The mixture was stirred at room temperature overnight then diluted with DCM and washed with saturated NaHCCte solution, water and brine. The organic layer was dried over Na 2 S04 and concentrated. The residue was dissolved in DCM (1 mL) then TFA (0.5 mL) was added. The resulting mixture was stirred at room temperature for 1 h then concentrated. The residue was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for &9H33N6O (M +H) + : m/z = 481.3; found 481.4.

Example 48

4-{8-{[(3R)-l-methylpiperidin-3-yl]methoxy}-5-[6-(2-oxopy rrolidin-l-yl)pyridin-3- yl] imidazo [1 ,2-a] pyrazin-6- l}benzonitrile

Step 1: 5-bromo-6-chloro-3-methoxypyrazin-2-amine

Sodium methoxide (25 wt% in methanol, 60 mL, 300 mmol) was added to a solution of

3,5-dibromo-6-chloropyrazin-2-amine (Combi-B locks, cat#ST-4448: 6.0 g, 21 mmol) in methanol (60 mL). The resulting mixture was stirred at 85 °C for 1.5 h then cooled to room temperature and concentrated to remove most of the methanol. The residue was poured into water and the precipitate was collected via filtration and washed with water then dried to give the desired product (4.0 g, 80 %), which was used in the next step without further purification. LC- MS calculated for CsHeBrClNsO (M +H) + : m/z = 237.9; found 237.9. Step 2: 6-bromo-5-chloro-8-methoxyimi zo [ 1 ,2-a] pyrazine

Chloroacetaldehyde (50wt % in water, 17.7 mL, 140 mmol) was added to a mixture of 5- bromo-6-chloro-3-methoxypyrazin-2-amine (3.33 g, 14.0 mmol) in isopropyl alcohol (56 mL). The resulting mixture was stirred at 95 °C overnight then cooled to room temperature and concentrated. The residue was dissolved in DCM then washed with saturated NaHCCte aqueous solution, water and brine. The organic layer was dried over Na 2 S04, filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 50 % EtOAc/Hexanes to give the desired product (2.4 g, 66 %). LC-MS calculated for CvHeBrClNsO (M+H) + : m/z = 261.9; found 261.9.

Step 3: 4-(5-chloro-8-methoxyimidazo 1 ,2-a] pyrazin-6-yl)benzonitrile

A mixture of 6-bromo-5-chloro-8-methoxyimidazo[l,2-a]pyrazine (1.1 g, 4.2 mmol), (4- cyanophenyl)boronic acid (800. mg, 5.45 mmol), tetrakis(triphenylphosphine)palladium(0) (300 mg, 0.2 mmol) and potassium phosphate (2.7 g, 12 mmol) in 1,4-dioxane (20 mL) and water (2.0 mL) was purged with nitrogen then stirred at 90 °C overnight. The reaction mixture was cooled to room temperature then filtered and concentrated. The residue was purified by flash

chromatography on a silica gel column eluting with 0 to 20 % EtOAc/DCM to give the desired product (960 mg, 80 %). LC-MS calculated for C14H10CIN4O (M+H) + : m/z = 285.1; found 285.1.

Step 4: 4-(5-chloro-8-hydroxyimidazo [ 1 ,2-a] pyrazin-6-yl)benzonitrile

To a solution of 4-(5-chloro-8-methoxyimidazo[l,2-a]pyrazin-6-yl)benzonitrile (1.30 g, 4.57 mmol) and sodium iodide (3.4 g, 23 mmol) in acetonitrile (10 mL) was

added chlorotrimethylsilane (2.900 mL, 23 mmol). The resulting reaction mixture was stirred at 65 °C for 3 h then cooled to room temperature. The reaction mixture was quenched with addition of a few drops of water then diluted with DCM. The precipitate was collected via filtration then dried to give the desired product as a yellow solid, which was used in the next step without further purification. LC-MS calculated for C13H8CIN4O (M+H) + : m/z = 271.0; found 271.0.

Step 5: tert-butyl (3R)-3-({[5-chloro-6-(4-cyanophenyl)imidazo[l,2-a]pyrazin-8- ylj oxy}methyl)piperidine-l -carbox late

To a solution of 4-(5-chloro-8-hydroxyimidazo[l,2-a]pyrazin-6-yl)benzonitrile (1.45 g, 5.36 mmol), tert-butyl (3R)-3-(hydroxymethyl)piperidine-l -carboxylate {Synnovator, cat#PB00890: 2.3 g, 11 mmol) and triphenylphosphine (2.8 g, 11 mmol) in tetrahydrofuran (36 mL) at 0 °C was added diisopropyl azodicarboxylate (2.1 mL, 11 mmol) dropwise. The reaction mixture was allowed to warm to room temperature and stirred overnight then concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 25 % EtOAc/DCM to give the desired product (1.95 g, 78 %). LC-MS calculated for C24H27CIN5O3 (M+H) + : m/z = 468.2; found 468.1.

Step 6: 4-{5-chloro-8-[(3R)-piperidin-3- lmethoxy]imidazo[l,2-a]pyrazin-6-yl}benz

To a solution of tert-butyl (3R)-3-({[5-chloro-6-(4-cyanophenyl)imidazo[l,2-a]pyrazin-8- yl]oxy}methyl)piperidine-l -carboxylate (1.0 g, 2.2 mmol) in methylene chloride (3.3 mL) was added trifluoroacetic acid (3.3 mL). The resulting mixture was stirred at room temperature for 1 h then concentrated. The residue was dissolved in DCM then washed with saturated NaHCCte aqueous solution, water and brine. The organic layer was dried over Na 2 S0 4 , filtered and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C19H19CIN5O (M+H) + : m z = 368.1; found 368.1.

Step 7: 4-(5-chloro-8-{[ (3R)- l-methylpiperidin-3-yl]methoxy}imidazo [ 1 ,2-a] pyrazin-6- yl)benzonitrile

To the solution of the crude product from Step 6 in DCM (5 mL) was added

formaldehyde (37wt % in water, 120 μί, 4.4 mmol). The resulting mixture was stirred at room temperature for 30 min, then sodium triacetoxyborohydride (930 mg, 4.4 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then diluted with DCM, washed with saturated NaHC03 aqueous solution, water and brine. The organic layer was dried over Na 2 S0 4 , filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 30 % MeOH/DCM to give the desired product (420 mg). LC-MS calculated for C20H21CIN5O (M+H) + : m/z = 382.1; found 382.1. ¾ NMR (400 MHz, CD3OD) δ 8.23 (d, J= 1.2 Hz, 1H), 8.03 (d, J= 8.5 Hz, 2H), 7.91 - 7.82 (m, 3H), 4.63 (dd, J= 11.0, 4.5 Hz, 1H), 4.47 (dd, J = 11.0, 7.0 Hz, 1H), 3.81 (d, J = 12.0 Hz, 1H), 3.55 (d, J = 10.7 Hz, 1H), 3.13 - 2.80 (m, 5H), 2.45 (m, 1H), 2.18 - 1.75 (m, 3H), 1.54 (m, 1H).

Step 8: 4-{8-{[ (3R)-l-methylpiperidin-3-yl]methoxy}-5-[ 6-(2-oxopyrrolidin-l-yl)pyridin-3- yl]imidazo[l,2-a]pyrazin-6-yl}benzonitrile

A mixture of 4-(5-chloro-8-{[(3R)-l-methylpiperidin-3-yl]methoxy}imidazo[ l,2- a]pyrazin-6-yl)benzonitrile (47. mg, 0.12 mmol), potassium phosphate (78 mg, 0.37 mmol), dichloro[l, -bis(dicyclohexylphosphino)ferrocene]palladium(II) (9.3 mg, 0.012 mmol), l-[5- (4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)pyridin-2-yl]pyrrolidin-2-one (JPM2 Pharma, cat#JPM2-00-744: 42 mg, 0.15 mmol) in 1,4-dioxane (3 mL) and water (1 mL) was purged with nitrogen then stirred at 90 °C for 3 h. The reaction mixture was cooled to room temperature then extracted with DCM. The combined extracts were concentrated and the residue was purified by flash chromatography on a silica gel column eluting with 0 to 30 % MeOH/DCM to give the desired product, which was further purification by prep-HPLC (pH = 10,

acetonitrile/water+NH40H) to give the desired product. LC-MS calculated for C29H30N7O2 (M+H) + : m/z = 508.2; found 508.2.

Example 49

4-(5-(4-methyl-3-oxo-3,4-dihydro-2H-l,4-benzoxazin-7-yl)-8-{ [(3R)-l-methylpiperidin-3- yl] methoxy}imidazo [ 1 ,2-a] pyr azin-6-yl)benzonitrile

Step 1 : 4-methyl- 7- ( 4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)-2H-l, 4-benzoxazin-3( 4H)-one

A mixture of 7-(4,4,5, 5-tetramethyl-l, 3,2-dioxaborolan-2-yl)-2H-l,4-benzoxazin-3(4H)- one (Combi-B locks, cat#FM-4852: 0.54 g, 2.0 mmol), methyl iodide (0.18 mL, 2.9 mmol) and potassium carbonate (0.81 g, 5.9 mmol) in N,N-dimethylformamide (8 mL) was stirred at room temperature for 3 hours. The reaction mixture was diluted with EtOAc then washed with water and brine. The organic layer was dried over Na 2 S04 and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C15H21BNO4 (M+H) + : m/z = 290.2; found 290.1.

Step 2: 4-(5-(4-methyl-3-oxo-3,4-dihydro-2H-l,4-benzoxazin-7-yl)-8-{ [(3R)-l-methylpiperidin^ 3-yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 4-methyl-7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2H- l,4-benzoxazin-3(4H)- one replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 10, acetonitrile/water+NlHUOH) to give the desired product. LC-MS calculated for C29H29N6O3 (M+H) + : m/z = 509.2; found 509.2. ¾ NMR (500 MHz, DMSO) δ 7.76 - 7.72 (m, 2H), 7.65 (d, J= 1.2 Hz, 1H), 7.56 - 7.50 (m, 3H), 7.26 (d, J= 8.4 Hz, 1H), 7.18 (d, J= 1.9 Hz, 1H), 7.09 (dd, J= 8.3, 1.9 Hz, 1H), 4.71 (s, 2H), 4.50 - 4.35 (m, 2H), 3.30 (s, 3H), 2.96 - 2.84 (m, 1H), 2.75 - 2.63 (m, 1H), 2.27 - 2.11 (m, 4H), 2.06 - 1.87 (m, 2H), 1.81 - 1.72 (m, 1H), 1.71 - 1.63 (m, 1H), 1.58 - 1.47 (m, 1H), 1.22 - 1.09 (m, 1H).

Example 50

4-(5-(2,3-dihy dr o-l ,4-benzodioxin-6-yl)-8- { [(3R)- l-methylpiperidin-3- yl] methoxy}imidazo [ 1 ,2-a] pyr azin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 2,3-dihydro-l,4-benzodioxin-6-ylboronic acid (Aldrich, cat#635995) replacing l-[5- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl]py rrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H28N5O3 (M+H) + : m/z = 482.2; found 482.2.

Example 51

4-(5- [6-(dimethylamino)pyridin-3-yl] -8-{ [(3R)-l-methylpiperidin-3- yl] methoxy}imidazo [ 1 ,2-a] pyr azin-6- l)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 6-(dimethylamino)pyridine-3-boronic acid (Ark Pharm, cat#AK-27114) replacing 1- [5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)pyridin-2-yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C27H30N7O (M+H) + : m/z = 468.3; found 468.2.

Example 52

4-(8-{[(3R)-l-methylpiperidin-3-yl]methoxy}-5-{6-[methyl(tet rahydrofuran-2- ylmethyl)amino] pyridin-3- l}imidazo [ 1 ,2-a] pyrazin-6-yl)benzonitrile

Step 1 : N-methyl-N- ( tetrahydrofuran-2-ylmethyl)-5-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2- yl)pyridin-2-amine

The mixture of 2-chloro-5-(4,4, 5, 5-tetramethyl-l, 3,2-dioxaborolan-2-yl)pyridine (Aldrich, cat#659843: 200 mg, 0.8 mmol), N-methyl-l-(tetrahydrofuran-2-yl)methanamine

(ChemBridge, cat#4018249: 96 mg, 0.84 mmol) and triethylamine (240 jxL, 1.7 mmol) in N,N- dimethylformamide (2 mL) was stirred at 140 °C for 2 h. The reaction mixture was cooled to room temperature then concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 50 % EtOAc/Hexanes to give the desired product. LC-MS calculated for C17H28BN2O3 (M+H) + : m/z = 319.2; found 319.2.

Step 2: 4-(8-{[(3R)-l-methylpiperidin-3-yl]methoxy}-5-{6-[methyl(tet rahydrofuran-2- ylmethyl)amino] pyridin-3-yl}imidazo[ 1 ,2-a] pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with N-methyl-N-(tetrahydrofuran-2-ylmethyl)-5-(4,4,5,5-tetrameth yl-l,3,2-dioxaborolan- 2-yl)pyridin-2-amine replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C31H36N7O2 (M+H) + : m/z = 538.3; found 538.3.

Example 53

4- [8-{ [(3R)-l-methylpiperidin-3-yl] methoxy}-5-(l-methyl-lH-pyrrolo [2,3-b] pyridin-5- yl)imidazo [1 ,2-a] pyrazin-6-yl] benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrrolo[2,3-b]pyridine (Combi-Blocks, cat#98552) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin- 2-yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H28N7O (M+H) + : m/z = 478.2; found 478.2.

Example 54

4- [8-{ [(3R)-l-methylpiperidin-3-yl] methoxy}-5-(l-methyl-lH-pyrazolo [3,4-b] pyridin-5- yl)imidazo [1 ,2-a] pyrazin-6-yl] benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 1 -methyl- lH-pyrozolo [3, 4-b]pyridine-5-boronic acid pinacol ester (Advanced ChemBlock, cat#I-9516) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C27H28N8O (M+H) + : m/z = 479.2; found 479.2. Example 55

4-(5-(l,3-benzothiazol-5-yl)-8-{[(3R)-l-methylpiperidin-3-yl ]methoxy}imidazo[l,2- a] pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3-benzothi azole (Aldrich, cat#CDS008108) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C27H25N6OS (M+H) + : m/z = 481.2; found 481.1.

Example 56

4-{8-{[(3S)-3-(dimethylamino)pyrrolidin-l-yl]methyl}-5-[6-(2 -oxopyrrolidin-l-yl)pyridin-3- yl] imidazo [1,2-a] pyrazin-6-yl benzonitrile

Step 1: 4-{8-methoxy-5-[6-(2-oxopyrrolidin-l-yl)pyridin-3-yl) 'imidazo [ 1,2-a] pyrazin-6- yljbenzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 4-(5-chloro-8-methoxyimidazo[l,2-a]pyrazin-6-yl)benzonitrile (Example 48, Step 3) replacing 4-(5-chloro-8- {[(3R)- 1 -methylpiperidin-3-yl]methoxy} imidazo[ 1 ,2-a]pyrazin-6- yl)benzonitrile. After cooling to room temperature, the reaction mixture was concentrated and purified by column chromatography (gradient 0-90% EtOAc in hexanes) to give the desired product. LC-MS calculated for C23H19N6O2 (M+H) + : m/z = 411.2; found 411.1.

Step 2: 4-{8-hydroxy-5-[ 6-(2-oxopyrrolidin-l-yl)pyridin-3-yl]imidazo[ l,2-a]pyrazin-6- yljbenzonitrile

To a solution of 4-{8-methoxy-5-[6-(2-oxopyrrolidin-l-yl)pyridin-3-yl]imidazo [l,2- a]pyrazin-6-yl}benzonitrile (120 mg, 0.29 mmol) and sodium iodide (0.22 g, 1.5 mmol) in acetonitrile (0.6 mL) was added chlorotrimethylsilane (180 1.5 mmol). The resulting mixture was stirred at 65 °C for 3 h then cooled to room temperature. The reaction mixture was quenched with addition of a few drops of water then diluted with DCM. The precipitate was collected via filtration then dried to give the desired product as a yellow solid, which was used in the next step without further purification. LC-MS calculated for C22H17N6O2 (M+H) + : m/z = 397.1; found 397.1.

Step 3: 6-(4-cyanophenyl)-5- [ 6-(2-oxopyrrolidin-l-yl)pyridin-3-yl]imidazo[ 1 ,2-a] pyrazin-8-yl 4- methylbenzenesulfonate

To a solution of 4-{8-hydroxy-5-[6-(2-oxopyrrolidin-l-yl)pyridin-3-yl]imidazo [l,2- a]pyrazin-6-yl}benzonitrile (60 mg, 0.2 mmol) in methylene chloride (0.5 mL) was added triethyl amine (40 μί, 0.3 mmol) and 4-dimethylaminopyridine (4 mg, 0.03 mmol) followed by p-toluenesulfonyl chloride (38 mg, 0.20 mmol) at 0 °C, then the resulting mixture was slowly warmed up and stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on a silica gel column (gradient 0-90% EtOAc in hexanes) to afford the desired product. LC-MS calculated for

C29H23N6O4S (M+H) + : m/z = 551.2; found 551.1.

Step 4: 4-{5-[ 6-(2-oxopyrrolidin-l-yl)pyridin-3-yl]-8-vinylimidazo[ l,2-a]pyrazin-6- yljbenzonitrile

A degassed solution of 6-(4-cyanophenyl)-5-[6-(2-oxopyrrolidin-l-yl)pyridin-3- yl]imidazo[l,2-a]pyrazin-8-yl 4-methylbenzenesulfonate (50 mg, 0.09 mmol), 4,4,5,5- tetramethyl-2-vinyl-l,3,2-dioxaborolane (20 μί, 0.12 mmol), dichloro[l,l'- bis(dicyclohexylphosphino)ferrocene]palladium(II) (7 mg, 0.009 mmol), potassium phosphate (80 mg, 0.4 mmol) in a mixed solvent of 1 ,4-dioxane (6 mL) and water (1 mL) was heated at 90 °C in a sealed vial for 2 h. After cooling to room temperature, the mixture was concentrated and purified by flash chromatography on a silica gel column (gradient 0-80% EtOAc in hexanes) to afford the desired product. LC-MS calculated for C24H19N6O (M+H) + : m/z = 407.2; found 407.2. Step 5: 4-{8-formyl-5-[ 6-(2-oxopyrrolidin-l-yl)pyridin-3-yl]imidazo[ l,2-a]pyrazin-6- yljbenzonitrile

Osmium tetraoxide in water (0.16 M, 0.05 mL, 0.008 mmol) was added to a mixture of 4- {5-[6-(2-oxopyrrolidin- 1 -yl)pyridin-3-yl]-8-vinylimidazo[ 1 ,2-a]pyrazin-6-yl}benzonitrile (31 mg, 0.076 mmol), sodium metaperiodate (80 mg, 0.4 mmol) in tetrahydrofuran (0.8 mL) and water (0.1 mL). The resulting mixture was heated to 70 °C and stirred for 2 h. The mixture was cooled to room temperature then diluted with methylene chloride, washed with saturated NaHCC , water, brine then dried over Na 2 S04. After filtration, the mixture was concentrated and the residue was used for next step without further purification. LC-MS calculated for

C23H17N6O2 (M+H) + : m/z = 409.1; found 409.2.

Step 6: 4-{8-{ [(3S)-3-(dimethylamino)pyrrolidin- 1-yl] methyl}-5- [ 6-(2-oxopyrrolidin-l- yl)pyridin-3-yl]imidazo[l,2-a] razin-6-yl}benzonitrile

To a stirred solution of 4-{8-formyl-5-[6-(2-oxopyrrolidin-l-yl)pyridin-3-yl]imidazo[ l,2- a]pyrazin-6-yl}benzonitrile (15 mg, 0.038 mmol) in methylene chloride (1 mL) was added (3S)- N,N-dimethylpyrrolidin-3 -amine (Aldrich cat#656704, 10 μί, 0.08 mmol) and the mixture was stirred at room temperature for 10 min. Then sodium triacetoxyborohydride (20 mg, 0.1 mmol) was added to the reaction mixture and stirred for another 2 h. Then the reaction mixture was concentrated and purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H31N8O (M+H) + : m/z = 507.3; found 507.2.

Example 57

4- {8- [4-(dimethylamino)piperidin- 1-yl] -5- [6-(2-oxopyrrolidin- l-yl)pyridin-3-yl] imidazo [1 ,2- a]pyrazin-6-yl}benzonitrile

To a solution of 4-{8-hydroxy-5-[6-(2-oxopyrrolidin-l-yl)pyridin-3-yl]imidazo [l,2- a]pyrazin-6-yl}benzonitrile {Example 56, Step 2, 110 mg, 0.28 mmol) in methylene chloride (0.9 mL, 10 mmol) was added triethylamine (80 0.6 mmol) and 4-dimethylaminopyridine (7 mg, 0.06 mmol) followed by p-toluenesulfonyl chloride (69 mg, 0.36 mmol). The mixture was stirred at room temperature for 1 h. Then the reaction mixture was concentrated and the residue was treated with triethylamine (200 and N,N-dimethylpiperidin-4-amine {Alfa Aesar cat#L20176, 80 μί). The resulting mixture was stirred at room temperature for 4 h. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H31N8O (M+H)+: m/z = 507.3; found 507.3. l U NMR (600 MHz, CD3OD) δ 8.52 (d, J= 8.7 Hz, 1H), 8.20 (d, J= 1.8 Hz, 1H), 7.90 (dd, J = 8.7, 2.4 Hz, 1H), 7.62 - 7.58 (m, 3H), 7.55 - 7.50 (m, 3H), 5.78 - 5.68 (m, 2H), 4.13 - 4.09 (m, 2H), 3.63 - 3.55 (m, 1H), 3.21 - 3.13 (m, 2H), 2.91 (s, 6H), 2.69 (t, J= 8.1 Hz, 2H), 2.26 - 2.20 (m, 2H), 2.20 - 2.13 (m, 2H), 1.91 - 1.81 (m, 2H).

Example 58

4- [8- [4-(dimethylamino)piperidin-l-yl]-5-(l-methyl-lH-pyrazolo [3,4-b] pyridin-5- yl)imidazo [1 ,2-a] pyrazin-6-yl] benzonitrile

Step 1: 4-(5-amino-3-chloropyrazin-2- l)benzonitrile

Dichloro(bis{di-tert-butyl[4-(dimethylamino)phenyl]phosphora nyl})palladium (150 mg, 0.22 mmol) was added to a mixture of 5-bromo-6-chloropyrazin-2-amine J&W, cat#65R0236: 1.51 g, 7.24 mmol), (4-cyanophenyl)boronic acid (1.08 g, 7.39 mmol), sodium carbonate (1.54 g, 14.5 mmol) in 1,4-dioxane (17.4 mL) and water (2.9 mL). The mixture was degassed with N2 then stirred at 90 °C for 2 h in a sealed vial. After cooling, the reaction mixture was diluted with water (100 mL). The precipitate was collected by filtration and purified by column

chromatography (gradient 0- 100% EtOAc/Hexanes followed by 20% MeOH in EtOAc). LC-MS calculated for CnH 8 ClN4 (M+H) + : m/z = 231.0; found 231.0.

Step 2: 4-(5-amino-6-bromo-3-chloro razin-2-yl)benzonitrile

N-Bromosuccinimide (620 mg, 3.5 mmol) in THF (2 mL) was added slowly to a solution of 4-(5-amino-3-chloropyrazin-2-yl)benzonitrile (0.73 g, 3.2 mmol) in N,N-dimethylformamide (12 mL) at 0 °C and then the reaction mixture was stirred at this temperature for 1 h. The mixture was diluted with saturated NaHCCte aqueous solution (50 mL) and the precipitate was collected via filtration then washed with water and dried under vacuum to afford the desired compound which was used in the next step without further purification. LC-MS calculated for CnHvBrClN4 (M+H) + : m/z = 308.9; found 308.9. Step 3: 4-(5, 8-dichloroimidazo[ 1, 2-a razin-6-yl)benzonitrile

Chloroacetaldehyde in water (2.4 mL, 18 mmol, 7.5 M) was added to a mixture of 4-(5- amino-6-bromo-3-chloropyrazin-2-yl)benzonitrile (0.8 g, 2 mmol) in isopropyl alcohol (6.3 mL) and the resulting mixture was stirred at 100 °C for 5 h. The mixture was cooled to room temperature then concentrated. The residue was dissolved in ethyl acetate then washed with saturated NaHCC , water and brine. The organic layer was dried over Na 2 SC"4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 70 % ethyl acetate in hexane to afford the desired product (610 mg, 80%). LC-MS calculated for C13H7CI2N4 (M+H) + : m/z = 289.0; found 289.0.

Step 4: 4-(5-chloro-8-(4-(dimethylamino)piperidin-l-yl)imidazo[l,2-a ]pym

To a mixture of N,N-diisopropylethylamine (890 μί, 5.1 mmol) and 4-(5,8- dichloroimidazo[l,2-a]pyrazin-6-yl)benzonitrile (850 mg, 2.9 mmol) in acetonitrile (20 mL) was added N,N-dimethylpiperidin-4-amine (720 5.1 mmol). The reaction was stirred at room temperature for 30 min, then heated at 60 °C for 3 h. After cooling to room temperature, the reaction mixture was concentrated, and purified by column chromatography (gradient 0-60% MeOH in DCM) to afford the desired product (503 mg, 46%). LC-MS calculated for C 20 H 22 C1N 6 (M+H) + : m/z = 381.1; found 381.1. 'H NMR (400 MHz, CD3OD) δ 8.07 (d, J= 1.2 Hz, 1H), 8.00 (d, J= 8.5 Hz, 2H), 7.84 (d, J= 8.5 Hz, 2H), 7.71 (d, J= 1.1 Hz, 1H), 5.77 - 5.61 (m, 2H), 3.65 - 3.50 (m, 1H), 3.14 (t, J= 12.2 Hz, 2H), 2.90 (s, 6H), 2.27 - 2.11 (m, 2H), 1.90 - 1.73 (m, 2H). Step 5: 4- [8- [4-(dimethylamino)piperidin- 1-ylj '-5-( 1 -methyl- lH-pyrazolo [3 ,4-b] pyridin-5- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile

A degassed solution of 4-{5-chloro-8-[4-(dimethylamino)piperidin-l-yl]imidazo[l,2- a]pyrazin-6-yl}benzonitrile (10 mg, 0.03 mmol), l-methyl-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazolo[3,4-b]pyridine {Advance ChemBlocks, cat#I-9516 : 8.8 mg, 0.034 mmol), potassium phosphate (20 mg, 0.1 mmol) and dichloro[l,l'- bis(dicyclohexylphosphino)ferrocene]palladium(II) (2 mg, 0.003 mmol) in a mixed solvent of 1,4-dioxane (1 mL) and water (0.15 mL) was heated in a sealed vial at 90 °C for 2 h. After cooling to room temperature, the mixture was concentrated, diluted with MeOH, filtered then purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C27H28N9 (M+H) + : m/z = 478.2; found 478.2.

Example 59

4- [8- [4-(dimethylamino)piperidin- 1-yl] -5-(3-methyl-2-oxo-2,3-dihydro- 1 ,3-benzoxazol-6- yl)imidazo [1 ,2-a] pyrazin-6-yl] benzonitrile

Step 1 : 3-methyl-6- ( 4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)-l, 3-benzoxazol-2 ( 3H)-one

A mixture of 6-bromo-3-methyl-l,3-benzoxazol-2(3H)-one (Acros Organics, cat#43271: 0.5 g, 2 mmol), 4,4,5,5,4 * ,4 * ,5 * ,5 * -octamethyl-[2,2 , ]bi[[l,3,2]dioxaborolanyl] (0.84 g, 3.3 mmol), [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1 : 1) (90 mg, 0.1 mmol) and potassium acetate (0.64 g, 6.6 mmol) in 1,4-dioxane (20 mL) was degassed and heated at 90 °C overnight. After cooling to room temperature, the reaction mixture was concentrated. The residue was purified by flash column chromatography eluting with 0 to 25% AcOEt in Hexanes to give the desired product. LC-MS calculated for C14H19BNO4 (M+H) + : m/z = 276.1; found 276.1.

Step 2: 4-f8-f4-(dimethylamino)piperidin-l-ylJ-5-(3-methyl-2-oxo-2,3 -dihydw

6- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with 3-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3 -benzoxazol-2(3H)-one replacing 1 -methyl-5-(4,4,5 ,5 -tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 H-pyrazolo[3 ,4-b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H28N7O2 (M+H) + : m/z = 494.2; found 494.2.

Example 60

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(4-methyl-3-oxo-3,4 -dihydro-2H-l,4-benzoxazin-

7- yl)imidazo [1 ,2-a] pyrazin-6-yl] benzonitrile

Step 1 : 4-methyl- 7- ( 4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)-2H-l, 4-benzoxazin-3( 4H)-one

To a mixture of 7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2H-l,4-benzo xazin- 3(4H)-one {Combi-B locks, cat#FM-4852: 0.3 g, 1 mmol) and potassium carbonate (150 mg, 1.1 mmol) in acetone (5 mL) was added methyl iodide (0.20 mL, 3.3 mmol). The reaction mixture was stirred at 80 °C overnight then cooled to room temperature and concentrated. The residue was dissolved in EtOAc, washed with water and brine. The organic layer was dried over Na2S0 4 and concentrated. The residue was used in the next step without further purification, calculated for C15H21BNO4 (M+H) + : m/z = 290.2; found 290.2.

Step 2: 4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(4-methyl-3-oxo-3,4 -dihydro-2H-l,4- benzoxazin- 7-yl)imidazo[ 1 ,2-a] pyrazin-6-yl] benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with 4-methyl-7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2H- l,4-benzoxazin-3(4H)- one replacing 1 -methyl-5-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 H-pyrazolo[3 ,4- b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H30N7O2 (M+H) + : m/z = 508.2; found 508.2.

Example 61

4-[8-{[(3R)-l-ethylpiperidin-3-yl]methoxy}-5-(l-methyl-lH-py rrolo[2,3-b]pyridin-5- yl)imidazo [1 ,2-a] pyrazin-6- l] benzonitrile

Step 1: 4-(5-chloro-8-{[ (3R)-l-ethylpiperidin-3-yl]methoxy}imidazo[l,2-a]pyrazin-6- yl)benzonitrile

To a solution of tert-butyl (3R)-3-({[5-chloro-6-(4-cyanophenyl)imidazo[l,2-a]pyrazin- 8-yl]oxy}methyl)piperidine-l-carboxylate {Example 48, Step 5: 20 mg, 0.03 mmol) in methylene chloride (52 was added trifluoroacetic acid (52 The mixture was stirred at room temperature for 1 h then concentrated. The residue was dissolved in methylene chloride (0.3 mL) then acetaldehyde (9 μΐ,, 0.2 mmol) and sodium triacetoxyborohydride (10 mg, 0.07 mmol) were added subsequently to the reaction mixture. The mixture was allowed to stir for 2 h at room temperature. The mixture was concentrated and purified by flash chromatography eluting with 0 to 40% MeOH in DCM to give the desired product. LC-MS calculated for C21H23CIN5O (M+H) + : m/z = 396.2; found 396.1.

Step 2: 4-[ 8-{[ ( 3R)-l-ethylpiperidin-3-yl]methoxy}-5-(l -methyl- lH-pyrrolo[ 2, 3-b]pyridin-5- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile

The title compound was prepared using similar procedures as described for Example 53 with 4-(5-chloro-8- {[(3R)- 1 -ethylpiperidin-3-yl]methoxy}imidazo[ 1 ,2-a]pyrazin-6- yl)benzonitrile replacing 4-(5-chloro-8-{[(3R)-l-methylpiperidin-3-yl]methoxy}imidazo[ l,2- a]pyrazin-6-yl)benzonitrile. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H30N7O (M+H) + : m/z = 492.3; found 492.2.

Example 62

4- [8- [4-(dimethylamino)piperidin- 1-yl] -5-(5-fluoro-3-methyl-2-oxo-2,3-dihydro- 1 ,3- benzoxazol-6-yl)imidazo [ 1 ,2-a] pyrazin-6-yl] benzonitrile

Step 1: 6-bromo-5-fluoro- 1 ,3-benzoxazol-2 (3H)-one

To a mixture of 2-amino-5-bromo-4-fluorophenol (0.3 g, 1 mmol) [Synquest Labs, cat#4656-B-15] and triethylamine (1.0 mL, 7.3 mmol) in tetrahydrofuran (20 mL) at 0 °C was added triphosgene (0.52 g, 1.7 mmol). The mixture was stirred for 1 h, then 1.0 M sodium hydroxide in water (2.9 mL, 2.9 mmol) was added to the reaction mixture. The mixture was stirred at room temperature for another hour then diluted with EtOAc, washed with water and brine. The organic layer was dried over Na 2 S0 4 and the solvents were removed under reduced pressure. The residue was used for next step directly without purification. Step 2: 6-bromo-5-fluoro-3-methyl-l,3-benzoxazol-2(3H)-one

A mixture of 6-bromo-5-fluoro-l,3-benzoxazol-2(3H)-one (crude product from Step 1), potassium carbonate (0.4 g, 3 mmol) and methyl iodide (0.2 mL, 3 mmol) in acetone (5 mL) was heated at 80 °C overnight. The reaction mixture was cooled to room temperature then

concentrated. The residue was dissolved in EtOAc then washed with water and brine. The organic layer was dried over Na 2 S0 4 , filtered then concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 25% EtOAc in Hexanes. LC-MS calculated for C8H 6 BrFN0 2 (M+H) + : m/z = 246.0; found 245.9. Step 3: 5-fluoro-3-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)-l,3-benzoxazol-2(3H)- one

A mixture of 6-bromo-5-fluoro-3-methylbenzo[d]oxazol-2(3H)-one (290 mg, 1.2 mmol), 4,4,5,5,4 , ,4 , ,5 * ,5 * -octamethyl-[2,2 , ]bi[[l,3,2]dioxaborolanyl] (450 mg, 1.8 mmol), [1,1 * - bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1 : 1) (50 mg, 0.06 mmol), potassium acetate (350 mg, 3.5 mmol) in 1,4-dioxane (10 mL) was purged with nitrogen and heated at 90 °C for 5 h. After cooling to room temperature, the reaction mixture was concentrated and the residue was purified by column chromatography eluting with 0 to 30%) EtOAc in hexanes to give the desired product. LC-MS calculated for Ci 4 Hi8BFN0 4 (M+H) + : m/z = 294.1 ; found 294.1. Step 4: 4- [8- [4-(dimethylamino)piperidin- 1-ylj ' -5-(5-fluoro-3-methyl-2-oxo-2 ,3-dihydro-l,3- benzoxazol-6-yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with 5-fluoro-3-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)benzo[d]oxazol- 2(3H)-one replacing l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazolo[3,4- b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H27FN7O2 (M+H) + : m/z = 512.2; found 512.2.

Example 63

4-[8-{[(3R)-l-ethylpiperidin-3-yl]methoxy}-5-(3-methyl-2-oxo -2,3-dihydro-l,3-benzoxazol- 6-yl)imidazo [1 ,2-a] pyrazin-6- l] benzonitrile

The title compound was prepared using similar procedures as described for Example 59,

Step 2 with 4-(5-chloro-8-{[(3R)-l-ethylpiperidin-3-yl]methoxy}imidazo[l ,2-a]pyrazin-6- yl)benzonitrile (Example 61, Step 1) replacing 4-(5-chloro-8-(4-(dimethylamino)piperidin-l- yl)imidazo[l,2-a]pyrazin-6-yl)benzonitrile. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H29N6O3 (M+H) + : m/z = 509.2; found 509.2.

Example 64

4-[8-{[(3R)-l-(2-cyanoethyl)piperidin-3-yl]methoxy}-5-(3-met hyl-2-oxo-2,3-dihydro-l,3- benzoxazol-6-yl)imidazo [ 1 ,2-a] pyrazin-6-yl] benzonitrile

Step 1: 4-(5-chloro-8-{[(3R)-l-(2-cyanoethyl)piperidin-3-yl]methoxy} imidazo[l,2-a]pyrazin-6- yl)benzonitrile

To a solution of tert-butyl (3R)-3-({[5-chloro-6-(4-cyanophenyl)imidazo[l,2-a]pyrazin-

8-yl]oxy}methyl)piperidine-l-carboxylate (Example 48, Step 5: 120 mg, 0.26 mmol) in methylene chloride (400 μί) was added trifluoroacetic acid (400 i ). The mixture was stirred at room temperature for 1 h. After concentration to remove most of the acid, 1,8- diazabicyclo[5.4.0]undec-7-ene (10 μί, 0.07 mmol) and 2-propenenitrile (800 μί, 10 mmol) were added to the resulting residue. Then the mixture was allowed to stir overnight at room temperature. The mixture was concentrated and purified by flash chromatograph on a silica gel column eluting with 0-60% EtOAc in Hexanes to give the desired product. LC-MS calculated for C22H22CIN6O (M+H) + : m/z = 421.2; found 421.2. Step 2: 4-[8-{[(3R)-l-(2-cyanoethyl)piperidin-3-yl]methoxy}-5-(3-met hyl-2-oxo-2,3-dihydro-l,3- benzoxazol-6-yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile

A degassed solution of 4-(5-chloro-8-{[(3R)-l-(2-cyanoethyl)piperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile (10 mg, 0.03 mmol), 3-methyl-6-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3-benzoxazol-2(3H)-on e (Example 59, Step 1: 9.4 mg, 0.034 mmol), potassium phosphate (20 mg, 0.1 mmol), dichloro[l,l'- bis(dicyclohexylphosphino)ferrocene]palladium(II) (2 mg, 0.003 mmol) in 1,4-dioxane (0.9 mL) and water (0.2 mL) was heated in a sealed vial at 90 °C for 2 h. After cooling to room temperature, the mixture was concentrated, diluted with MeOH and filtered. The filtrate was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C30H28N7O3 (M+H) + : m/z = 534.2; found 534.2.

Example 65

4-[8-{[(3R)-l-(2-hydroxyethyl)piperidin-3-yl]methoxy}-5-(l-m ethyl-lH-indazol-5- yl)imidazo [1 ,2-a] pyrazin-6- l] benzonitrile

Step 1: 4-(5-chloro-8-{[(3R)-l-(2-hydroxyethyl)piperidin-3-yl]methox y}im

6-yl)benzonitrile

To a solution of tert-butyl (3R)-3-({[5-chloro-6-(4-cyanophenyl)imidazo[l,2-a]pyrazin-

8-yl]oxy}methyl)piperidine-l-carboxylate {Example 48, Step 5: 200 mg, 0.4 mmol) in methylene chloride (660 μί) was added trifluoroacetic acid (660 μί). The mixture was stirred at room temperature for 1 h. Then the mixture was concentrated and the residue was mixed with triethylamine (1 mL) followed by addition of 2-bromoethanol (120 μί, 1.7 mmol). The resulting mixture was stirred at room temperature overnight and then concentrated in vacuo. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 40% MeOH in DCM to give the desired product. LC-MS calculated for C21H23CIN5O2 (M+H) + : m/z = 412.2; found 412.1. Step 2: 4-[8-{[(3R)-l-(2-hydroxyethyl)piperidin-3-yl]methoxy}-5-(l-m ethyl-lH-indazol-5- yl)imidazo[l,2-a]pyrazin-6-yl] benzonitrile

A mixture of 4-(5-chloro-8-{[(3R)-l-(2-hydroxyethyl)piperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile (10 mg, 0.03 mmol), (1 -methyl- lH-indazol- 5-yl)boronic acid (6.0 mg, 0.034 mmol), potassium phosphate (20 mg, 0.1 mmol) and dichloro[l, -bis(dicyclohexylphosphino)ferrocene]palladium(II) (2 mg, 0.003 mmol) in 1,4- dioxane (0.9 mL) and water (0.2 mL) was purged with nitrogen then stirred in a sealed vial at 90 °C for 2 h. After cooling to room temperature, the mixture was concentrated, diluted with MeOH and filtered. The filtrate was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H30N7O2 (M+H) + : m/z = 508.2; found 508.2.

Example 66

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(3-methyl-2-oxo-2,3 -dihydro[l,3]oxazolo[4,5- b] pyridin-6-yl)imidazo [ 1 ,2-a] pyrazin-6-yl] benzonitrile

Step 1 : 6-bromo-3 -methyl [ 1, 3 Joxazolof 4, 5-b]pyridin-2 ( 3H)-one

To a solution of 6-bromo[l,3]oxazolo[4,5-b]pyridin-2(3H)-one (Ark P harm, catUAK-

24539: 0.394 g, 1.83 mmol) in N,N-dimethylformamide (5 mL) at - 40 °C was added sodium hydride (60 wt % in mineral oil, 290 mg, 7.3 mmol). The resulting mixture was stirred at -40 °C for 1 hour then methyl iodide (1.14 mL, 18.3 mmol) was added dropwise. The reaction mixture was stirred at -40 °C for another 2 hours, then warmed to 0 °C and quenched by saturated NH4CI aqueous solution. The mixture was extracted with EtOAc, then DCM/iPrOH (2: 1). The combined extracts were dried over Na 2 S04, filtered and concentrated. The residue was used in the next step without further purification. LC-MS calculated for CvH6BrN 2 0 2 (M+H) + : m/z = 229.0; found 229.0. Step 2: 3-methyl-6- ( 4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl) [ 1, 3 ]oxazolo[ 4, 5-bJpyridin- 2(3H)-one

A mixture of 6-bromo-3-methyl[l,3]oxazolo[4,5-b]pyridin-2(3H)-one (0.15 g, 0.66 mmol), 4,4,5,5,4 * ,4 , ,5 * ,5 * -octamethyl-[2,2 * ]bi[[l,3,2]dioxaborolanyl] (250 mg, 0.98 mmol), [1,1 * - bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1 : 1) (30 mg, 0.03 mmol) and potassium acetate (190 mg, 2.0 mmol) in 1,4-dioxane (6 mL) was purged with nitrogen then heated at 90 °C overnight. After cooling to room temperature, the reaction mixture was concentrated. The crude material was purified by flash chromatography on a silica gel column eluting with 0 to 5 % MeOH in DCM to give the desired product. LC-MS calculated for C13H18BN2O4 (M+H) + : m/z = 277.1; found 277.1.

Step 3: 4-[8-[ 4-(dimethylamino)piperidin-l-yl]-5-(3-methyl-2-oxo-2, 3-dihydro[ 1, 3]oxazolo[ 4, 5- b]pyridin-6-yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with 3-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)[l,3 ]oxazolo[4,5-b]pyridin- 2(3H)-one replacing l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazolo[3,4- b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C27H27N8O2 (M+H) + : m/z = 495.2; found 495.2. ¾ NMR (600 MHz, CD3OD) δ 7.95 (d, J= 1.7 Hz, 1H), 7.75 (d, J= 1.7 Hz, 1H), 7.62 - 7.58 (m, 3H), 7.57 - 7.53 (m, 3H), 5.80 - 5.69 (m, 2H), 3.65 - 3.54 (m, 1H), 3.46 (s, 3H), 3.20 - 3.14 (m, 2H), 2.92 (s, 6H), 2.27 - 2.20 (m, 2H), 1.91 - 1.81 (m, 2H).

Example 67

4- {8- [4-(dimethylamino)piperidin- 1-yl] -5- [6-(2-oxo- 1 ,3-oxazolidin-3-yl)pyridin-3- yl] imidazo [1,2-a] pyrazin-6-yl}benzonitrile

Step 1: 3-(5-bromopyridin-2-yl)-l,3-oxazolidin-2-one

To a solution of oxazolidin-2-one (183 mg, 2.10 mmol) in N,N-dimethylformamide (2.1 mL) at 0 °C was added sodium hydride (83.9 mg, 2.10 mmol) in portions. The mixture was stirred for 30 min at room temperature then a solution of 5-bromo-2-fluoropyridine (Aldrich cat#520438, 0.216 mL, 2.10 mmol) in N,N-dimethylformamide (0.42 mL) was added dropwise. The resulting mixture was stirred overnight at room temperature then heated at 80 °C for 1.5 h. The reaction mixture was cooled to room temperature, quenched by methanol and water then extracted with dichloromethane. The combined extracts were dried over Na 2 SC"4, filtered and concentrated. The residue was purified by flash chromatography on a silica column eluting with 0 to 50% ethyl acetate in hexanes to afford the desired product. LC-MS calculated for

C8HsBrN 2 0 2 (M+H) + : m/z = 243.0; found 243.0. Step 2: 3-[5-(4 ,5,5-tetramethyl-l,3, -dioxaborolan-2-yl)pyridin-2-yl]-l,3-oxazolidin-2-one

A mixture of 3-(5-bromopyridin-2-yl)-l,3-oxazolidin-2-one (240 mg, 1.0 mmol), 4,4,5,5,4 , ,4 , ,5 * ,5 * -octamethyl-[2,2 , ]bi[[l,3,2]dioxaborolanyl] (280 mg, 1.1 mmol), [1,1 * - bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1 : 1) (88 mg, 0.11 mmol) and potassium acetate (300 mg, 3 mmol) in DMF (5 mL) was purged with nitrogen then heated at 70 °C overnight. After cooling to room temperature, the mixture was concentrated. The residue was dissolved in EtOAc then filtered. The filtrate was concentrated and the residue was purified by column chromatography eluting with 0-60% EtOAc in hexanes to give the desired product. LC-MS calculated for C14H20BN2O4 (M+H) + : m/z = 291.2; found 291.2 Step 3: 4-{8-[ 4-(dimethylamino)piperidin-l-yl]-5-[ 6-(2-oxo-l, 3-oxazolidin-3-yl)pyridin-3- yl]imidazo[l,2-a]pyrazin-6-yl}benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with 3-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl)oxazolidin-2-one replacing 1 -methyl-5-(4,4,5 ,5 -tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 H-pyrazolo[3 ,4-b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H2 N8O2 (M+H) + : m/z = 509.2; found 509.2.

Example 68

4-{5-(3-amino-l-methyl-lH-indazol-5-yl)-8-[4-(dimethylami no)piperidin-l-yl]imidazo[l,2- a]pyrazin-6-yl}benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- indazol-3-amine {Combi-Blocks, cat#FF-5931) replacing i-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-lH-pyrazolo[3,4-b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H30N9 (M+H) + : m z = 492.3; found 492.2. Example 69

5-(6-(4-cyanophenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methoxy }imidazo[l,2-a]pyrazin-5- yl)-2-methylbenzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 2-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benz onitrile (Sigma- Aldrich, cat#CDS019666) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H27N6O (M+H) + : m/z = 463.2; found 463.2.

Example 70

4-(5-[3-(hydroxymethyl)-4-methylphenyl]-8-{[(3R)-l-methylpip eridin

yl]methoxy}imidazo[l,2-a]pyr

The title compound was prepared using similar procedures as described for Example 48, Step 8 with (2-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phe nyl)methanol (Combi- Blocks, cat#FM-2080) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H30N5O2 (M+H) + : m/z = 468.2; found 468.2.

Example 71

4-(5-(4-methyl-3-{[4-(methylsulfonyl)piperazin-l-yl]methyl}p henyl)-8-{[(3R)-l- methylpiperidin-3-yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benz onitrile

Step 1 : 2-methyl-5- ( 4, 4, 5, 5-tetramethyl- -dioxaborolan-2-yl)benzaldehyde

A stream of nitrogen gas was bubbled through a mixture of 5-bromo-2- methylbenzaldehyde (1550 mg, 7.79 mmol), 4,4,5,5,4',4',5',5'-octamethyl- [2,2']bi[[l,3,2]dioxaborolanyl] (2200 mg, 8.6 mmol), and potassium acetate (2300 mg, 23 mmol) in N,N-dimethylformamide (30 mL) for ~15 minutes. Then palladium acetate (90 mg, 0.4 mmol) was added, the vial was sealed, and the reaction was heated to 85 °C for 3 h. After cooling, the mixture was concentrated and the residue was partitioned between 75 mL of EtOAc and 75 mL water. The suspension was filtered through celite, the filter cake was washed with EtOAc, then the layers were separated. The organic phase was washed with water, brine, dried over sodium sulfate, and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 10 % EtOAc/hexanes to give the desired compound (1025 mg, 54%). LC-MS calculated for C14H20BO3 (M+H) + : m/z = 247.2; found 247.1.

Step 2: I -(2 -methyl- 5 -(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)benzyl)-4- (methylsulfonyl)piperazine

A solution of 2-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benz aldehyde (100 mg, 0.4 mmol), l-(methylsulfonyl)piperazine (0.080 g, 0.49 mmol), and acetic acid (50 μΐ,, 0.9 mmol) in methylene chloride (6 mL) was first stirred for 30 minutes, then sodium

triacetoxyborohydride (260 mg, 1.2 mmol) was added and the reaction mixture was stirred at room temperature overnight. The mixture was diluted with methylene chloride, was with saturated NaHCC , water, and brine, dried over sodium sulfate, and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C19H32BN2O4S (M+H) + : m/z = 395.2; found 395.2.

Step 3: 4-(5-(4-methyl-3-{ [4-(methylsulfonyl)piperazin- 1-ylj ' methyl} phenyl)- 8- { [(3R)- 1- methylpiperidin-3-yl]methoxy}imidazo[ 1, 2 -a ]pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with l-(2-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)b enzyl)-4- (methylsulfonyl)piperazine replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin- 2-yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C33H40N7O3S (M+H) + : m/z = 614.3; found 614.3.

Example 72

4-(5-[4-(hydroxymethyl)-3-methylphenyl]-8-{[(3R)-l-methylpip eridin

yl] methoxy}imidazo [ 1 ,2-a] pyr azin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 4-hydroxymethyl-3-methylphenylboronic acid (Sigma- Aldrich, cat#005902) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H30N5O2 (M+H) + : m/z = 468.2; found 468.2.

Example 73

4-(5-(3-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[(3R)-l-methyl piperidin

yl]methoxy}imidazo[l,2-a]pyrazin-6- l)benzonitrile

Step 1: 6-bromo-2,3-dihydro-lH-inden-l-ol

To a solution of 6-bromoindan-l-one {Aldrich, cat#597147: 250 mg, 1.2 mmol) in methanol (3 mL) was added sodium tetrahydroborate (49 mg, 1.3 mmol) in 2 portions. The reaction mixture was stirred at room temperature for 2 h leading to complete conversion. The solvent was removed and the residue was partitioned between water and EtOAc. The EtOAc layer was washed with brine, dried over sodium sulfate, and the solvent was removed to obtain 6-bromoindan-l-ol (racemic, 240 mg, 95%) which was used in the next step without further purification. LC-MS calculated for C 9 H 8 Br (M+H-H 2 0) + : m/z = 195.0; found 195.0.

Step 2: 6-(4, 4, 5, 5-tetramethyl-l, 3, 2- 3-dihydro-lH-inden-l-ol

A suspension of 6-bromoindan-l-ol (240 mg, 1.1 mmol), potassium acetate (550 mg, 5.6 mmol) and 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[l,3,2]dioxaborolany l] (430 mg, 1.7 mmol) in 1,4-doxane (3.3 mL) was first degassed with stream of nitrogen for ~5 min, then [Ι,Γ- bis(diphenylphosphino)ferrocene]dichloropalladium(II),comple x with dichloromethane (1 : 1) (92 mg, 0.11 mmol) was added and the mixture was heated to 90 °C overnight. The reaction mixture was then diluted with EtOAc, filtered through celite, and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 25 % EtOAc/hexanes to provide the desired product (256 mg, 87%). LC-MS calculated for CisftoBC (M+H-H 2 0) + : m/z = 243.2; found 243.2.

Step 3: 4-(5-(3-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[ (3R)-1 -methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro- lH-inden-l-ol replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product (a mixture of two diastereomers) as the TFA salt. LC-MS calculated for C 2 9H3oNs0 2 (M+H) + : m/z = 480.2; found 480.2. Example 74

4-(5- [4-(hydr oxymethyl)phenyl] -8-{ [(3R)- l-methylpiperidin-3-yl] methoxy}imidazo [ 1 ,2- a] pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 4-(hydroxymethyl)phenylboronic acid (Sigma- Aldrich, cat#512338) replacing l-[5- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl]py rrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C27H28N5O2 (M+H) + : m/z = 454.2; found 454.2.

Example 75

4-{8-{[(3R)-l-methylpiperidin-3-yl]methoxy}-5-[4-(morpholin- 4- ylmethyl)phenyl] imidazo [ 1 ,2-a] pyrazin-6-yl}benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 4-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzyl)mor pholine (Combi- Blocks, cat#PN-8855) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C31H35N6O2 (M+H) + : m/z = 523.3; found 523.2.

Example 76

methyl [5-(6-(4-cyanophenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methox y}imidazo[l,2- a] pyrazin-5-yl)-2-methylphenyl] methylcarbamate

Step 1: methyl methyl(2-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenyl)carbamate

Methyl chloroformate (52 ed to a solution of N,2-dimethyl-5-

(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)aniline (Combi-Blocks, cat#PN-1190: 1 10 mg, 0.45 mmol) and N,N-diisopropylethylamine (0.20 mL, 1.1 mmol) in methylene chloride (2.0 mL). The resulting mixture was stirred at room temperature for 2 h, then diluted with DCM, washed with 0.1 M HCl, dried over sodium sulfate, and concentrated. The product obtained was used in the next step without further purification. LC-MS calculated for C16H25BNO4 (M+H) + : m/z = 306.2; found 306.2.

Step 2: methyl [5-(6-(4-cyanophenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methox y}imidazo[l,2- a]pyrazin-5-yl)-2-methylphenyl]methylcarbamate

The title compound was prepared using similar procedures as described for Example 48,

Step 8 with methyl methyl(2-methyl-5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2- yl)phenyl)carbamate replacing l-[5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for CsoffcNeOs (M+H) + : m/z = 525.3; found 525.2. Example 77

methyl [4-(6-(4-cyanophenyl)-8- { [(3R)-l-methylpiperidin-3-yl] methoxy}imidazo [ 1 ,2- a] pyr azin-5-yl)phenyl] meth lcarbamate

Step 1: methyl methyl(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl )carbamate

The title compound was prepared using similar procedures as described for Example 76, Step 1 with N-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)anil ine (Combi-Blocks, cat#PN-8673) replacing N,2-dimethyl-5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)aniline. LC-MS calculated for C15H23BNO4 (M+H) + : m/z = 292.2; found 292.2.

Step 2: methyl [4-(6-(4-cyanophenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methox y}imidazo[l,2- ajpyrazin- 5 -yl)phenylj methylcarbamate

The title compound was prepared using similar procedures as described for Example 48, Step 8 with methyl methyl(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl )carbamate replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H31N6O3 (M+H) + : m/z = 511.2; found 511.2.

Example 78

4-(5-(2-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[(3R)-l-methyl piperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile Step 1 : 5-(4, 4, 5, 5-tetramethyl-l, ro-lH-inden-2-ol

A suspension of 5-bromoindan-2-ol (Combi-B locks, cat#QA3834: 114 mg, 0.535 mmol), potassium acetate (160 mg, 1.6 mmol) and 4,4,5,5,4',4',5',5'-octamethyl-

[2,2']bi[[l,3,2]dioxaborolanyl] (200 mg, 0.80 mmol) in 1,4-dioxane (2.4 mL) was first degassed with stream of nitrogen for ~5 min, then [Ι,Γ- bis(diphenylphosphino)ferrocene]dichloropalladium(II),comple x with dichloromethane (1 : 1) (20 mg, 0.03 mmol) was added and the mixture was heated to 100 °C overnight. The reaction mixture was cooled to room temperature, concentrated then diluted with 1 : 1 ethyl

acetate/hexanes, filtered through celite, and concentrated. The residue obtained was purified by flash chromatography on a silica gel column eluting with 0 to 40 % EtOAc/Hexanes to provide the desired intermediate in nearly quantitative yield. Step 2: 4-(5-(2-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[(3R)-l-methyl piperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro- lH-inden-2-ol replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H30N5O2 (M+H) + : m/z = 480.2; found 480.2.

The above product, epimeric at the indanol stereocenter, was further purified using prep- HPLC on a column containing a chiral stationary phase (Phenomenex Lux Cellulose C-2, 5 μιη, 21.2x250 mm) and eluting with 45% EtOH in hexane, to obtain the desired product as the free base.

Peak 1 : = 10.1 min. LC-MS calculated for C29H30N5O2 (M+H) + : m/z = 480.2; found 480.3. ¾ NMR (500 MHz, MeOD) δ 7.62 (m, 1H), 7.60 - 7.54 (m, 4H), 7.50 (m, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.30 (s, 1H), 7.17 (d, J= 7.5 Hz, 1H), 4.70 - 4.65 (m, 1H), 4.59 (dd, J= 10.9, 5.7 Hz, 1H), 4.46 (dd, J= 10.8, 7.3 Hz, 1H), 3.28 - 3.11 (m, 3H), 2.99 - 2.82 (m, 3H), 2.37 - 2.24 (m, 4H), 2.13 - 2.00 (m, 2H), 1.97 - 1.89 (m, 1H), 1.84 - 1.76 (m, 1H), 1.73 - 1.64 (m, 1H), 1.36 - 1.17 (m, 2H).

Peak 2: = 12.9 min. LC-MS calculated for C29H30N5O2 (M+H) + : m/z = 480.2; found 480.2. l U NMR (600 MHz, MeOD) δ 7.62 (s, 1H), 7.60 - 7.54 (m, 4H), 7.53 - 7.47 (m, 1H),

7.37 (d, J= 7.6 Hz, 1H), 7.30 (s, 1H), 7.17 (d, J= 7.6 Hz, 1H), 4.70 - 4.65 (m, 1H), 4.59 (dd, J = 10.8, 5.7 Hz, 1H), 4.46 (dd, J= 10.8, 7.3 Hz, 1H), 3.28 - 3.13 (m, 3H), 2.97 - 2.83 (m, 3H), 2.36 - 2.29 (m, 4H), 2.12 - 2.03 (m, 2H), 1.96 - 1.90 (m, 1H), 1.83 - 1.76 (m, 1H), 1.72 - 1.63 (m, 1H), 1.30 - 1.20 (m, 1H).

Example 79

4-(5-(7-fluoro-3-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[(3R) -l-methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6- l)benzonitrile

Step 1: 6-bromo-4-fluoro-2,3-dihydro-lH-inden-l-ol

To a solution of 6-bromo-4-fluoroindan-l-one {Sigma-Aldrich, cat#775819: 120 mg, 0.54 mmol) in methanol (2 mL) was added sodium tetrahydroborate (22 mg, 0.60 mmol) in 2 portions. The reaction mixture was stirred at room temperature for 2 h leading to complete conversion. The solvent was removed and the residue partitioned between water and EtOAc. The EtOAc layer was washed with brine, dried over sodium sulfate, and the solvent was removed to the desired product (115 mg, 92%) which was used in the next step without further purification. LC-MS calculated for CgHvBrF (M+H-H 2 0) + : m/z = 213.0; found 213.0.

Step 2: 4-fluoro-6-(4,4,5,5-tetramethyl- -dioxaborolan-2-yl)-2,3-dihydro-lH-inden-l-ol

The title compound was prepared using similar procedures as described for Example 78, Step 1 with 6-bromo-4-fluoro-2,3-dihydro-lH-inden-l-ol replacing 5-bromoindan-2-ol. LC-MS calculated for C15H19BFO2 (M+H-H 2 0) + : m/z = 261.1; found 261.1.

Step 3: 4-(5-(7-fluoro-3-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[ (3R)-l-methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48,

Step 8 with 4-fluoro-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3 -dihydro-lH-inden-l-ol replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product (a mixture of two diastereomers) as the TFA salt. LC-MS calculated for

C29H29FN5O2 (M+H) + : m/z = 498.2; found 498.2.

Example 80

4-(5-(l-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[(3R)-l-methyl piperidin-3- yl] methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

Step 1 : 5-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)-2 , 3-dihydro-lH-inden-l-ol

The title compound was prepared using similar procedures as described for Example 78,

Step 1 with 5-bromo-2,3-dihydro-lH-inden-l-ol (Aurum Pharmatech, cat#NE44343) replacing 5-bromoindan-2-ol. LC-MS calculated for C15H20BO2 (M+H-H 2 0) + : m/z = 243.2; found 243.2.

Step 2: 4-(5-(l-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[ (3R)-1 -methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro- lH-inden-l-ol replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product (a mixture of two diastereomers) as the TFA salt. LC-MS calculated for C29H30N5O2 (M+H) + : m/z = 480.2; found 480.2.

Example 81

4-(5-[3-fluoro-4-(hydroxymethyl)-5-methylphenyl]-8-{[(3R)-l- methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

Step 1: (4-bromo-2-fluoro-6-methylphen l)methanol

2.0 M Lithium tetrahydroborate in THF (0.92 mL, 1.8 mmol) was added to a solution of methyl 4-bromo-2-fluoro-6-methylbenzoate (AstaTech, cat#CL9030: 207 mg, 0.838 mmol) in tetrahydrofuran (1.0 mL). The solution was heated to reflux for 4 h, and then the mixture was cooled to room temperature, quenched with water, and extracted 3 times with EtOAc. The combined extracts were washed with brine, dried over sodium sulfate and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 3 to 30% EtOAc/hexanes to provide the desired compound (109 mg, 60%). LC-MS calculated for CsHvBrF (M+H-H 2 0) + : m/z = 201.0; found 201.0.

Step 2: (2-fluoro-6-methyl-4-(4, 4, 5, 5-tetramethyl-l, 3,2-dioxaborolan-2-yl)phenyl)methanol

The title compound was prepared using similar procedures as described for Example 78,

Step 1 with (4-bromo-2-fluoro-6-methylphenyl)methanol replacing 5-bromoindan-2-ol. LC-MS calculated for Ci4Hi 9 BF0 2 (M+H-H 2 0) + : m/z = 249.1; found 249.1.

Step 3: 4-(5-[3-fluoro-4-(hydroxymethyl)-5-methylphenyl]-8-{[(3R)-l- methylpiperidin-3- yljmethoxy imidazof l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with (2-fluoro-6-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan -2-yl)phenyl)methanol replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H29FN5O2 (M+H) + : m/z = 486.2; found 486.2. Example 82

4-(5- [3-fluoro-4-(morpholin-4-ylmethyl)phenyl] -8- { [(3R)-1 -methylpiperidin-3- yl]methoxy}imidazo[l,2-a] razin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 4-(2-fluoro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)b enzyl)morpholine (Combi-Blocks, cat#PN-8769) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyridin-2-yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C31H34FN6O2 (M+H) + : m/z = 541.3; found 541.2.

Example 83

4-(5-[3,5-difluoro-4-(hydroxymethyl)phenyl]-8-{[(3R)-l-methy lpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6- l)benzonitrile

The title compound was prepared using similar procedures as described for Example 48,

Step 8 with 3,5-difluoro-4-(hydroxymethyl)phenylboronic acid (Combi-Blocks, cat#BB-8390) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C27H26F2N5O2 (M+H)

found 490.2.

Example 84

4-(5-(5-fluor o-6-methoxypyridin-3-yl)-8- { [(3R)- l-methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6- l)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 5-fluoro-6-methoxypyridin-3-ylboronic acid (Comb i-B locks, cat#BB-84600) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C26H26FN6O2 (M+H) + : m/z = 473.2; found 473.2.

Example 85

methyl [4-(6-(4-cyanophenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methox y}imidazo[l,2- a] pyrazin-5-yl)-2-fluorobenz l] methylcarbamate

Step 1: l-[ 2-fluoro-4- ( 4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)phenyl] -N- methylmethanamine

F 2.0 M Methylamine in THF (3 mL, 6 mmol) was added dropwise to a solution of 2-[4- (bromomethyl)-3-fluorophenyl]-4,4,5,5-tetramethyl-l,3,2-diox aborolane (Combi-Blocks, cat#PN-5656: 200 mg, 0.6 mmol) in THF (10 mL) over 1 hour. After stirring for an additional 2 h, the reaction was concentrated and used without further purification. LC-MS calculated for C14H22BFNO2 (M+H) + : m/z = 266.2; found 266.2.

Step 2: methyl [2-fluoro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)ben zyl]methylcarbamate

Methyl chloroformate (19 0.24 mmol), followed by N,N-diisopropylethylamine (0.056 mL, 0.32 mmol) were added to a solution of l-[2-fluoro-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl]-N-methylmethanamine (40 mg, 0.2 mmol) in methylene chloride (2.0 mL). After 2h the reaction mixture was concentrated and used without further purification. LC- MS calculated for C16H24BFNO4 (M+H) + : m/z = 324.2; found 324.2.

Step 3: methyl [4-(6-(4-cyanophenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methox y}imidazo[l,2- a] pyrazin-5-yl)-2-fluorobenzyl] methylcarbamate

The title compound was prepared using similar procedures as described for Example 48, Step 8 with methyl 2-fluoro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)benzyl(methyl)carbamate replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin- 2-yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C30H32FN6O3 (M+H) + : m/z = 543.3; found 543.2.

Example 86

4-(5-[4-(l-hydroxyethyl)-3-methylphenyl]-8-{[(3R)-l-methylpi peridin

yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

Step 1: l-(4-bromo-2-methylphenyl)ethanol

3.0 M methylmagnesium bromide in diethyl ether (2.7 mL, 8.2 mmol) was added over ~5 min to a solution of 4-bromo-2-methylbenzaldehyde (AstaTech, cat#BL005480: 325 mg, 1.63 mmol) in tetrahydrofuran (3.0 mL) at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 3 h, after which time saturated aqueous ammonium chloride was added carefully. The solution was then extracted 3 times with EtOAc, dried over sodium sulfate, and concentrated. The residue was purified by flash chromatography on silica gel eluting with 0 to 25% EtOAc/hexanes to afford the desired product (351 mg, 84%). LC-MS calculated for CgHioBr (M+H-H 2 0) + : m/z = 197.0; found 197.0.

Step 2: l-(2-methyl-4-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)phenyl)ethanol

A suspension of l-(4-bromo-2-methylphenyl)ethanol (296 mg, 1.38 mmol), potassium acetate (400 mg, 4.1 mmol) and 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[l ,3,2]dioxaborolanyl] (520 mg, 2.1 mmol) in 1 ,4-dioxane (6.3 mL) was purged with stream of nitrogen for ~5 min, then [1 ,1 '-bis(diphenylphosphino)ferrocene]dichloropalladium(II),comp lex with dichloromethane (1 : 1) (60 mg, 0.07 mmol) was added and the mixture was heated at 100 °C overnight. The reaction mixture was then cooled to room temperature and concentrated. The residue was diluted with ethyl acetate, filtered through a pad of celite, and the filtrate was concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 25% EtOAc/hexanes to afford the desired product (300 mg, 83%). LC-MS calculated for C15H22BO2 (M+H-H 2 0) + : m/z = 245.2; found 245.1.

Step 3: 4-(5-[4-(l-hydroxyethyl)-3-methylphenyl]-8-{[ (3R)-l-methylpiperidin-3- yljmethoxy imidazof l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with l-(2-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)p henyl)ethanol replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H32N5O2 (M+H) + : m/z = 482.3; found 482.2.

Example 87

4-(5-[3-(l-hydroxyethyl)-4-methylphenyl]-8-{[(3R)-l-methylpi peridin-3- l]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 86, Step 1 with 5-bromo-2-methylbenzaldehyde (ArkPharm, cat#AK-36810) replacing 4-bromo-2- methylbenzaldehyde. LC-MS calculated for CgHioBr (M+H-H 2 0) + : m/z = 197.0; found 197.0.

Step 2: l-(2-methyl-5-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)phenyl)ethanol

The title compound was prepared using similar procedures as described for Example 86, Step 2 with l-(5-bromo-2-methylphenyl)ethanol replacing l-(4-bromo-2-methylphenyl)ethanol. LC-MS calculated for C15H22BO2 (M+H-H 2 0) + : m/z = 245.2; found 245.2.

Step 3: 4-(5-[3-(l-hydroxyethyl)-4-methylphenyl]-8-{[ (3R)-1 -methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with l-(2-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)p henyl)ethanol replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H32N5O2 (M+H) + : m/z = 482.3; found 482.2.

Example 88

4-(5-(7-fluoro-l-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[(3R) -l-methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6- l)benzonitrile

Step 1: 5-bromo-7-fluoro-2 ,3-dihydro- lH-inden- l-ol

The title compound was prepared using similar procedures as described for Example 79, Step 1 with 5-bromo-7-fluoro-2,3-dihydro-lH-inden-l-one (AstaTech, cat#31063) replacing 6- bromo-4-fluoroindan-l-one. LC-MS calculated for CgHvBrF (M+H-H 2 0) + : m/z = 213.0; found 212.9.

Step 2: 7-fluoro-5-(4,4,5,5-tetrameth -l,3,2-dioxaborolan-2-yl)-2,3-dihydro-lH-inden-l-ol

The title compound was prepared using similar procedures as described for Example 79, Step 2 with 5-bromo-7-fluoro-2,3-dihydro-lH-inden-l-ol replacing 6-bromo-4-fluoro-2,3- dihydro-lH-inden-l-ol. LC-MS calculated for C15H19BFO2 (M+H-H 2 0) + : m/z = 261.1; found 261.2.

Step 3: 4-(5-(7-fluoro-l-hydroxy-2,3-dihydro-lH-inden-5-yl)-8-{[ (3R)-1 -methylpiperidin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 7-fluoro-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3 -dihydro-lH-inden-l-ol replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product (a mixture of two diastereomers) as the TFA salt. LC-MS calculated for C29H29FN5O2 (M+H) + : m/z = 498.2; found 498.2. Example 89

4-(5- [2-fluoro-4-(morpholin-4-ylmethyl)phenyl] -8- { [(3R)-1 -methylpiperidin-3- yl]methoxy}imidazo[l,2-a] razin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 4-(3-fluoro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)b enzyl)morpholine (Combi-Blocks, cat#PN-6786) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyridin-2-yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C31H34FN6O2 (M+H) + : m/z = 541.3; found 541.2.

Example 90

4-(5-[2-(hydroxymethyl)-4-methylphenyl]-8-{[(3R)-l-methylpip eridin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6- l)benzonitrile

The title compound was prepared using similar procedures as described for Example 48,

Step 8 with 2-(hydroxymethyl)-4-methylphenylboronic acid (Aurum PharmaTech, cat#Q-7538) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H30N5O2 (M+H) + : m/z = 468.2; found 468.2.

Example 91

4-(5- [3-(cyanomethyl)-4-methylphenyl] -8- { [(3R)- l-methylpiperidin-3- yl] methoxy}imidazo [ 1 ,2-a] pyr azin-6-yl)benzonitrile

Step 1 : 2 -(2 -methyl- 5 -(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)phenyl)acetonitrile

The title compound was prepared using similar procedures as described for Example 78, Step 1 with 2-(5-bromo-2-methylphenyl)acetonitrile (AstaTech, cat#CL9129) replacing 5- bromoindan-2-ol. LC-MS calculated for C15H22BNO3 (M+ H 2 0) + : m/z = 275.2; found 275.2.

Step 2: 4-(5-[3-(cyanomethyl)-4-methylphenyl]-8-{[(3R)-l-methylpiper idin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using similar procedures as described for Example 48, Step 8 with 2-(2-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)p henyl)acetonitrile replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H29N6O (M+H) + : m/z = 477.2; found 477.2. Example 92

4- [8- [4-(dimethylamino)piperidin- 1-yl] -5-(5,6-dimethylpyridin-3-yl)imidazo [ 1 ,2-a] pyr azin- 6-yl]benzonitrile

A degassed solution of 4-{5-chloro-8-[4-(dimethylamino)piperidin-l-yl]imidazo[l,2- a]pyrazin-6-yl}benzonitrile {Example 58, Step 4: 10 mg, 0.03 mmol), 2,3-dimethyl-5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (Combi-Blocks, cat#FM-6236: 7.9 mg,

0.034mmol), potassium phosphate (20 mg, 0.1 mmol), dichloro[l,l'- bis(dicyclohexylphosphino)ferrocene]palladium(II) (2 mg, 0.003 mmol) in 1,4-dioxane (1 mL) and water (0.15 mL) was heated at 90 °C for 2 h. The reaction mixture was cooled to room temperature and purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C27H30N7 (M+H) + : m/z = 452.3; found 452.2.

Example 93

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(2-hydroxy-2,3-d ihydro-lH-inden-5- yl)imidazo [1 ,2-a] pyrazin-6-yl] benzonitrile

The title compound was prepared using similar procedures as described for Example 92 with 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro- lH-inden-2-ol {Example 78, Step 1) replacing 2,3-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product (racemic) as the TFA salt. LC-MS calculated for C29H31N6O (M+H) + : m/z = 479.3; found 479.2. Example 94

4- [8- [4-(dimethylamino)piperidin- 1-yl] -5-(5-hydroxy-6-methylpyridin-3-yl)imidazo [ 1 ,2- a] pyrazin-6-yl] benzonitrile

Step 1 : 2-methyl-5- ( 4, 4, 5, 5-tetramethyl- -dioxaborolan-2-yl)pyridin-3-ol

OH The title compound was prepared using similar procedures as described for Example 78, Step 1 with 5-bromo-2-methylpyridin-3-ol (Combi-Blocks, cat#QA-0238) replacing 5- bromoindan-2-ol. LC-MS calculated for C12H19BNO3 (M+ H) + : m/z = 236.1; found 236.1. Step 2: 4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(5-hydroxy-6-methyl pyridin-3-yl)M

aJpyrazin-6-ylJbenzonitrile

The title compound was prepared using similar procedures as described for Example 92 with 2-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyri din-3-ol replacing 2,3- dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyri dine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C26H28N7O (M+H) + : m/z = 454.2; found 454.2.

Example 95

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(3-hydroxy-2,3-dihy dro-lH-inden-5- yl)imidazo [1 ,2-a] pyrazin-6-yl] benzonitrile

The title compound was prepared using similar procedures as described for Example 92 with 6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro- lH-inden-l-o/ {Example 73, Step 2) replacing 2,3-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product (racemic) as the TFA salt. LC-MS calculated for C29H31N6O (M+H) + : m/z = 479.3; found 479.2.

Example 96

4- {8- [4-(dimethylamino)piperidin- 1-yl] -5- [3-(hydroxymethyl)-4-methylphenyl] imidazo [1 ,2- a] pyr azin-6-yl}benzonitrile

The title compound was prepared using similar procedures as described for Example 92 with (2-methyl-5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)phenyl)methanol (Combi-Blocks, cat#FM-2080) replacing 2,3-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H31N6O (M+H) + : m/z = 467.3; found 467.2.

Example 97

4- {8- [4-(dimethylamino)piperidin- 1-yl] -5- [3-fluoro-4-(hydroxymethyl)-5- methylphenyl] imidazo [ 1 ,2-a] pyrazin-6-yl}benzonitrile

The title compound was prepared using similar procedures as described for Example 92 with (2-fluoro-6-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan -2-yl)phenyl)methanol (Example 81, Step 2) replacing 2,3-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H30FN6O (M+H) + : m/z = 485.2; found 485.2. Example 98

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(l-methyl-2-oxo-2,3 -dihydro-lH-indol-5- yl)imidazo [1 ,2-a] pyrazin-6-yl] benzonitrile

Step 1 : l-methyl-5-(4, 4, 5, 5-tetramethyl-l , 3,2-dioxaborolan-2-yl)-l, 3-dihydro-2H-indol-2-one

A mixture of 5-bromo-l -methyl- l,3-dihydro-2H-indol-2-one (Maybridge, cat#CC63010, 0.30 g, 1.3 mmol), 4,4,5,5,4 * ,4 * ,5 * ,5 * -octamethyl-[2,2 , ]bi[[l,3,2]dioxaborolanyl] (500 mg, 2.0 mmol), [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with

dichloromethane (1 : 1) (50 mg, 0.07 mmol) and potassium acetate (390 mg, 4.0 mmol) in 1,4- dioxane (10 mL) was purged with nitrogen and heated at 90°C overnight. After cooling it was concentrated. The crude material was purified by flash chromatography on a silica gel column eluting with 0 to 25% EtOAc in hexanes to give the desired product. LC-MS calculated for C15H21BNO3 (M+H) + : m/z = 274.2; found 274.1.

Step 2: 4- [8- [4-(dimethylamino)piperidin- 1-yl] '-5-( l-methyl-2-oxo-2 ,3-dihydro- lH-indol-5- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile

The title compound was prepared using similar procedures as described for Example 58,

Step 5 with l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3 -dihydro-2H-indol-2- one replacing l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazolo[3,4- b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H30N7O (M+H) + : m/z = 492.2; found 492.2.

Example 99

4- {8- [3-(dimethylamino)piperidin- 1-yl] -5- [6-(2-oxopyrrolidin- l-yl)pyridin-3-yl] imidazo [1 ,2- a] pyr azin-6-yl}benzonitrile

The title compound was prepared using similar procedures as described for Example 57 with N,N-dimethylpiperidin-3 -amine (ChemBridge Corp., cat#4018212) replacing N,N- dimethylpiperidin-4-amine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for

C29H31N8O (M+H) + : m/z = 507.3; found 507.2. ¾ NMR (400 MHz, CD3OD) δ 8.54 (d, J= 8.7 Hz, 1H), 8.23 (d, J= 1.7 Hz, 1H), 7.93 (dd, J= 8.7, 2.4 Hz, 1H), 7.68 - 7.60 (m, 3H), 7.59 - 7.52 (m, 3H), 5.22 (d, J= 12.8 Hz, 2H), 4.15 (m, 3H), 3.78 (t, J= 10.3 Hz, 1H), 3.61 - 3.45 (m, 1H), 3.14 (s, 3H), 3.00 (s, 3H), 2.71 (t, J= 8.1 Hz, 2H), 2.33 - 2.13 (m, 3H), 2.12 - 1.94 (m, 2H), 1.93 - 1.75 (m, 1H).

Example 100

4-{8-[4-(dimethylamino)piperidin-l-yl]-5-[6-(3-methyl-2-oxoi midazolidin-l-yl)pyridin-3- yl] imidazo [1,2-a] pyrazin-6-yl}benzonitrile

To a solution of l-methylimidazolidin-2-one (0.210 g, 2.10 mmol) in N,N- dimethylformamide (2.1 mL) at 0 °C was added sodium hydride (60% dispersion in mineral oil, 83.9 mg, 2.10 mmol) in portions. The mixture was stirred for 30 min at room temperature. Then 5-bromo-2-fluoropyridine (0.216 mL, 2.10 mmol) in N,N-dimethylformamide (0.42 mL) was added dropwise. The reaction was stirred overnight, then heated to 80 °C for 1.5 h before quenching with a methanol and water mixture. The mixture was extracted with dichloromethane, dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by chromatography on silica eluting with 0-50% EtOAc in hexanes to afford the desired product. LC-MS calculated for CgHnBrNsO (M+H) + : m/z = 256.0; found 256.0.

Step 2: l-methyl-3-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)p yridin-2-ylJimidazo one

4,4,5,5,4 , ,4 , ,5 * ,5 * -octamethyl-[2,2 , ]bi[[l,3,2]dioxaborolanyl] (230 mg, 0.92 mmol), [1,1 * - bis(diphenylphosphino)ferrocene]dichloropalladium(II),comple x with dichloromethane (1 : 1) (74 mg, 0.090 mmol) and potassium acetate (200 mg, 2 mmol) in 1,4-dioxane (5 mL) was purged with nitrogen and heated at 80 °C overnight. After cooling to room temperature, it was concentrated, then diluted with EtOAc followed by filtration through Celite. The filtrate was concentrated and purified by chromatography on silica with 0-50% EtOAc in hexanes to afford the desired prod. LC-MS calculated for C15H23BN3O3 (M+H) + : m/z = 304.2; found 304.2.

Step 3: 4-{8-[4-(dimethylamino)piperidin-l -ylj -5-[6-(3-methyl-2-oxoimidazolidin-l-yl)pyridin- 3-ylJimidazof l,2-a]pyrazin-6-yl}benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with l-methyl-3-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)p yridin-2- yl]imidazolidin-2-one replacing l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazolo[3,4-b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for

C29H32N9O (M+H) + : m/z = 522.3; found 522.2. ¾ NMR (400 MHz, CD3OD) δ 8.40 (d, J= 8.5 Hz, 1H), 8.12 (s, 1H), 7.83 (dd, J= 8.8, 2.3 Hz, 1H), 7.62 - 7.50 (m, 6H), 5.73 (d, J= 13.6 Hz, 2H), 4.12 - 4.00 (m, 2H), 3.66 - 3.53 (m, 3H), 3.33 (s, 3H), 3.25 - 3.11 (m, 2H), 2.94 (s, 6H), 2.24 (d, J= 10.7 Hz, 2H), 1.88 (d, J= 8.6 Hz, 2H).

Example 101

4-{8-[4-(dimethylamino)piperidin-l-yl]-5-quinoxalin-6-yli midazo[l,2-a]pyrazin-6- yl}benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with 6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)quinoxaline (Aldrich, cat#708631) replacing 1 -methyl-5-(4,4,5 ,5 -tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 H-pyrazolo[3 ,4-b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H27N8 (M+H) + : m/z = 475.2; found 475.2. ¾ NMR (400 MHz, CD3OD) δ 8.99 - 8.90 (m, 2H), 8.24 (d, J= 8.7 Hz, 1H), 8.10 (d, J = 1.6 Hz, 1H), 7.87 (dd, J= 8.7, 1.8 Hz, 1H), 7.61 (d, J= 1.2 Hz, 1H), 7.57 - 7.49 (m, 5H), 5.85 - 5.70 (m, 2H), 3.68 - 3.54 (m, 1H), 3.20 (t, J= 12.5 Hz, 2H), 2.93 (s, 6H), 2.32 - 2.16 (m, 2H), 1.98 - 1.80 (m, 2H).

Example 102

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(l-methyl-2-oxo- l,2,3,4-tetrahydroquinolin-6- yl)imidazo [1 ,2-a] pyrazin-6-yl] benzonitrile

Step 1 : l-methyl-6- ( 4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)-3, 4-dihydroquinolin-2 ( lH)-one

A mixture of 6-bromo-l-methyl-3,4-dihydroquinolin-2(lH)-one {Matrix Scientific, cat#101386: 0.4 g, 2 mmol), 4,4,5,5,4 , ,4 , ,5 * ,5 * -octamethyl-[2,2 , ]bi[[l,3,2]dioxaborolanyl] (630 mg, 2.5 mmol), [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II),compl ex with dichloromethane (1 : 1) (70 mg, 0.08 mmol) and potassium acetate (490 mg, 5.0 mmol) in 1,4- dioxane (20 mL) was purged with nitrogen then heated at 90 °C overnight. After cooling it was concentrated. The crude material was purified by flash column eluting with 0 to 35% AcOEt in hexanes to give the desired product. LC-MS calculated for C16H23BNO3 (M+H) + : m/z = 288.2; found 288.2.

Step 2: 4-f8-f4-(dimethylamino)piperidin-l-ylJ-5-(l-methyl-2-oxo-l,2 ,3,4-tetm

yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with l-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4 -dihydroquinolin- 2( 1 H)-one replacing 1 -methyl-5-(4,4, 5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 H-pyrazolo[3 ,4- b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C30H32N7O (M+H) + : m/z = 506.3; found 506.2. ¾ NMR (400 MHz, CD3OD) δ 7.63 - 7.58 (m, 5H), 7.51 (d, J= 1.1 Hz, 1H), 7.32 - 7.22 (m, 3H), 5.70 (d, J= 13.6 Hz, 2H), 3.60 (t, J= 12.1 Hz, 1H), 3.41 (s, 3H), 3.37 (m, 2H), 3.18 (t, J= 11.9 Hz, 2H), 2.94 (s, 6H), 2.68 (q, J= 7.0 Hz, 2H), 2.25 (d, J= 11.1 Hz, 2H), 1.97 - 1.80 (m, 2H).

Example 103

4-{8-[4-(dimethylamino)piperidin-l-yl]-5-[2-(hydroxymethyl)- l-methyl-lH-pyrrolo[2,3- b] pyridin-5-yl] imidazo [ 1 ,2-a] pyrazin-6-yl}benzonitrile

Step 1: methyl 5-bromo-l-methyl-lH-p rrolo[2,3-b]pyridine-2-carboxylate

To a suspension of 5-bromo-lH-pyrrolo[2,3-b]pyridine-2-carboxylic acid (Adesis, cat#4-

453: 101 mg, 0.419 mmol) and potassium carbonate (300 mg, 2 mmol) in acetonitrile (2 mL) was added dimethyl sulfate (75 μί, 0.80 mmol) dropwise at room temperature. The mixture was stirred at room temperature for 30 min then at 60 °C overnight. Then the reaction mixture was cooled to room temperature, filtered and the filtrate was concentrated and used directly in the next step without further purification. LC-MS calculated for CioHioBrN 2 0 2 (M+H) + : m/z = 269.0; found 269.0.

Step 2: (5-bromo-l-methyl-lH-pyrrolo 2, 3-b]pyridin-2-yl)methanol

To a solution of methyl 5-bromo-l-methyl-lH-pyrrolo[2,3-b]pyridine-2-carboxylate (0.1 g, 0.4 mmol) in tetrahydrofuran (2 mL) was slowly added 1.0 M lithium tetrahydroaluminate in tetrahydrofuran (0.28 mL, 0.28 mmol) at 0 °C. The reaction mixture was slowly warmed to room temperature and stirred for 30 min. Then the reaction was quenched by EtOAc, the reaction mixture was concentrated and purified by column chromatography on silica gel with 0-60% EtOAc in hexanes to afford the desired product. LC-MS calculated for C9HioBrN 2 0 (M+H) + : m/z = 241.0; found 241.0.

Step 3: [ 1 -methyl- 5 -(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)-lH-pyrrolo[ 2, 3-b]pyridin-2- yljmethanol

A mixture of (5-bromo-l-methyl-lH-pyrrolo[2,3-b]pyridin-2-yl)methanol (56 mg, 0.23 mmol), 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[l,3,2]dioxaborolany l] (65 mg, 0.26 mmol), [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II),comple x with dichloromethane (1 : 1) (20. mg, 0.025 mmol) and potassium acetate (60 mg, 0.7 mmol) in 1,4-dioxane (1 mL) was purged with nitrogen and heated at 90 °C for 6 hrs. After cooling the reaction mixture was concentrated, then diluted with EtOAc followed by filtration through Celite. The filtrate was concentrated and purified by chromatography on silica gel with 0-90% EtOAc in hexanes to afford the desired product. LC-MS calculated for C15H22BN2O3 (M+H) + : m/z = 289.2; found 289.1.

Step 4: 4-{8-[4-(dimethylamino)piperidin-l-yl]-5-[2-(hydroxymethyl)- l-me

b]pyridin-5-yl]imidazo[l,2-a]pyrazin-6-yl}benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with [l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH -pyrrolo[2,3-b]pyridin- 2-yl]methanol replacing l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazolo[3,4-b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H31N8O (M+H) + : m/z = 507.3; found 507.2. ¾ NMR (400 MHz, CD3OD) δ 8.10 (s, 1H), 8.05 (s, 1H), 7.61 - 7.47 (m, 6H), 6.55 (s, 1H), 5.71 (m, 2H), 4.86 (s, 2H), 3.93 (s, 3H), 3.61 (m, 1H), 3.24 - 3.11 (m, 2H), 2.94 (s, 6H), 2.25 (d, J= 10.8 Hz, 2H), 1.90 (m, 2H).

Example 104

4- {8- [(3 S)-3-(dimethylamino)pyrrolidin- 1-yl] -5- [6-(2-oxopyrrolidin- l-yl)pyridin-3- yl] imidazo [1,2-a] pyrazin-6-yl}benzonitrile

The title compound was prepared using similar procedures as described for Example 57 with (3S)-N,N-dimethylpyrrolidin-3-amine {TCI, cat#D2I93) replacing N,N-dimethylpiperidin- 4-amine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H2 N8O (M+H) + : m/z = 493.2; found 493.2. ¾ NMR (400 MHz, CD3OD) δ 8.52 (d, J= 8.7 Hz, 1H), 8.21 (s, 1H), 7.92 (dd, J= 8.7, 2.1 Hz, 1H), 7.67 - 7.49 (m, 6H), 4.64 (dd, J= 12.5, 7.5 Hz, 1H), 4.50 (t, J= 8.7 Hz, 1H), 4.36 (dd, J= 12.4, 6.7 Hz, 1H), 4.20 - 4.00 (m, 4H), 3.07 (s, 6H), 2.76 - 2.58 (m, 3H), 2.42 - 2.25 (m, 1H), 2.24 - 2.09 (m, 2H).

Example 105

4- [8- [4-(dimethylamino)piperidin-l-yl] -5-(3-ethyl-2-oxo-2,3-dihydro [1,3] oxazolo [4,5- b] pyridin-6-yl)imidazo [ 1 ,2-a] pyrazin-6-yl] benzonitrile

Step I: 6-bromo-3-ethyl[ 1 ,3] Oxazolo [4, 5 -b 'pyridin- 2(311) -one

To a mixture of 6-bromo[l,3]oxazolo[4,5-b]pyridin-2(3H)-one {Ark Pharm, catUAK- 24539: 192 mg, 0.893 mmol) and cesium carbonate (440 mg, 1.3 mmol) in tetrahydrofuran (3 mL) was added iodoethane (0.4 mL, 4 mmol). The reaction mixture was stirred at 50 °C overnight. The mixture was filtered, concentrated and purified by column chromatography eluting with 0-30% EtOAc in hexanes. LC-MS calculated for CsHsBr^C (M+H) + : m z = 243.0; found 243.0.

Step 2: 3-ethyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)fl,3J oxazolof4,5-bJpyridin- 2(3H)-one

A mixture of 6-bromo-3-ethyl[l,3]oxazolo[4,5-b]pyridin-2(3H)-one (81 mg, 0.33 mmol), 4,4,5,5,4 , ,4 , ,5 * ,5 * -octamethyl-[2,2 , ]bi[[l,3,2]dioxaborolanyl] (93 mg, 0.37 mmol), [1,1 * - bis(diphenylphosphino)ferrocene]dichloropalladium(II),comple x with dichloromethane (1 : 1) (29 mg, 0.036 mmol) and potassium acetate (90 mg, 1 mmol) in 1,4-dioxane (2 mL) was purged with nitrogen and heated at 90 °C for 6 hrs. After cooling it was concentrated, then diluted with EtOAc followed by filtration through Celite. The filtrate was concentrated and purified by chromatography on silica with 0-90% EtOAc in hexanes to afford the desired prod. LC-MS calculated for C14H20BN2O4 (M+H) + : m/z = 291.2; found 291.2.

Step 3: 4-[8-[ 4-(dimethylamino)piperidin-l-yl]-5-(3-ethyl-2-oxo-2, 3-dihydro[ 1, 3]oxazolo[ 4, 5- b Jpyridin- 6-yl) imidazof 1, 2-aJpyrazin- 6-ylJ benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with 3-ethyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)[l,3] oxazolo[4,5-b]pyridin- 2(3H)-one replacing l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazolo[3,4- b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H2 N8O2 (M+H) + : m/z = 509.2; found 509.2. Example 106

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(l-methyl-lH-benzim idazol-5-yl)imidazo[l,2- a] pyrazin-6-yl] benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- benzimidazole {Combi-Blocks, cat#FA-4841) replacing l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-lH-pyrazolo[3,4-b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H29N8 (M+H) + : m/z = 477.2; found 477.2. l U NMR (400 MHz, CD3OD) δ 9.18 (s, 1H), 7.98 (d, J= 8.6 Hz, 1H), 7.83 (s, 1H), 7.66 - 7.57 (m, 2H), 7.54 - 7.48 (m, 4H), 7.44 (d, J= 1.1 Hz, 1H), 5.79 - 5.68 (m, 2H), 4.14 (s, 3H), 3.67 - 3.53 (m, 1H), 3.18 (t, J= 12.2 Hz, 2H), 2.92 (s, 6H), 2.30 - 2.19 (m, 2H), 1.97 - 1.81 (m, 2H).

Example 107

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(4-methyl-3-oxo-3,4 -dihydro-2H-pyrido[3,2- b] [1 ,4] oxazin-7-yl)imidazo [ 1 ,2-a] pyrazin-6-yl] benzonitrile

Step 1: 7-bromo-4-methyl-2H-pyrido [3 ,2-b] [ 1 ,4] oxazin-3 (4H)-one

To a mixture of 7-bromo-2H-pyrido[3,2-b][l,4]oxazin-3(4H)-one (Ark Pharma, catUAK- 30821: 204 mg, 0.893 mmol) and cesium carbonate (440 mg, 1.3 mmol) in tetrahydrofuran (3 mL) was added methyl iodide (2.0 mL, 30 mmol). The mixture was stirred at 50 °C overnight. After cooling to room temperature, the reaction mixture was filtered and concentrated. The residue was used in the next step without further purification. LC-MS calculated for CsHsBr^Ch (M+H) + : m/z = 243.0; found 242.9. Step 2: 4-methyl- 7 -(4, 4, 5, 5-tetramethyl-l, 3,2-dioxaborolan-2-yl)-2H-pyrido[ 3,2-bJf 1, 4]oxazin- 3(4H)-one

A mixture of 7-bromo-4-methyl-2H-pyrido[3,2-b][l,4]oxazin-3(4H)-one (200 mg, 0.8 mmol), 4,4,5,5,4 * ,4 * ,5 * ,5 * -octamethyl-[2,2 , ]bi[[l,3,2]dioxaborolanyl] (230 mg, 0.90 mmol), [1,1 * - bis(diphenylphosphino)ferrocene]dichloropalladium(II),comple x with dichloromethane (1 : 1) (70 mg, 0.08 mmol) and potassium acetate (300 mg, 3 mmol) in 1 ,4-dioxane (3 mL) was purged with nitrogen then stirred at 90 °C for 6 h. After cooling to room temperature, the reaction mixture was concentrated and the residue was dissolved in EtOAc then filtered. The filtrate was concentrated and the residue was purified by flash chromatography on a silica gel column eluting with 0-90% EtOAc in hexanes to afford the desired product. LC-MS calculated for C14H20BN2O4 (M+H) + : m/z = 291.2; found 291.1.

Step 3: 4-[8-[4-(dimethylamino)piperidin-l-yl] -5-(4-methyl-3-oxo-3 - b] [l,4]oxazin-7-yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile

The title compound was prepared using similar procedures as described for Example 58,

Step 5 with 4-methyl-7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2H- pyrido[3,2- b][l,4]oxazin-3(4H)-one replacing l-methyl-5-(4,4,5, 5-tetramethyl-l, 3,2-dioxaborolan-2-yl)-lH- pyrazolo[3,4-b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H29N8O2 (M+H) + : m/z = 509.2; found 509.2. ¾ NMR (400 MHz, CD3OD) δ 7.86 (d, J= 1.8 Hz, 1H), 7.66 - 7.53 (m, 6H), 7.44 (d, J= 1.8 Hz, 1H), 5.81 - 5.66 (m, 2H), 4.79 (s, 2H), 3.65 - 3.53 (m, 1H), 3.45 (s, 3H), 3.16 (t, J= 12.3 Hz, 2H), 2.91 (s, 6H), 2.29 - 2.17 (m, 2H), 1.93 - 1.78 (m, 2H). Example 108

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(l-methyl-2-oxo-l,2 ,3,4-tetrahydroquinolin-7- yl)imidazo [1 ,2-a] pyrazin-6-yl] benzonitrile

Step 1 : 1 -methyl- 7- ( 4, 4, 5, 5-tetramethyl-l , 3, 2-dioxaborolan-2-yl)-3, 4-dihydroquinolin-2 ( lH)-one

A mixture of 7-bromo-l-methyl-3,4-dihydroquinolin-2(lH)-one {Alfa Aesar,

cat#H33197: 0.260 g, 1.08 mmol), 4,4,5,5,4 , ,4 , ,5*,5*-octamethyl-[2,2 , ]bi[[l ,3,2]dioxaborolanyl] (410 mg, 1.6 mmol), [l , -bis(diphenylphosphino)ferrocene]dichloropalladium(II),compl ex with dichloromethane (1 : 1) (40 mg, 0.05 mmol) and potassium acetate (320 mg, 3.2 mmol) in 1 ,4- dioxane (10 mL) was purged with nitrogen and heated at 90 °C overnight. After cooling it was concentrated, then diluted with EtOAc followed by filtration through Celite. The filtrate was concentrated and purified by chromatography on silica with 0-50% EtOAc in hexanes to afford the desired product. LC-MS calculated for CieffeBNOs (M+H) + : m/z = 288.2; found 288.2.

Step 2: 4-[8-[ 4-(dimethylamino)piperidin-l -ylj -5-(l -methyl-2-oxo-l ,2, 3,4-tetrahydroquinolin- 7- yl)imidazo[l,2-a]pyrazin-6-yl] benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with l-methyl-7-(4,4,5,5-tetramethyl- l ,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin- 2( 1 H)-one replacing 1 -methyl-5-(4,4, 5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 H-pyrazolo[3 ,4- b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C30H32N7O (M+H) + : m/z = 506.3; found 506.3. Example 109 4-{8-[4-(dimethylamino)piperidin-l-yl]-5-[6-(4-methyl-3-oxop iperazin-l-yl)pyridin-3- yl] imidazo [1,2-a] pyrazin-6-yl}benzonitrile

Step 1: 4-(5-bromopyridin-2-yl)-l-methylpiperazin-2-one

To a solution of 5-bromo-2-fluoropyridine (0.100 mL, 0.972 mmol) ίη Ν,Ν- dimethylformamide (4.0 mL) was added triethylamine (0.284 mL, 2.04 mmol) and 1- methylpiperazin-2-one hydrochloride (0.161 g, 1.07 mmol). The resulting mixture was heated at 100 °C for 12 h then cooled to room temperature, diluted with DCM, washed with water and brine. The organic layer was dried over Na 2 SC"4, filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 100 % EtoAc/Hexanes to give the desired product. LC-MS calculated for CioHi3BrN30 (M+H) + : m/z = 270.0; found 270.0. Step 2: l-methyl-4-[5-(4A,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)py ridin-2-yl]p

A mixture of 4-(5-bromopyridin-2-yl)-l-methylpiperazin-2-one (0.117 g, 0.433 mmol), 4,4,5,5,4 , ,4 , ,5 * ,5 * -octamethyl-[2,2 , ]bi[[l,3,2]dioxaborolanyl] (0.165 g, 0.649 mmol), [1,1 * - bis(diphenylphosphino)ferrocene]dichloropalladium(II),comple x with dichloromethane (1 : 1) (40 mg, 0.05 mmol) and potassium acetate (0.127 g, 1.30 mmol) in 1,4-dioxane (2 mL) was purged with nitrogen and heated at 90 °C overnight. After cooling it was concentrated, then diluted with EtOAc followed by filtration through Celite. The filtrate was concentrated and the residue was used in the next step without further purification.

Step 3: 4-{8-[4-(dimethylamino)piperidin-l-yl]-5-[6-(4-methyl-3-oxop iperazin-l-yl)pyridin-3 yl]imidazo[l,2-a]pyrazin-6-yl}benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with l-methyl-4-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)p yridin-2-yl]piperazin-2 one replacing 1 -methyl-5-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 H-pyrazolo[3 ,4- b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C30H34N9O (M+H) + : m/z = 536.3; found 536.3.

Example 110

4-{8-[4-(dimethylamino)piperidin-l-yl]-5-[3-(hydroxymethyl)- l-methyl-lH-indazol-5- yl] imidazo [1,2-a] pyrazin-6-yl}benzonitrile

Step 1: methyl 5-bromo-l -methyl- lH-indazole-3-carboxylate

To a solution of 5-bromo-lH-indazole-3-carboxylic acid {J&W PharmLab, cat#45- 0107: 210.0 mg, 0.87 mmol) and methyl iodide (200 μί, 3 mmol) in tetrahydrofuran (2 mL) was added cesium carbonate (0.42 g, 1.3 mmol). The mixture was stirred at 65 °C overnight. After filtration, the filtrate was concentrated and the residue was dissolved in THF (3 mL) and treated with sodium hydride (45 mg, 1.1 mmol) followed by addition of methyl iodide (200 μί, 3 mmol). The reaction mixture was further stirred at room temperature for 5 h before heated to 65 °C for 2 h. The reaction mixture was concentrated and used directly for next step. LC-MS calculated for CioHioBrN 2 0 2 (M+H) + : m/z = 269.0; found 269.0.

Step 2: (5-bromo-l-methyl-lH-indazol-3-yl)methanol

To a solution of methyl 5 -bromo-1 -methyl- lH-indazole-3-carboxylate (110 mg, 0.41 mmol) in tetrahydrofuran (2 mL, 20 mmol) was added lithium tetrahydroaluminate in THF (1.0 M, 120 0.12 mmol) dropwise at 0 °C. The reaction mixture was stirred for 1 h, and the reaction was quenched by EtOAc, water followed by NaOH aqueous solution then extracted with EtOAc. The combined extracts were dried over Na 2 S0 4 , filtered and concentrated. The residue was purified by column chromatography eluting with 0-80% EtOAc in hexanes. LC-MS calculated for C 9 HioBrN 2 0 (M+H) + : m/z = 241.0; found 241.0.

Step 3: [l-methyl-5-(4 ,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazol-3-yl]me thanol

A mixture of (5-bromo-l-methyl-lH-indazol-3-yl)methanol (20 mg, 0.083 mmol), 4,4,5,5,4 * ,4 * ,5 * ,5 * -octamethyl-[2,2 , ]bi[[l,3,2]dioxaborolanyl] (23 mg, 0.091 mmol), [1,1 * - bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1 : 1) (7 mg, 0.008 mmol) and potassium acetate (20 mg, 0.2 mmol) in 1,4-dioxane (0.8 mL) was degassed and heated at 90 °C overnight. After cooling to room temperature, the reaction mixture was concentrated. The residue was purified by flash column chromatography eluting with 0 to 60% EtOAc in hexanes to give the desired product. LC-MS calculated for CisH 22 BN 2 03

(M+H) + : m/z = 289.2; found 289.2. Step 4: 4-{8-[4-(dimethylamino)piperidin-l-yl]-5-[3-(hydroxymethyl)- l-m

yl]imidazo[l,2-a]pyrazin-6-yl}benzonitrile The title compound was prepared using similar procedures as described for Example 58, Step 5 with [l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH -indazol-3-yl]methanol replacing 1 -methyl-5-(4,4,5 ,5 -tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 H-pyrazolo[3 ,4-b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H31N8O (M+H) + : m/z = 507.3; found 507.2. ¾ NMR (400 MHz, CD3OD) δ 7.96 (s, 1H), 7.67 (d, J= 8.7 Hz, 1H), 7.63 - 7.55 (m, 3H), 7.52 (d, J= 8.6 Hz, 2H), 7.46 (d, J= 1.2 Hz, 1H), 7.36 (dd, J= 8.7, 1.5 Hz, 1H), 5.70 (d, J = 13.5 Hz, 2H), 4.90 (s, 2H), 4.10 (s, 3H), 3.70 - 3.54 (m, 1H), 3.19 (t, J= 12.8 Hz, 2H), 2.94 (s, 6H), 2.26 (d, J= 11.0 Hz, 2H), 1.92 (m, 2H).

Example 111

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(l-methyl-2-oxo-2,3 -dihydro-lH-pyrrolo[2,3- b] pyridin-5-yl)imidazo [ 1 ,2-a] pyrazin-6-yl] benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3 -dihydro-2H- pyrrolo[2,3-b]pyridin-2-one (ChemBridge Corp., cat#4038124) replacing l-methyl-5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazolo[3,4-b]pyrid ine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H29N8O (M+H) + : m/z = 493.2; found 493.2.

Example 112

4- [8- [4-(dimethylamino)piperidin-l-yl] -5-(l-methyl-lH-pyrrolo [2,3-b] pyridin-5- yl)imidazo [1 ,2-a] pyrazin-6-yl] benzonitrile

The title compound was prepared using similar procedures as described for Example 58, Step 5 with l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrrolo[2,3-b]pyridine (Combi-Blocks, cat#98552) replacing l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- lH-pyrazolo[3,4-b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C28H29N8 (M+H) + : m/z = 477.2; found 477.2. l U NMR (400 MHz, CD3OD) δ 8.16 - 8.08 (m, 2H), 7.61 (d, J= 1.2 Hz, 1H), 7.59 - 7.50 (m, 5H), 7.47 (d, J= 1.2 Hz, 1H), 6.59 (d, J= 3.5 Hz, 1H), 5.72 (d, J= 12.8 Hz, 2H), 3.92 (s, 3H), 3.68 - 3.55 (m, 1H), 3.20 (t, J= 12.0 Hz, 2H), 2.94 (s, 6H), 2.26 (d, J= 11.9 Hz, 2H), 1.99 - 1.80 (m, 2H).

Example 113

4-(8-[4-(dimethylamino)piperidin-l-yl]-5-{2-[(lR)-l-hydroxye thyl]-l-methyl-lH- benzimidazol-5-yl}imidazo[ -a]pyrazin-6-yl)benzonitrile

Step 1: (lR)-l-(5-bromo-l-methyl-lH-benzimidazol-2- l)ethanol

A mixture of (2R)-2-hydroxypropanamide (Aldrich, cat#436801: 186 mg, 2.09 mmol) and triethyloxonium tetrafluoroborate (Aldrich, cat#90520: 370 mg, 2.0 mmol) in tetrahydrofuran (10 mL) was stirred at room temperature for 2 hrs. After concentration, the residue was dissolved in ethanol (4.5 mL) and added to a suspension of 4-bromo-Nl- methylbenzene-l ,2-diamine (Combi-B locks, cat#AN-3666: 128 mg, 0.64 mmol) in ethanol (2.1 mL). The mixture was stirred at 80 °C for 1 h then cooled to room temperature and concentrated. The residue was purified by column chromatography on a silica gel column eluting with 0-90% EtOAc in hexanes to give the desired product. LC-MS calculated for CioHi 2 BrN 2 C ) (M+H) + : m/z = 255.0; found 255.0.

Step 2: ( lR)-l-[ I -methyl- 5 -(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)-lH-benzimidazol-2- yljethanol

A mixture of (1R)-1 -(5 -bromo-1 -methyl- lH-benzimidazol-2-yl)ethanol (63 mg, 0.24 mmol), 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[l ,3,2]dioxaborolanyl] (62 mg, 0.24 mmol), [1 ,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1 : 1) (20 mg, 0.02 mmol) and potassium acetate (60 mg, 0.7 mmol) in 1 ,4-dioxane (4 mL) was purged with nitrogen and stirred at 80 °C overnight. After cooling to room temperature, the reaction mixture was concentrated. The residue was purified by flash column chromatography eluting with 0 to 60% EtOAc in hexanes to give the desired product. LC-MS calculated for

C16H24BN2O3 (M+H) + : m/z = 303.2; found 303.2.

Step 3: 4-(8-[4-(dimethylamino)piperidin-l-yl]-5-{2-[(lR)-l-hydroxye thyl]-l-methyl-lH- benzimidazol-5-yl}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using procedures analogous to those described in Example 58, Step 5 with (lR)-l-[l-methyl-5-(4,4,5, 5-tetramethyl-l , 3,2-dioxaborolan-2-yl)-lH- benzimidazol-2-yl]ethanol replacing 1 -methyl-5-(4,4,5 ,5 -tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- lH-pyrazolo[3,4-b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for CsoffcNsO (M+H) + : m z = 521.3; found 521.3.

Example 114 4-(8-[4-(dimethylamino)piperidin-l-yl]-5-{2-[(lS)-l-hydroxye thyl]-l-methyl-lH- benzimidazol-5-yl}imidazo[l,2-a]pyrazin-6-yl)benzonitrile

The title compound was prepared using procedures analogous to those described in Example 113 with (2S)-2-hydroxypropanamide (Aldrich, cat#436828) replacing (2R)-2- hydroxypropanamide in Step 1. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for CsoffcNsO (M+H) + : m/z = 521.3; found 521.3.

Example 115

4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(l,2-dimethyl-lH-be nzimidazol-5-yl)imidazo[l,2- a] pyrazin-6-yl] benzonitrile

Step 1: l,2-dimethyl-5-(4A,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- lH-benzimidazole

A mixture of [l , -bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1 : 1) (40 mg, 0.04 mmol), 5-bromo-l ,2-dimethyl-lH-benzimidazole (Combi-Blocks, cat#WZ-9484: 200 mg, 0.9 mmol), 4,4,5,5,4*,4*,5*,5*-octamethyl- [2,2']bi[[l,3,2]dioxaborolanyl] (340 mg, 1.3 mmol) and potassium acetate (300 mg, 3 mmol) in 1,4-dioxane (7 mL) was purged with nitrogen then stirred at 90 °C overnight. The reaction mixture was cooled to room temperature then filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with 0 to 30 % MeOH in DCM to give the desired product. LC-MS calculated for C15H22BN2O2 (M+H) + : m/z = 273.2; found 273.2.

Step 2: 4-[8-[ 4-(dimethylamino)piperidin-l-yl]-5-(l,2-dimethyl-lH-benzimid azol-5- yl)imidazo[l,2-a]pyrazin-6-yl]benzonitrile

The title compound was prepared using procedures analogous to those described in Example 58, Step 5 with l,2-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) -lH- benzimidazole replacing 1 -methyl-5-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 H- pyrazolo[3,4-b]pyridine. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C29H31N8 (M+H) + : m/z = 491.3; found 491.3.

Example 116

4- [8- [4-(dimethylamino)piperidin- 1-yl] -5-(5-methoxy-6-methylpyridin-3-yl)imidazo [ 1 ,2- a] pyrazin-6-yl] benzonitrile

The title compound was prepared using procedures analogous to those described in

Example 92 with 3-methoxy-2-methyl-5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)pyridine (Anichem, cat#GS2824) replacing 2,3-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C27H30N7O (M+H) + : m z = 468.3; found 468.2.

Example 117 5-(6-(4-cyanophenyl)-8-{[(3R)-l-methylpiperidin-3-yl]methoxy }imidazo[l,2-a]pyrazin-5- yl)-2-methylnicotinonitrile

Step 1 : 2-methyl-5- ( 4, 4, 5, 5-tetrameth -l, 3, 2-dioxaborolan-2-yl)nicotinonitrile

A suspension of 5-bromo-2-methylnicotinonitrile (Combi-B locks, cat#PY-1861: 148 mg, 0.75 mmol), potassium acetate (220 mg, 2.3 mmol) and 4,4,5, 5,4',4',5',5'-octamethyl- [2,2']bi[[l,3,2]dioxaborolanyl] (290 mg, 1.1 mmol) in 1,4-dioxane (3.4 mL, 44 mmol) was degassed with stream of nitrogen for ~5 min. Then [l,l'-bis(diphenylphosphino)ferrocene]- dichloropalladium(II) complexed with dichloromethane (1 : 1) (30 mg, 0.04 mmol) was added, the vial was sealed and then heated at 100 °C overnight. The reaction mixture was then concentrated, diluted with ethyl acetate and filtered through celite, concentrated and used without further purification. LC-MS calculated for C13H18BN2O2 (M+H) + : m/z = 245.1; found 245.1. Step 2. 5-(6-(4-cyanophenyl)-8-{[ (3R)-l-methylpiperidin-3-yl]methoxy}imidazo[l,2-a]pyrazin-5- yl)-2-methylnicotinonitrile

The title compound was prepared using procedures analogous to those described in

Example 48, Step 8 with 2-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)nico tinonitrile replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C27H26N7O (M+H) + : m/z = 464.2; found

464.2.

Example 118 4- [8- [4-(dimethylamino)piperidin- 1-yl] -5-(5-hydroxy-6-methoxypyridin-3-yl)imidazo [ 1 ,2- a] pyrazin-6-yl] benzonitrile

Step 1 : 2-methoxy-5-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)pyridin-3-ol

A suspension of 5-bromo-2-methoxypyridin-3-ol (AstaTech, cat#73402: 150 mg, 0.75 mmol), potassium acetate (220 mg, 2.2 mmol) and 4,4,5,5,4',4',5',5'-octamethyl- [2,2']bi[[l,3,2]dioxaborolanyl] (280 mg, 1.1 mmol) in 1,4-dioxane (3.4 mL) was degassed with stream of nitrogen, then [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1 :1) (30 mg, 0.04 mmol) was added, the vial was sealed, and the reaction mixture was heated at 90 °C overnight. The reaction mixture was cooled to room temperature, filtered through celite and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C12H19BNO4 (M+H) + : m/z = 252.1; found 252.1. Step 2: 4-[8-[4-(dimethylamino)piperidin-l-yl]-5-(5-hydroxy-6-methox ypyridin-3- yl)imidazo[l,2-a]pyrazin-6-yl] benzonitrile

The title compound was prepared using procedures analogous to those described in

Example 92 with 2-methoxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyr idin-3-ol replacing 2,3-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) pyridine. The reaction mixture was purified by prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C26H28N7O2 (M+H) + : m/z = 470.2; found 470.2.

Example 119 4-(5-(5-hydroxy-6-methoxypyridin-3-yl)-8-{[(3R)-l-methylpipe ridin-3- yl]methoxy}imidazo[l,2-a]pyrazin-6- l)benzonitrile

The title compound was prepared using procedures analogous to those described in Example 48, Step 8 with 2-methoxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyr idin-3-ol (Example 118, Step 1) replacing l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]pyrrolidin-2-one. The reaction mixture was purified by prep-HPLC (pH = 2,

acetonitrile/water+TFA) to give the desired product as the TFA salt. LC-MS calculated for C26H27N6O3 (M+H) + : m/z = 471.2; found 471.2.

Example A: LSD1 histone demethylase biochemical assay

LANCE LSD1/KDM1A demethylase assay- 10 of 1 nM LSD-1 enzyme (ENZO BML-SE544-0050) in the assay buffer (50 mM Tris, pH 7.5, 0.01% Tween-20, 25 mM NaCl, 5 mM DTT) were preincubated for 1 hour at 25 °C with 0.8 compound/DMSO dotted in black 384 well polystyrene plates. Reactions were started by addition of 10 of assay buffer containing 0.4 μΜ Biotin-labeled Histone H3 peptide substrate: ART-K(Mel)- QTARKSTGGKAPRKQLA-GGK(Biotin) SEQ ID NO: l (AnaSpec 64355) and incubated for 1 hour at 25°C. Reactions were stopped by addition of 10 IX LANCE Detection Buffer (PerkinElmer CR97-100) supplemented with 1.5 nM Eu-anti-unmodified H3K4 Antibody (PerkinElmer TRF0404), and 225 nM LANCE Ultra Streptavidin (PerkinElmer TRF 102) along with 0.9 mM Tranylcypromine-HCl (Millipore 616431). After stopping the reactions plates were incubated for 30 minutes and read on a PHERAstar FS plate reader (BMG Labtech). IC50 data for the example compounds is provided in Table 1 (+ refers to IC50 < 50 nM; ++ refers to IC50 > 50 nM and < 500 nM; +++ refers to ICso > 500 nM and < 1000 nM).

Table 1 Example No. ICso (nM)

1 +

2 +

3 ++

4 +

5 +

6 +++

7 +

8 ++

9 +

10 +

11 +

12 +

13 +

14 +

15 ++

16 ++

17 ++

18 +

19 +

20 +

21 ++

22 +++

23 ++

24 ++

25 ++

26 ++

27 ++

28 ++

29 +

30 +

31 ++

32 ++

33 +

34 ++

35 ++

36 +

37 +

38 +

39 +

40 +

41 +

42 +

43 +

44 + Example No. ICso (nM)

82 ++

83 ++

84 ++

85 +

86 ++

87 +

88 +

(mixture of

diastereomers)

89 ++

90 +

91 +

92 +

93 +

(racemic)

94 +

95 +

(racemic)

96 +

97 +

98 +

99 +

100 +

101 +

102 +

103 +

104 ++

105 +

106 +

107 +

108 ++

109 +

110 +

111 +

112 +

113 +

114 ++

115 +

116 ++

117 ++

118 +

119 + Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.